

NEW DATA ON LONGTERM OUTCOME AFTER PERCUTANEOUS CORONARY INTERVENTION

Abstracts

Chairperson(s): H.H. Pereira (Almada, PT); M.C. Morice (Massy, FR)

- 08:30 **Optimizing the time-interval between DES or BMS implantation and non-cardiac surgery.** 4947
 – J.P. Van Kuijk, W.J. Flu, O. Schouten, S.E. Hoeks, F. Van Lier, T. Winkel, P.P.T. De Jaegere, J.J. Bax, R.T. Van Domburg, D. Poldermans (Rotterdam and Leiden, NL)
- 08:45 **A 10-year results of unprotected left main stenting: LEMANS registry.** 4948
 – P. Buszman, P.P. Buszman, M. Konkolewska, B. Trela, M. Krol, M. Kondys, E. Peszek-Przybyla, J.L. Martin, R.S. Kiesz, M. Tendera (Katowice, Ustron and Dabrowa Gornicza, PL; Bryn Mawr and San Antonio, US)
- 09:00 **High repeat revascularisation after Intracoronary beta-radiation brachytherapy: a ten-year follow-up study.** 4949
 – J.M. Cheng, J. Eindhoven, P.W. Serruys, R.T. Van Domburg, W.J. Van Der Giessen (Rotterdam, NL)
- 09:15 **Prognostic impact of nonresponsivness platelet residual reactivity to clopidogrel therapy in patients with left main disease treated with coronary drug-eluting stent implantation.** 4950
 – A. Migliorini, R. Valenti, G. Giuliani, P. Buonamici, G. Cerisano, N. Carrabba, G. Parodi, G. Moschi, D. Antonucci (Florence, IT)
- 09:30 **Impact of socioeconomic status on medication compliance and major adverse cardiac events (MACE) following percutaneous coronary intervention (PCI).** 4951
 – L. Lefkovits, N. Andrianopoulos, D. Stub, D.J. Clark, A.E. Ajani, A.L. Brennan, G. New, C.M. Reid, A.M. Dart, S.J. Duffy (Melbourne, AU)
- 09:45 **Long-term clinical outcomes and predictors of adverse cardiac events after percutaneous intervention on unprotected distal left main bifurcation stenosis.** 4952
 – M.S.Y. Min, D.W. Park, J.Y. Lee, W.J. Kim, S.W. Lee, Y.H. Kim, C.W. Lee, S.W. Park, S.J. Park (Seoul, KR)

10:00 Coffee break (Moderated Posters)



NEW TECHNOLOGY TO IMPROVE STENT SAFETY

Abstracts

Chairperson(s): H. Gamra (Monastir, TN); F. Alfonso Manterola (Madrid, ES)

- 11:00 **Black spot surrounding stent struts observed by optical coherence tomography; what do these represent?** 4953
 – T. Teramoto, F. Ikeno, J. Lyons, H. Ootake, A.C. Yeung (Palo Alto, US)
- 11:15 **Comparison of plaque prolapse in consecutive patients treated with Xience V and Taxus Liberté stents.** 4954
 – Z.J. Shen, J. Lighthart, H. Garcia-Garcia, N. Piazza, P.W.J. Serruys (Rotterdam, NL)
- 11:30 **In many patients undergoing primary PCI in STEMI coronary stent does not fully cover thin-cup fibroatheroma (TCFA) related to the culprit lesion. Virtual Histology (VH-IVUS) study.** 4955
 – J. Legutko, J. Jakala, M. Wizimirski, L. Rzeszutko, L. Partyka, A. Richter, P. Margolis, P. Kleczynski, D. Dudek (Krakow, PL; Rancho Cordova, US)
- 11:45 **Vessel size predicts acute stent malapposition after stent implantation in patients with acute myocardial infarction.** 4956
 – S.C. Bergheanu, B.L. Van Der Hoeven, J. Atary, S.S. Liem, J. Dijkstra, D.E. Atsma, M. Bootsma, K. Zeppenfeld, J.W. Jukema, M.J. Schalij (Leiden, NL)
- 12:00 **Long-term local inflammatory response after coronary artery stenting -BMS vs SES vs PES-** 4957
 – T. Wakatsuki, K. Yamaguchi, T. Niki, K. Kusunose, K. Koshiba, T. Iwase, H. Yamada, T. Soeki, M. Akaike, M. Sata (Tokushima, JP)
- 12:15 **Increased Ig E and complement component C3 levels in diabetic patients after drug eluting stent implantation.** 4958
 – E. Bernardo Garcia, D.J. Angiolillo, P. Jimenez-Quevedo, A. Fernandez-Ortiz, F. Alfonso, R. Hernandez-Antolin, C. Macaya, M. Sabate (Madrid and Barcelona, ES; Jacksonville, US)

12:50 End of Congress



THE 'FULL MONTY' OF EXERCISE TRAINING: HEART AND PERIPHERY WORK TOGETHER

Abstracts

Chairperson(s): A. Cohen-Solal (Paris, FR); To be announced

- 08:30 **Prevention of muscle wasting in chronic heart failure: Does exercise work equally well in all age groups?** 4959
 – S. Gielen, M. Sandri, V. Adams, N. Mangner, R. Hoellriegel, S. Erbs, I. Kozarez, R. Hambrecht, G. Schuler (Leipzig and Bremen, DE)
- 08:45 **Exercise training reverses dysfunction of endothelial progenitor cells in patients with chronic heart failure.** 4960
 – E. Van Craenenbroeck, P. Beckers, N. Possemiers, K. Wuyts, V. Hoymans, G. Frederix, G. Ennekens, I. Goovaerts, C. Vrints, V. Conraads (Edegem, BE)
- 09:00 **Early exercise training intervention attenuates left ventricular dysfunction and prevents calcium handling abnormalities in streptozotocin-diabetic rats submitted to myocardial infarction.** 4961
 – B. Rodrigues, L. Jorge, K.T. Rosa, A. Medeiros, G.O. Candido, P.C. Brum, K. De Angelis, M.C. Irigoyen (Sao Paulo, BR)
- 09:15 **Cardiac rehabilitation in heart failure patients decreases concentration of MMP-1 and TIMP-1 and ameliorates serum ability to sustain CFU-EC proliferation.** 4962
 – F. Molinari, A. Armani, L. Gatta, C. Consoli, G. Marazzi, G. Caminiti, C. Mammì, C. Vitale, M. Volterrani, M.C.G. Rosano (Rome, IT)
- 09:30 **Regular physical exercise training improves function of circulating endothelial progenitor cells and endothelial function in pre-diabetic, adipose patients with coronary heart disease.** 4963
 – R. Hoellriegel, A. Burmann, V. Adams, S. Erbs, M. Sonnabend, M. Blueher, M. Stumvoll, G. Schuler, A. Linke (Leipzig, DE)
- 09:45 **Long-term regular exercise training prevents aortic valve disease in mice: importance of regular exercise training at earlier-stage of disease.** 4964
 – Y. Matsumoto, V. Adams, A. Linke, S. Jacob, G. Schuler (Leipzig, DE)

10:00 Coffee break (Moderated Posters)



PREDICTING TRAINING BENEFIT: FINALLY GETTING SOMEWHERE?

Abstracts

Chairperson(s): S. Gielen (Leipzig, DE); M. Mendes (Carnaxide, PT)

- 11:00 **The acute effect of exercise on endothelial progenitor cell function in chronic heart failure patients depends on their training level.** 4965
 – E. Van Craenenbroeck, P. Beckers, N. Possemiers, K. Wuyts, V. Hoymans, B. Paelinck, C. Vrints, V. Conraads (Edegem, BE)
- 11:15 **Age-related changes in endothelial function in patients with chronic heart failure and healthy subjects - effects of exercise training.** 4966
 – M. Sandri, S. Gielen, V. Adams, N. Mangner, A. Linke, S. Erbs, R. Hoellriegel, S. Moebius-Winkler, R. Hambrecht, G. Schuler (Leipzig, DE)
- 11:30 **Endothelial genetic contribution to response to physical training in patients with coronary artery disease?** 4967
 – S. Onkelinx, R. Fagard, S. Amandels, T. Thomaes, R. Buys, L. Vanhees (Leuven, BE)
- 11:45 **Effect of exercise-based cardiac rehabilitation on vascular endothelial function and exercise capacity in patients with stable coronary artery disease.** 4968
 – T.H. Luk, Y.L. Dai, C.W. Siu, K.H. Yiu, H.T. Chan, S. Lee, S.W. Li, S. Tam, C.P. Lau, H.F. Tse (Hong Kong, HK)
- 12:00 **Mood disturbances affect change in physical exercise capacity during cardiac rehabilitation.** 4969
 – W. Benzer, S. Knapp, K. Mayr, H. Harpf, A. Philippi, E. Miller Mayer, W. Ziegelmeier, G. Zenker, S. Hoefler (Feldkirch, Linz, Graz, Salzburg, Steyr, Bruck A. D. Mur and Innsbruck, AT)
- 12:15 **Effects of frequency of exercise for improving aerobic capacity: training and de-training.** 4970
 – H. Hatle, P.K. Stobakk, E. Bronstad, T. Stolen, A.E. Tjonna, H.E. Molmen, C.B. Ingul, U. Wisloff, O.R. Rognmo (Trondheim, NO)

12:50 End of Congress



EXERCISE TRAINING: LESS CAN BE MORE ...

Abstracts

Chairperson(s): F. Carre (Rennes, FR); L.E.M. Vanhees (Leuven, BE)

- 08:30 **Effects of endurance training on telomere length and senescence of circulating cells in professional athletes and matched controls without physical exercise.** 4971
 – C.M. Werner, T. Fuerster, T. Widmann, C. Roggia, J. Scharhag, M. Boehm, U. Laufs (Homburg and Saarbrücken, DE)
- 08:45 **Time dependent mobilization of circulating progenitor cells during strenuous exercise in healthy individuals.** 4972
 – S. Moebius-Winkler, T. Hilberg, K. Menzel, E. Golla, A. Burman, G. Schuler, V. Adams (Leipzig and Wuppertal, DE)
- 09:00 **Evaluation of myocardial damage by cardiac MRI following troponin positive endurance exercise.** 4973
 – R. O'Hanlon, G.P. Whyte, G. Smith, R. Wage, F. Alpendurada, J. Wong, M. Wilson, A. Dahl, D.J. Pennell, S.K. Prasad (London and Liverpool, GB)
- 09:15 **Exercise-induced increases in Right Ventricular End-Systolic Wall Stress (RV-ESWS) are greater than for the Left Ventricle (LV-ESWS) and may cause preferential RV enlargement in endurance athletes.** 4974
 – A. La Gerche, A.T. Burns, D.J. Mooney, H. Heidbuchel, A.I. Macisaac, D.L. Prior (Melbourne, AU; Leuven, BE)
- 09:30 **Cardiac MR reference values in endurance athletes and matched non-athletes: the importance of correction for gender, body surface area, and training intensity.** 4975
 – N.H.J. Prakken, B.K. Velthuis, A.J. Teske, A. Mosterd, W.P. Mali, M.J. Cramer (Utrecht, NL)
- 09:45 **Sport-specific adaptation on cardiac MRI.** 4976
 – T. Luijckx, N.H.J. Prakken, M.J. Cramer, W.P. Mali, B.K. Velthuis (Utrecht, NL)

10:00 Coffee break (Moderated Posters)



IMPROVING OUTCOMES: WHAT CAN WE AFFORD?

Abstracts

Chairperson(s): M. Volpe (Rome, IT); P. Sousa (Lisbon, PT)

- 11:00 **Outcomes of elderly patients with non-ST-elevation acute coronary syndromes according to treatment strategy.** 4977
 – S. Nabais, J. Costa, S. Rocha, A. Gaspar, S. Ribeiro, J. Marques, P. Azevedo, M. Alvares Pereira, A. Correia (Braga, PT)
- 11:15 **Lifetime incremental effectiveness and cost-effectiveness of high-dose statin therapy versus standard-dose statin therapy in German patients with recent myocardial infarction.** 4978
 – D. Rublee, J. Rieber, E. Giannitsis, K. Berger, B. Ehlken, Y. Asukai, C. Plesnila-Frank, J. Mardekian (New York, US; Munich and Heidelberg, DE; London, GB)
- 11:30 **Economic impact of invasive vs. medical strategies for acute coronary syndromes in older patients.** 4979
 – S. Otto, C. Menzel, M. Ferrari, B. Goebel, H.R. Figulla, T.C. Poerner (Jena, DE)
- 11:45 **Changes in the incidence, mortality and treatment of CHD in Scotland 1998-2008.** 4980
 – A. Redpath (Edinburgh, GB)
- 12:00 **Influence of equity of access to health care and socio-economic status on the blood pressure profile of vulnerable communities: Results from a national survey of 13,825 adults.** 4981
 – M.C. Carrington, G. Jennings, S. Stewart (Melbourne, AU)
- 12:15 **STEMI outcomes and predictors for cardiac death in older patients: a community-based study.** 4982
 – S. Otto, C. Menzel, B. Goebel, M. Ferrari, H.R. Figulla, T.C. Poerner (Jena, DE)

12:50 End of Congress



EVOLVING CONCEPTS IN VULNERABLE PLAQUE ASSESSMENT

Abstracts

Chairperson(s): T. Akasaka (Wakayama, JP); B. Merkely (Budapest, HU)

- 08:30 **Necrotic core touching the lumen is most frequently exposed to high shear stress in advanced disease.** 4983
 – J.J. Wentzel, J.C.H. Schuurbiens, N. Gonzalo Lopez, F.J.H. Gijzen, J. Ligthart, A.G. Van Der Giessen, H.C. Groen, J. Dijkstra, P.W. Serruys (Rotterdam and Leiden, NL)
- 08:45 **Increased heat energy in culprit lesions: new insights in the detection of high risk plaques from a new approach.** 4984
 – K. Toutouzas, M. Drakopoulou, T. Papaioannou, A. Synetos, E. Tsiamis, C. Tentolouris, A. Androulakis, J. Karabelas, E. Stefanadi, C. Stefanadis (Athens, GR)
- 09:00 **Myeloperoxidase for risk stratification and early diagnosis in patients with acute chest pain.** 4985
 – R. Twerenbold, N. Schaub, T. Reichlin, W. Hochholzer, S. Bassetto, S. Steurer, D. Jauslin, A. Mebazaa, C.H. Mueller (Basel, Olten, Zurich and Bruderholz, CH; Paris, FR)
- 09:15 **Local release of C-reactive protein and plaque characteristics by integrated backscatter intravascular ultrasound: a comparison between stable and unstable angina.** 4986
 – Y. Miyamoto, H. Okura, T. Maehama, K. Saito, K. Imai, T. Tsuchiya, A. Hayashida, Y. Neishi, T. Kawamoto, K. Yoshida (Kurashiki, JP)
- 09:30 **Evaluation of plaque characteristics on virtual histology radiofrequency intravascular ultrasound in relation to degree of stenosis and the presence of ischemia.** 4987
 – J. Van Velzen, J.D. Schuijff, G. Pundziute, F.R. De Graaf, M.P. Stokkel, J.W. Jukema, E.E. Van Der Wall, M.J. Schalij, J.J. Bax (Leiden, NL)
- 09:45 **Relation between plaque components and plaque prolapse after drug-eluting stent implantation: virtual histology-intravascular ultrasound analysis.** 4988
 – Y.J. Hong, M.H. Jeong, S.W. Kim, J.S. Ko, M.G. Lee, K.H. Park, D.S. Sim, J.H. Kim, Y. Ahn, J.C. Kang (Gwangju and Seoul, KR)

10:00 Coffee break (Moderated Posters)

CONTEMPORARY INSIGHTS IN PERCUTANEOUS CORONARY INTERVENTIONS FOR ACUTE CORONARY SYNDROMES Abstracts

Chairperson(s): J. Belardi (Buenos Aires, AR); L.A. Providencia (Coimbra, PT)

- 11:00 **Impact of low response to aspirin and/or clopidogrel in 1001 patients undergoing coronary stenting: 1-month results of the VERIFRENCHY registry.** 4989
 – G. Range, P. Richard, S. Chassaing, L. Belle, C. Thuair, P. Cazaux, F. Barbou, J.P. Collet, F. Albert, G. Montalescot (Chartres, Caen, Tours, Annecy, Lorient and Paris, FR)
- 11:15 **Platelets and haemostatic gene polymorphisms and risk of bleeding in patients undergoing elective coronary angiography -analysis of the PRAGUE-8 genetic substudy.** 4990
 – Z. Motovska, P. Widimsky, P. Kala, J. Kvasnicka, R. Petr, D. Bilkova, M. Poloczek, R. Miklik, J. Hajkova (Prague and Brno, CZ)
- 11:30 **Four year follow-up of the TYPHOON trial comparing SES and BMS in primary PCI for AMI.** 4991
 – C. Spaulding, P. Commeau, A. Tirouvanziam, J. Fajadet, P.R. Stella, T. Lefevre, U. Abildgaard, B. Merkely, A. Cebrian, P. Henry (Paris, Ollioules, Nantes, Toulouse and Massy, FR; Utrecht, NL; Hellerup, DK; Budapest, HU; Waterloo, BE)
- 11:45 **Evaluation of infarct related coronary patency and microcirculatory function after facilitated percutaneous primary coronary angioplasty. The FINESSE-ANGIO study.** 4992
 – F. Prati, A.S. Petronio, A.J. Van Boven, M. Tendera, M.A. De Belder, G. Montalescot, J. Peruga, E.S. Barnathan, S. Ellis, S. Savonitto (Rome, Pisa and Milan, IT; Leeuwarden, NL; Katowice and Lodz, PL; Middlesbrough, GB; Paris, FR; Malvern and Cleveland, US)
- 12:00 **Current practice of PCI for ACS and stable angina in Europe 2005-2008: lessons from the Euro Heart Survey PCI registry.** 4993
 – A.K. Gitt, U. Zeymer, R. Zahn, F. Weidinger, R. Seabra Gomes, F. Eberli, P. Serruys, T. Bauer, C. Hamm, J. Marco (Ludwigshafen am Rhein and Bad Nauheim, DE; Vienna, AT; Lisbon, PT; Zurich, CH; Rotterdam, NL; Monaco, MC)
- 12:15 **Impact of renal impairment and major bleeding complications in patients after PCI in acute coronary syndromes - results of the Euro Heart Survey PCI registry.** 4994
 – B. Klein, A.K. Gitt, M. Hochadel, R. Zahn, J. Marco, U. Zeymer (Ludwigshafen, DE; Vienna, AT; Monte Carlo, MC)

12:50 End of Congress



**STATE OF THE ART –
PHARMACOGENOMICS – THE NEW
FRONTIER IN HYPERTENSION TRIALS?**

Featured Research

Chairperson(s): R. Fagard (Leuven, BE); A.F. Dominiczak (Glasgow, GB)

- 08:30 **Genetic determinants of blood pressure and blood pressure response to ACE-inhibitor therapy in patients with stable coronary artery disease.** 4995
– J. Brugts, A. Isaacs, M. De Maat, C. Van Duijn, W. Remme, K. Fox, R. Ferrari, E. Boersma, M.L. Simoons, A.H.J. Danser (Rotterdam and Rhooon, NL; London, GB; Ferrara, IT)
- 08:45 **Argumentation of antihypertensive treatment application in patients with essential arterial hypertension depending on individual pharmacogenetic susceptibility.** 4996
– L. Sydorchuk, K.M. Amosova, I.I. Sydorchuk, R.I. Sydorchuk (Chernivtsi and Kyiv, UA)
- 09:00 **Immediate benefit of treating very elderly hypertensives: results from an active-treatment extension to the hypertension in the very elderly trial (HYVET).** 4997
– N.S. Beckett, R. Peters, A. Fletcher, C. Bulpitt (London, GB)
- 09:15 **T45G polymorphism on adiponectin gene modifies cardiovascular risk by affecting arterial hypertension: its impact on adiponectin serum levels.** 4998
– A.S. Antonopoulos, D. Tousoulis, C. Antoniadis, A. Miliou, N. Koumallos, G. Hatzis, N. Papageorgiou, C. Bakogiannis, C. Tsioufis, C. Stefanadis (Athens, GR)
- 09:30 **State of the Art - Pharmacogenomics - the new frontier in hypertension trials?** 4999
– A.F. Dominiczak (Glasgow, GB)

10:00 Coffee break (Moderated Posters)

DRUGS AND BLOOD PRESSURE

Abstracts

Chairperson(s): R. Schmieder (Erlangen, DE); F. Enseleit (Zurich, CH)

- 11:00 **Regression of left ventricular hypertrophy with effect of anemia improvement in chronic kidney disease patients.** 5000
– M. Akaishi, M. Suzuki, Y. Hada, M. Hiroe, Y. Tsubakihara, T. Akizawa (Tokyo and Osaka, JP)
- 11:15 **Effects of valsartan and amlodipine on cardio-renal protection in Japanese hypertensive patients: Valsartan Amlodipine Randomized Trial (VART).** 5001
– H. Narumi, H. Takano, S. Shindo, K. Nakayama, M. Fujita, H. Mizuma, Y. Kuwabara, I. Komuro (Chiba, JP)
- 11:30 **Prevention of congestive heart failure in hypertension: a bayesian network meta-analysis involving more than 210.000 subjects.** 5002
– S. Sciarretta, F. Palano, F. Paneni, M. Volpe (Rome, IT)
- 11:45 **HIV protease inhibitors activate the adipocyte renin-angiotensin system.** 5003
– F. Boccaro, M. Auclair, A. Cohen, C. Lefevre, M. Prot, J.P. Bastard, J. Capeau, M. Caron (Paris, FR)
- 12:00 **Erectile dysfunction in high-risk hypertensive patients treated with beta-blockade agents.** 5004
– A. Cordero, V. Bertomeu Martinez, P. Mazon, V. Bertomeu-Gonzalez, L. Facila, P. Conthe, J.R. Gonzalez-Juanatey (Alicante, Santiago de Compostela, Castellon and Madrid, ES)
- 12:15 **Combination therapy of angiotensin II receptor blockers plus a calcium channel blocker, but not a diuretic, improve late systolic pressure augmentation in elderly patients with essential hypertension.** 5005
– M. Doi, T. Miyoshi, S. Hirohata, S. Kusachi, K. Kusano (Takamatsu and Okayama, JP)

12:50 End of Congress



**STATE OF THE ART – ADVANCING
KNOWLEDGE, CHANGING PRACTICE:
NURSE-LED INTERVENTIONS IN HEART
FAILURE**

Featured Research

Chairperson(s): S. Dunbar (Atlanta, US); P. Hall (Dublin, IE)

- 08:30 **Feasibility and effects of home based intra-venous diuretic therapy in NYHA class III/IV CHF-patients.** **5006**
– H. Van De Wetering, M. De Zwaan, A. Wienke, A.W.J. Van 't Hof (Zwolle, NL)
- 08:45 **Effect of a nurse-led multidisciplinary heart failure clinic on professional practice: a randomized trial.** **5007**
– O. Doyon, J.L. Rouleau, J. Lemaire, L. Raymond, A. Ducharme, J. Brophy, S. Heppell (Trois-Rivieres, Montreal and Sherbrooke, CA)
- 09:00 **Heart failure nurses- where to now?** **5008**
– J.F. Pattenden, R.J.P. Lewin, L. Blue (York and London, GB)
- 09:15 **Telemonitoring in heart failure increases patients' confidence in self care but identifies additional healthcare needs: the Home-HF study.** **5009**
– J. Riley, O. Dar, C. Chapman, S.W. Dubrey, S.D. Rosen, J.P.N. Gabe, M.R. Cowie (London and Middlesex, GB)
- 09:30 **State of the Art - Advancing knowledge, changing practice: nurse-led interventions in heart failure.** **5010**
– S. Dunbar (Atlanta, US)

10:00 Coffee break (Moderated Posters)



**IMPROVING SKILLS AND KNOWLEDGE IN PATIENT CARE
AND ASSESSMENT**

Abstracts

Chairperson(s): D. Lehwaldt (Dublin, IE); N. De Michelis (Orange, US)

- 11:00 **Accuracy and reliability in electrocardiogram leads placement.** **5011**
– J. Ruiz Garcia, J. Almendral, P. Avila Alonso, L. Bravo Calero, S. Castrejon Castrejon, M.A. Espinosa Castro, L. Gallego Parra, C. Perez Del Villar Moro, A. Nunez Garcia, F. Fernandez-Aviles (Madrid, ES)
- 11:15 **Clinical decision support for glucose regulation on the intensive cardiac care unit.** **5012**
– J.A. Lipton, R. Barendse, E.F.H.A. Eenkhoorn, J. Van Der Ende, M.G.G. Veldhuijzen, T.B. Van Dam, M.J.B. Van Ettinger, S.P. Nelwan, M. Van Der Ent, N.H.J.J. Van Der Putten (Rotterdam, NL)
- 11:30 **Gender differences in presentation of symptoms associated to the acute myocardial infarction.** **5013**
– A.R. Alconero Camarero, J.L. Cobo Sanchez, P. Munoz Cacho (Santander, ES)
- 11:45 **Simple adjectives can measure patient autonomy, depression, anxiety, social support and social isolation.** **5014**
– A.G.O. Stewart, D. Hare (Melbourne, AU)
- 12:00 **Nurse-assisted evaluation of exercise tolerance in patients with chest pain: is 6-minutes walk test enough?** **5015**
– J.D. Kasprzak, A. Boehm, M. Kurpesa, M. Krzeminska-Pakula (Lodz, PL)
- 12:15 **Hidden renal failure in patients with an acute coronary syndrome: prevalence and associated factors.** **5016**
– J.L. Cobo Sanchez, A.R. Alconero Camarero, P. Munoz Cacho (Santander, ES)

12:50 End of Congress

CLINICAL TRIAL UPDATE III

Clinical Trial Update

Chairperson(s): A.A. Bove (Philadelphia, US);
J.L. Zamorano Gomez (Madrid, ES)



08:30	Impact of bleeding types on mortality after PCI: Results from a patient-level pooled analysis of the REPLACE-2, ACUITY and HORIZONS trials. – R. Mehran (New York, US)	5017
08:40	Discussant. – W. Wijns (Aalst, BE)	5018
08:45	Comparison between the effects of dabigatran versus warfarin in vitamin K antagonist naive and experienced patients with atrial fibrillation in the RELY Trial. – M.D. Ezekowitz (Wynnewood, US)	5019
08:55	Discussant. – J.-P. Collet (Paris, FR)	5020
09:00	Clinical outcome after thrombectomy or standard angioplasty in patients with ST elevation myocardial infarction: individual patient-data pooled analysis of 11 randomized trials. ATTEMPT. – F. Burzotta (Rome, IT)	5021
09:10	Discussant. – E. Eeckhout (Lausanne, CH)	5022
09:15	Optimal revascularisation strategy in patients with three-vessel disease and/or left main disease: The 2 year outcomes of the SYNTAX Trial. – A.P. Kappetein (Rotterdam, NL)	5023
09:25	Discussant. – M.J. Antunes (Coimbra, PT)	5024
09:30	Fractional flow reserve versus angiography for guiding PCI - 2 year outcome. FAME. – N.H.J. Pijls (Eindhoven, NL)	5025
09:40	Discussant. – T.F. Luescher (Zurich, CH)	5026
09:45	Survival in patients with heart failure and preserved versus impaired left ventricular ejection fraction: an individual patient data meta-analysis. – R. Doughty (Auckland, NZ)	5027
09:55	Discussant. – D.M. Kaye (Melbourne, AU)	5028

10:00 Coffee break (Moderated Posters)

HIGHLIGHT SESSION

Main Session

Chairperson(s): F.J. Pinto (Lisbon, PT); R. Ferrari (Ferrara, IT)



11:00	ESC Congress 2009 Awards.	5029
11:10	Basic science. – B. Casadei (Oxford, GB)	5030
11:21	Hypertension and risk factors. – R. Fagard (Leuven, BE)	5031
11:32	Imaging. – F.E. Rademakers (Leuven, BE)	5032
11:43	Arrhythmias. – P.E. Vardas (Heraklion, GR)	5033
11:54	Acute coronary syndromes. – K.A.A. Fox (Edinburgh, GB)	5034
12:05	Interventional cardiology. – C. Di Mario (London, GB)	5035
12:16	Valvular heart disease. – R. Rosenhek (Vienna, AT)	5036
12:27	Heart failure and cardiomyopathies. – M. Metra (Brescia, IT)	5037
12:38	Prevention. – J. Perk (Oskarshamn, SE)	5038

12:50 End of Congress

**STATE OF THE ART –
HEART FAILURE ... INEVITABLY FATAL?**

Featured Research

Chairperson(s): J.G.F. Cleland (Kingston upon Hull, GB); M. Jessup (Philadelphia, US)

- 08:30 **Low risk of arrhythmic events in dystrophin genotyped patients with dilated cardiomyopathy.** 5039
 – M. Diegoli, A. Serio, M. Pasotti, F.I. Gambarin, M. Grasso, N. Marziliano, E. Porcu, P. Cassini, C. Campana, E. Arbustini (Pavia, IT)
- 08:45 **Recovery from pregnancy related heart failure: peripartum cardiomyopathy (PPCM).** 5040
 – L. Christie (Eugene, US)
- 09:00 **Predictors of outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in heart failure with preserved ejection fraction trial (I-PRESERVE).** 5041
 – P.E. Carson, M. Komajda, M.R. Zile, R. Mckelvie, J.J. McMurray, S. Hetzel, D. Demets, C. Staiger, A. Ptaszynska, B.M. Massie (Washington, Charleston, Madison, Bridgewater, Princeton and San Francisco, US; Paris, FR; Hamilton, CA; Glasgow, GB)
- 09:15 **Diastolic versus systolic left ventricular dysfunction as independent predictors for unfavourable postoperative evolution in patients with aortic regurgitation undergoing aortic valve replacement.** 5042
 – L. Iliuta, H. Moldovan, D. Filipescu, B. Radulescu, A. Vasilescu (Bucharest, RO)
- 09:30 **State of the Art - Heart failure ... inevitably fatal?** 5043
 – J.G.F. Cleland (Kingston upon Hull, GB)

10:00 Coffee break (Moderated Posters)

REASSESSING THERAPEUTIC STRATEGIES IN HEART FAILURE

Abstracts

Chairperson(s): C. O'Connor (Durham, US); A.P. Maggioni (Florence, IT)

- 11:00 **Effects of rosuvastatin and allopurinol administration on endothelial progenitor cells in patients with chronic heart failure.** 5044
 – I. Andreou, D. Tousoulis, C. Papadimitriou, C. Tentolouris, A. Bamias, M. Tsiatas, G. Siasos, M.A. Dimopoulos, C. Stefanadis (Athens, GR)
- 11:15 **Renin-angiotensin system inhibition and reduction in all-cause mortality in hospitalized elderly diastolic heart failure patients with chronic kidney disease: a propensity-matched study.** 5045
 – A. Ahmed, R.M. Allman, I. Aban, P.W. Sanders, L.J. Dell'italia, D. Arnett, T.E. Love, M.W. Rich, G.L. Bakris (Birmingham, Cleveland, St. Louis and Chicago, US)
- 11:30 **Impact of off-label utilization of Ivabradine on exercise capacity and gas exchange in patients with ischaemic chronic heart failure.** 5046
 – F.M. Sarullo, D. Guttilla, G. Fazio, S. Paterna, P. Di Pasquale, A. Castello (Palermo, IT)
- 11:45 **Eplerenone favourably alters collagen metabolism in diastolic heart failure.** 5047
 – G. Mak, M. Ledwidge, N.F. Murphy, D. Phelan, I. Dawkins, C. Watson, J. Baugh, K. McDonald (Dublin, IE)
- 12:00 **Higher dose of perindopril improves diastolic function in patients with diastolic heart failure due to decreased compliance.** 5048
 – K.G. Adamyan, A.L. Chilingaryan, A.V. Astvatsatryan (Yerevan, AM)
- 12:15 **Mode of death in patients with heart failure and a preserved ejection fraction: results from irbesartan heart failure with preserved ejection fraction study (I-Preserve) trial.** 5049
 – M.R. Zile, W.H. Gaasch, I. Anand, M. Haass, W.C. Little, A. Miller, J. Lopez-Sendon, J.R. Teerlink, M. White, P.E. Carson (Charleston, Burlington, Minneapolis, Winston-Salem, Jacksonville, San Francisco and Washington, US; Mannheim, DE; Madrid, ES; Montreal, CA)

12:50 End of Congress



**ELECTRICAL AND FUNCTIONAL MYOCARDIAL
REMODELLING**

Abstracts

Chairperson(s): S.E. Harding (London, GB); H.-R. Neuberger (Homburg, DE)

- 08:30 **Importance of circulating IGF-I for normal cardiac function, morphology and postinfarction remodeling.** 5050
– E. Omerovic, M. Lindbom, T. Ramunddal, M. Scharin Tang, C. Ohlsson (Gothenburg, SE)
- 08:45 **Elevated cytosolic [Na⁺] increases mitochondrial formation of reactive oxygen species during excitation-contraction coupling in failing cardiac myocytes.** 5051
– M. Kohlhaas, A. Knopp, T. Zeller, T. Liu, B. O'Rourke, M. Bohm, C. Maack (Homburg, DE; Baltimore, US)
- 09:00 **Electrophysiological remodeling in post-myocardial infarcted rats: focus on f-current and heart rate.** 5052
– S. Suffredini, S. Stillitano, S. Brogioni, L. Comini, C. Ceconi, L. Sartiani, M. Bouly, R. Ferrari, A. Mugelli, E. Cerbai (Florence, Gussago and Ferrara, IT; Courbevoie, FR)
- 09:15 **Endurance training improve cardiomyocyte function, restore calcium handling and reduce diastolic calcium leak in cardiomyocytes from mice with transgenic overexpression of CaMKII.** 5053
– M. Hoydal, T. Stolen, L. Maier, G.L. Smith, U. Wisloff (Trondheim, NO; Gottingen, DE; Glasgow, GB)
- 09:30 **Atorvastatin prevents left ventricular systolic dysfunction in a model of septic cardiomyopathy induced by exogenous interleukin-1 beta.** 5054
– R. Robati, B.W. Van Tassel, F.N. Salloum, I.M. Seropian, A. Varma, A. Abbate (Richmond, US)
- 09:45 **Cardiomyocyte-specific deletion of the mineralocorticoid receptor protects against cardiac dilatation and dysfunction after myocardial infarction.** 5055
– J. Bauersachs, D. Fraccarollo, P. Galuppo, L. Hein, C. Dienesch, B. Bayer, G. Schuetz, S. Frantz, S. Berger, G. Ertl (Wurzburg, Freiburg and Heidelberg, DE)

10:00 Coffee break (Moderated Posters)

HEART FAILURE: A SYSTEMIC DISEASE?

Abstracts

Chairperson(s): M. Kearney (Leeds, GB); B.M. Pieske (Graz, AT)

- 11:00 **The role of essential amino acid supplementation in chronic heart failure.** 5056
– A. Macchi, I. Franzoni, F. Buzzetti, M.C. Pedrighi, I. Rosa, G. Gaudio, A. Margonato (Milan, IT)
- 11:15 **Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy secondary to variant transthyretin (Ala60).** 5057
– P. Sattianayagam, S.D.J. Gibbs, C. Waterworth, M. De Cruz, B. Pawarova, D. Rowcenzio, H.J. Lachmann, A. Wechalekar, P.N. Hawkins, J.D. Gillmore (London, GB)
- 11:30 **Elevated muscle proteasome activity in chronic heart failure - a fluent transition to cachectic disease state?** 5058
– T. Szabo, A. Sandek, A. Hartmann, J. Springer, S. Von Haehling, V. Adams, S.D. Anker, W. Doehner (Berlin and Leipzig, DE)
- 11:45 **Impaired heart rate response to exercise and recovery in men with systolic chronic heart failure.** 5059
– B. Krakowiak, A. Rydlewska, W. Banasiak, E.A. Jankowska, P. Ponikowski (Wroclaw, PL)
- 12:00 **Natural history of preclinical diastolic dysfunction to the development of heart failure symptoms.** 5060
– H. Chen, D. Correa De Sa, J. Slusser, D. Hodge (Rochester Mn, US)
- 12:15 **The impact of heart failure with preserved or reduced left ventricular ejection fraction on 30-day and long-term cardiac outcome of vascular surgery patients.** 5061
– W.J. Flu, J.P. Van Kuijk, S.E. Hoeks, R. Kuijper, O. Schouten, T.A. Winkel, D. Goei, Y.R.B.M. Van Gestel, J.J. Bax, D. Poldermans (Rotterdam and Leiden, NL)

12:50 End of Congress

CARDIAC RESYNCHRONISATION THERAPY: ADDRESSING THE CHALLENGES

Abstracts

Chairperson(s): V. Conraads (Edegem, BE); M. Gasparini (Rozzano, IT)

- 08:30 **Left ventricular only pacing is at least as good as biventricular pacing according to both intention to treat and per protocol analysis of the double-blind B-LEFT HF trial.** **5062**
 – G. Boriani, W. Kranig, E. Donal, L. Calo, P. Zecchi, N. Delarche, I.F. Lozano, G. Ansalone, E. Boulogne, C. Leclercq (Bologna and Rome, IT; Bad Rothenfelde, DE; Rennes and Pau, FR; Madrid, ES; Zaventem, BE)
- 08:45 **Biventricular or left ventricular only pacing for cardiac resynchronization therapy: echocardiographic results of the double-blind randomized B-LEFT HF study.** **5063**
 – G. Ansalone, G. Boriani, W. Kranig, E. Donal, L. Calo, M. Casella, N. Delarche, I. Lozano, E. Boulogne, C. Leclercq (Rome and Bologna, IT; Bad Rothenfelde, DE; Rennes and Pau, FR; Madrid, ES; Zaventem, BE)
- 09:00 **Subphoid pericardioscopic positioning of pacemaker leads and subsequent four chamber stimulation.** **5064**
 – N. Hatam, G. Dohmen, M. Schmid, J. Sachweh, R. Autschbach, J. Spillner (Aachen, DE)
- 09:15 **Anatomical variants of coronary venous system.** **5065**
 – R. Mlynarski, A. Wlodyka, J. Brzoska, W. Kargul, M. Sosnowski (Katowice, PL)
- 09:30 **Localization of coronary sinus ostium by identification of radiolucent area within cardiac silhouette at routine RAO coronary angiography projection.** **5066**
 – A. Anic, A. Jovic, Z. Bakotic, D. Nekic (Zadar, HR)
- 09:45 **Detection of the site of latest mechanical contraction in patients scheduled for cardiac resynchronization therapy using four echocardiographic methods.** **5067**
 – J. Klimusina, F. Faletta, C. Conca, A. Evangelista, F. Regoli, M. Averaimo, E. Pasotti, G. Pedrazzini, T. Moccetti, A. Auricchio (Lugano, CH)

10:00 Coffee break (Moderated Posters)

INCREASING SAFETY FOR PATIENTS AND OPERATORS DURING CORONARY ANGIOPLASTY

Abstracts

Chairperson(s): S. James (Uppsala, SE); A. Mehta (Mumbai, IN)

- 11:00 **Cataracts in interventional cardiology personnel. Retrospective evaluation study of lens injuries and dose (RELID Study).** **5068**
 – A.D. Duran, G.D. Duran, R.R. Ramirez, E.V. Vano, N.K. Kleinman, D.E. Echeverri, G.G. Gomez, M.C. Cabrera (Montevideo, UY; Bogota, CO)
- 11:15 **Marked reduction of operator radiation exposure by using a patient lead cover during coronary angiography or percutaneous intervention.** **5069**
 – B. Radulescu, P. Bouyer, L. Mertz, O. Morel, S. Le Dret, M. Zupan, F. Bronner, A. Constantinesco, P. Ohlmann (Strasbourg, FR)
- 11:30 **Myocardial injury following Coronary Artery bypass Surgery compared with percutaneous coronary Angioplasty (MICASA) trial. A randomised controlled trial using magnetic resonance imaging.** **5070**
 – W.J. Van Gaal, R. Arnold, L. Testa, C.C.S. Lim, F.A. Ponnuthurai, T. Karamitsos, J. Selvanayagam, S. Westaby, S. Neubauer, A.P. Banning (Oxford, GB)
- 11:45 **Correlation between cardiac markers elevation and major adverse cardiac events in 3900 consecutive patients following PCI. Impact of new post-procedural myocardial infarction definition.** **5071**
 – S. Galli, M. Villa, P. Montorsi, P. Ravagnani, F. Fabbiochi, D. Trabattoni, A. Lualdi, C. Rossetti, C. Fiorentini, A.L. Bartorelli (Milan, IT)
- 12:00 **Hospital mortality is unrelated to procedural volume in elective and emergency PCI: analysis of complete nationwide reporting.** **5072**
 – A. Vogt, S. Hahn, O. Boy (Kassel and Dusseldorf, DE)
- 12:15 **Are neurologic complications following percutaneous coronary diagnostic or interventions more common in transfemoral versus transradial approach?** **5073**
 – H. Tizon Marcos, G.R. Barbeau, L. Roy, O. Gleeton, J.R. Boudreault, G.R. Proulx, J.P. Dery, O. Bertrand, C.M. Nguyen, R. Delarochelliere (Quebec, CA)

12:50 End of Congress



ACUTE HEART FAILURE: MARKERS AND MECHANISMS

Abstracts

Chairperson(s): H.P. Brunner-La Rocca (Basel, CH); G. Jondeau (Paris, FR)

- 08:30 **Prevalence, characteristics and outcomes of patients presenting with cardiogenic unilateral pulmonary oedema.** 5074
 – D. Attias, N. Mansencal, B. Auvert, A. Vieillard-Baron, A. Delos, P. Lacombe, R. Ngetta, F. Jardin, O. Dubourg (Boulogne, FR)
- 08:45 **Combined measurement of a novel virtual analyte NT-proXNP and pro-inflammatory cytokines in the prognostic evaluation of patients with acute decompensated heart failure.** 5075
 – K. Miettinen, J. Magga, O. Vuolteenaho, J. Lassus, V.P. Harjola, K. Siirila-Waris, K.R. Punnonen, M.S. Nieminen, K.J. Peuhkurinen (Kuopio, Oulu and Helsinki, FI)
- 09:00 **Bilirubin is an independent predictor of mortality in patients with left ventricular systolic dysfunction following acute myocardial infarction.** 5076
 – N. Valeur, C. Andersson, M. Schou, F. Gustafsson, C. Torp-Pedersen, L. Kober (Gentofte, Hillerod and Copenhagen, DK)
- 09:15 **Relation between NT-proBNP plasma level changes and dosage of diuretic therapy in patients with acute or decompensated heart failure.** 5077
 – F.A. Gabrielli, R. Natali, E. De Marco, M. Savino, M. Lotrionte, B. Garramone, G. Comerci, F. Loperfido (Rome, IT)
- 09:30 **Incremental prognostic value of myeloperoxidase in patients with acute decompensated heart failure.** 5078
 – T. Reichlin, M. Potocki, T. Breidhardt, M. Noveanu, T.H. Socrates, R. Twerenbold, C. Stelzig, S. Biedert, M. Freese, C.H. Mueller (Basel, CH)
- 09:45 **Survival by intravenous treatment in acute heart failure using propensity scoring in the international ALARM-HF study.** 5079
 – A. Mebazaa, J. Parissis, R. Porcher, E. Gayat, F. Vilas Boas, J.F. Delgado, F. Follath (Paris, FR; Athens, GR; Salvador De Bahia, BR; Barcelona, ES; Zurich, CH)

10:00 Coffee break (Moderated Posters)



HEART FAILURE PROGNOSTIC FACTORS: WHAT'S NEW?

Abstracts

Chairperson(s): K. McDonald (Dublin, IE); M.C. Fonseca (Oeiras, PT)

- 11:00 **Cardiac outcome in nonischemic cardiomyopathy is predicted by Late gadolinium enhancement cardiovascular magnetic resonance regardless baseline ejection fraction.** 5080
 – F. Ridocci Soriano, A. Valle, J. Estornell, C.J. Soriano, R. Romaguera, E. Lucas, J. Perez, J. Restrepo, N. Martinez, R. Paya (Valencia and Xativa, ES)
- 11:15 **Prevalence & prognostic importance of micro- & macro-albuminuria in heart failure- an analysis from the Candesartan in Heart failure:Assessment of Reduction in Mortality and morbidity (CHARM) Programme.** 5081
 – C.E. Jackson, S.D. Solomon, H.C. Gerstein, S. Andersson, E.L. Michelson, C.B. Granger, K. Swedberg, M.A. Pfeffer, S. Yusuf, J.J.V. McMurray (Glasgow, GB; Boston, Wilmington and Durham, US; Ontario, CA; Molndal and Gothenburg, SE)
- 11:30 **Cause-specific death and long-term prognosis in heart failure: the interdisciplinary network heart failure registry wurzburg.** 5082
 – S. Stork, S. Guentner, G. Gueder, M. Hanke, H.W. Hense, G. Ertl, C.E. Angermann (Wurzburg and Munster, DE)
- 11:45 **COPD predicts mortality in CHF: the Norwegian Heart Failure Registry.** 5083
 – J. De Blois, S. Simard, D. Atar, S. Agewall (Quebec, CA; Oslo, NO)
- 12:00 **Predictors of early readmission or death in elderly patients with heart failure.** 5084
 – S. Muzzarelli, G. Leibundgut, D. Tobler, U. Jeker, F. Nietlisbach, M. Pfisterer, F. Follath, D. Burckhardt, W. Kiowski, H.P. Brunner La-Rocca (Basel, Lucerne and Zurich, CH)
- 12:15 **Predictive role of QRS duration in patients with chronic heart failure. Data from the GISSI-HF trial.** 5085
 – S. Baldasseroni, K.N. Jones, P. Mida, R. Latini, R. Urso, M.G. Franzosi, L. Tavazzi, A.P. Maggioni (Florence, Seregno, Genzano di Roma, Milan and Cotignola, IT)

12:50 End of Congress

STATE OF THE ART – IMAGING BEYOND CORONARY ARTERY STENOSIS **Featured Research**

Chairperson(s): V. Fuster (New York, US); J.-L. Vanoverschelde (Brussels, BE)

- 08:30 **The predictive role of arterial age calculated with the use of coronary artery calcium score on mortality rates in asymptomatic individuals.** **5086**
 – L. Shaw, N. Alexopoulos, M. Budoff, S.T. Liu, D. Chow, P.H. Tseng, F. Flores, A. Stillman, P. Raggi (Atlanta and Torrance, US)
- 08:45 **Diagnostic value of perfusion-CMR in patients with angina pectoris but normal coronary angiograms assessed by intracoronary acetylcholine-testing.** **5087**
 – A. Yilmaz, H. Mahrholdt, A. Athanasiadis, P. Ong, M. Voehringer, U. Sechtem (Stuttgart, DE)
- 09:00 **Strain and strain rate predict outcome in patients with acute myocardial infarction.** **5088**
 – M.L. Antoni, S.A. Mollema, V. Delgado, J.Z. Atary, E. Boersma, E.R. Holman, E.E. Van Der Wall, M.J. Schalij, J.J. Bax (Leiden and Rotterdam, NL)
- 09:15 **Prognostic value of cardiac sympathetic nerve activity evaluated by 123I-metaiodobenzylguanidine imaging in patients with ST-segment elevation myocardial infarction.** **5089**
 – S. Kasama, S. Ichikawa, M. Kurabayashi (Gunma, JP)
- 09:30 **State of the Art - Imaging beyond coronary artery stenosis.** **5090**
 – V. Fuster (New York, US)

10:00 Coffee break (Moderated Posters)

NEW INSIGHTS INTO VENTRICULAR FUNCTION: THE ADDED VALUE OF ECHO **Abstracts**

Chairperson(s): C. Zito (Catona, IT); B.A. Popescu (Bucharest, RO)

- 11:00 **Left ventricular strain and strain rate: characterisation of the effect of load and relation with invasive indices of cardiac function in human subjects.** **5091**
 – A.T. Burns, A. Lagerche, D. Prior, A. Macisaac (Melbourne, AU)
- 11:15 **Effect of aging on left ventricular mechanical parameters assessed by real-time 3D echocardiography.** **5092**
 – M. Takeuchi, K. Kaku, K. Otani, H. Nakai, N. Haruki, H. Yoshitani, Y. Otsuji, R.M. Lang (Kitakyushu, JP; Chicago, US)
- 11:30 **Variability in the assessment of left ventricular function by echocardiography between centers in elderly heart failure patients.** **5093**
 – B.A. Kaufmann, S.Y. Min, R. Zakher, U. Oswald, R. Fahrner, M. Paul, S. Suter, A. Bernheim, M.E. Pfisterer, H.P. Brunner-La Rocca (Basel, Wolhusen, Chur, Aarau and Berne, CH)
- 11:45 **Left ventricular rotational mechanics in acute myocardial infarction and in chronic (ischemic and non-ischemic) heart failure patients.** **5094**
 – M. Bertini, G. Nucifora, N. Ajmone Marsan, V. Delgado, R.J. Van Bommel, G. Boriani, M. Biffi, E.E. Van Der Wall, M.J. Schalij, J.J. Bax (Leiden, NL; Bologna, IT)
- 12:00 **Left ventricular twists mechanics in patients with apical hypertrophic cardiomyopathy: assessment with 2D speckle tracking echocardiography.** **5095**
 – S.-A. Chang, H.-K. Kim, Y.-J. Kim, D.-W. Sohn (Seoul, KR)
- 12:15 **Real-time three dimensional echocardiography and pulsed wave tissue Doppler echocardiography in assessment of right ventricular function in acute phase of right ventricular infarction.** **5096**
 – M. Kidawa, J.D. Kasprzak, M. Plewka, M. Krzeminska-Pakula (Lodz, PL)

12:50 End of Congress

CATHETER ABLATION FOR NON ATRIAL FIBRILLATION PATIENTS. SPECIAL GROUPS, SPECIAL CONCERNS

Abstracts

Chairperson(s): G. Theodorakis (Athens, GR); S. Ernst (London, GB)

- 08:30 **Epicardial ablation of ventricular tachycardia (VT) - a multicentric safety study.** **5097**
 – A. Jadidi, F. Sacher, D. Steven, P. Maury, U. Tedrow, K. Roberts-Thomson, M. Hocini, M. Haissaguerre, P. Jais, W. Stevenson (Bordeaux and Toulouse, FR; Boston, US)
- 08:45 **Atrial tachycardia after surgical repair of congenital heart disease:3D-electroanatomic mapping identifies the right atrial free wall as the main site of the mid-diastolic isthmus or the ectopic focus.** **5098**
 – F. Drago, M.S. Russo, M.S. Silvetti (Rome, IT)
- 09:00 **Gastroparesia as a frequent complication after extensive left atrial ablation for atrial arrhythmias.** **5099**
 – B. Godin, A. Milhem, A. Savoure, G. Savoye, S. Hommel, S. Leclaire, M. Antonietti, F. Anselme (Rouen, FR)
- 09:15 **Catheter ablation of idiopathic right and left ventricular outflow tract tachycardia.** **5100**
 – I. Deisenhofer, D. Kogler, S. Tzeis, J. Wu, S. Fichtner, M.R. Karch, G. Hessling (Munich, DE)
- 09:30 **Catheter ablation of atypical left atrial flutters in patients with prosthetic mitral valve: safety, acute success and long term outcome.** **5101**
 – L. Di Biase, G. Spadacini, P. Moretti, M. Tritto (Austin, US; Castellanza, IT)
- 09:45 **Acute effectiveness of radiofrequency catheter ablation during ventricular tachycardia without prior pacing manoeuvres using substrate-based information.** **5102**
 – E. Gonzalez Torrecilla, J. Almendral, A. Arenal, F. Atienza, L.F. Atea, D. Calvo, C. Hadid, M. Pachon, F. Fernandez-Aviles (Madrid, ES)

10:00 Coffee break (Moderated Posters)

ARE THERE ANY MARKERS FOR ATRIAL FIBRILLATION RECURRENCE?

Abstracts

Chairperson(s): D. Cavaco (Lisbon, PT); F.K. Triposkiadis (Larissa, GR)

- 11:00 **Association between inflammation markers and recurrence of atrial fibrillation after successful cardioversion.** **5103**
 – S. Grigoryan, K.G. Adamyan, L.G. Hazarapetyan (Yerevan, AM)
- 11:15 **Low plasma apelin levels predict arrhythmia recurrence in patients with persistent atrial fibrillation.** **5104**
 – M.P. Buzzi, R. Rordorf, A. D'Angelo, S. Schirinzi, S. Lucibello, M. Gritti, M. Landolina, C. Storti, C. Falcone (Pavia, IT)
- 11:30 **Effects of enalapril, irbesartan, and angiotensin-(1-7) on long-term atrial tachycardia-induced ionic remodeling in dogs.** **5105**
 – E. Liu, Z.H. Xu, J. Li, S.H. Yang, W. Yang, G. Li (Tianjin, CN)
- 11:45 **Can non-inducibility after cardioversion of organized atrial tachycardia (AT) or atypical flutter (AFL) be predictable factor of recurrence after atrial fibrillation (AF) ablation?** **5106**
 – Y.S. Oh, C.Y.S. Choi, S.W.S. Shin, K.J.H. Kim, J.S.W. Jin, Y.H.J. Youn, L.M.Y. Lee, J.W.S. Jung, S.K.B. Seung, R.T.H. Rho (Seoul, KP)
- 12:00 **Can we predict the atrial arrhythmia recurrences in patients undergoing robotically-guided catheter ablation of paroxysmal atrial fibrillation?** **5107**
 – P. Hlavak, H. Mlcochova, P. Peichl, R. Chihak, D. Wichterle, J. Kautzner (Prague, CZ)
- 12:15 **Predictive value of Nt-proBNP levels and body mass index for recurrence of atrial fibrillation after successful cardioversion.** **5108**
 – M. Freynhofer, R. Jarai, K. Aydinkoc, T. Hoechtl, I. Brozovic, P. Smetana, B. Vogel, V. Bruno, A. Geppert, K. Huber (Vienna, AT)

12:50 End of Congress

STATE OF THE ART – ASSESSING RISK IN ST ELEVATION INFARCTION: FROM GENES TO CLINICAL SCORES **Featured Research**

Chairperson(s): F. Van de Werf (Leuven, BE); F. Crea (Rome, IT)

- 08:30 **Influence of Variations of secretory PLA2-IIa gene on sPLA2 activity and one-year clinical outcome in patients with AMI. Results from FAST-MI registry.** **5109**
 – T. Simon, N. Danchin, S. Kotti-Tounsi, J. Benessiano, G. Lambreau, C. Verstuyft, G. Steg, P.H. Bonnet, A. Tedgui, Z. Mallat (Paris, Sophia-Antipolis, Kremlin-Bicetre and Le Havre, FR)
- 08:45 **Long-term impact of plaque colour by angiographic evaluation on clinical outcomes in patients with acute myocardial infarction.** **5110**
 – K. Saratani, Y. Iwanaga, T. Hayashi, S. Miyazaki (Osakasayama, JP)
- 09:00 **Mortality benefit of primary PCI over thrombolysis in STEMI patients: impact of baseline risk profile and implications for non-PCI centres.** **5111**
 – M.J. Claeys, A. De Meester, C. Convens, P. Dubois, J. Boland, P. Vranckx, P. Sinnaeve, P. Coussement, P. Evrard, H. De Raedt (Antwerp, Jolimont, Charleroi, Liège, Hasselt, Leuven, Brugge, Mont-Godinne and Aalst, BE)
- 09:15 **Sum of ST-segment elevation best predicts microvascular obstruction in patients successfully treated with primary percutaneous coronary intervention - a cardiovascular magnetic resonance study.** **5112**
 – O. Husser, V. Bodi, J. Sanchis, J. Nunez, L. Mainar, E. Rumiz, M.P. Lopez-Lereu, J.V. Monmeneu, F.J. Chorro, A. Llacer (Valencia, ES)
- 09:30 **State of the Art - Assessing risk in ST elevation infarction: from genes to clinical scores.** **5113**
 – F. Van de Werf (Leuven, BE)

10:00 Coffee break (Moderated Posters)

NEW CHALLENGES FOR ANTIPLATELET TREATMENT

Abstracts

Chairperson(s): R.F. Storey (Sheffield, GB); L. Badimon (Barcelona, ES)

- 11:00 **Impact of concomitant oral anticoagulation with a coumarine derivate on the antiplatelet effects of clopidogrel.** **5114**
 – D. Sibbing, T. Morath, J. Stegherr, S. Braun, W. Vogt, M. Hadamitzky, A. Schomig, A. Kastrati, N. Von Beckerath (Munich, DE)
- 11:15 **The clopidogrel-insensitive pool of P2Y12 receptors exposed upon platelet activation contributes to thrombus formation and can be blocked by elinogrel, a direct acting, reversible P2Y12 inhibitor.** **5115**
 – H. Haberstock-Debic, P. Andre, S. Delaney, S. Mills, Y. Pak, D. Phillips, P. Conley (South San Francisco, US)
- 11:30 **Antiplatelet effect of clopidogrel after selective dose-adjustment in a large cohort of patients following percutaneous coronary intervention with stent implantation.** **5116**
 – D. Trenk, W. Hochholzer, S. Leggewie, M. Cap, C.M. Valina, C. Stratz, H.-P. Bestehorn, H.-J. Buettner, F.-J. Neumann (Bad Krozingen, DE; Basel, CH)
- 11:45 **Adrenergic receptor polymorphisms modulate platelet reactivity after treatment with clopidogrel in acute coronary syndrome.** **5117**
 – T. Cuisset, M. Hamilos, L. Delrue, C. Frere, K. Verhamme, J. Bartunek, J.L. Bonnet, M. Eijgelshem, M.C. Alessi, E. Barbato (Marseille, FR; Aalst, BE; Rotterdam, NL)
- 12:00 **An interaction between glycation and acetylation may be one mechanism for the reduced clinical efficacy of aspirin in individuals with diabetes.** **5118**
 – R.A. Ajan, K.F. Standeven, S. Mughal, F. Phoenix, R.A.S. Ariens, P.J. Grant (Leeds, GB)
- 12:15 **Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel non responders: a prospective, randomized study.** **5119**
 – T. Cuisset, C. Frere, J. Quilici, L. Bali, R. Poyet, P. Morange, M.C. Alessi, J.L. Bonnet (Marseille, FR)

12:50 End of Congress

STATE OF THE ART – GENETICS IN THE ELECTRICAL ARENA **Featured Research**

Chairperson(s): P. Brugada Terradellas (Brussels, BE); G. Breithardt (Munster, DE)

- 08:30 **Long-term prognosis of patients diagnosed with Brugada syndrome: Results from the FINGER Brugada registry.** **5120**
 – V. Probst, C. Veltmann, L. Eckardt, P.G. Meregalli, F. Gaita, F. Sacher, P. Mabo, H. Le Marec, C. Wolpert, A. Wilde (Nantes, Pessac and Rennes, FR; Mannheim and Munster, DE; Amsterdam, NL; Turin, IT)
- 08:45 **Role of genetic testing in risk stratification of brugada syndrome.** **5121**
 – B. Benito, O. Campuzano, R. Ishac, A. Iglesias, M.J. Junttila, J. Michaud, J. Brugada, P. Brugada, R. Brugada (Montreal, CA; Girona and Barcelona, ES; Oulu, FI; Brussels, BE)
- 09:00 **Early repolarization syndrome: identification of a malignant form in a large French family.** **5122**
 – V. Probst, S. Le Scouarnec, D. Pavin, F. Kyndt, F. Sacher, J.J. Schott, H. Le Marec, M. Haissaguerre, P. Mabo (Nantes, Rennes and Pessac, FR)
- 09:15 **Efficacy of ICD therapy in a highly malignant SCN5A mutation causing the Brugada and Long QT phenotype.** **5123**
 – C. Veltmann, R. Schimpf, F. Streitner, J. Kuschyk, M. Borggreffe, C. Wolpert (Mannheim, DE)
- 09:30 **State of the Art - Genetics in the electrical arena.** **5124**
 – P. Brugada Terradellas (Brussels, BE)

10:00 Coffee break (Moderated Posters)

CARDIAC RESYNCHRONISATION THERAPY: HOW TO IMPROVE PATIENTS' SELECTION **Abstracts**

Chairperson(s): A. Auricchio (Lugano, CH); E. Goncalvesova (Bratislava, SK)

- 11:00 **Determinants of long-term outcome in ischemic heart failure patients treated with cardiac resynchronization therapy.** **5125**
 – V. Delgado, R.J. Van Bommel, M. Bertini, N. Ajmone Marsan, C.J.W. Borleffs, G. Nucifora, C. Ypenburg, E.R. Holman, M.J. Schalij, J.J. Bax (Leiden, NL)
- 11:15 **Prognostic value of charlson comorbidity index in heart failure patients with cardiac resynchronization therapy devices with defibrillator functions (CRT-D).** **5126**
 – D.A.M.J. Theuns, B.A. Schaer, O.I.I. Soliman, D. Altmann, T. Szili-Torok, S. Osswald, L. Jordaens (Rotterdam, NL; Basel, CH)
- 11:30 **Evaluation of heart rate deceleration after exercise can improve patient selection for CRT.** **5127**
 – D. Thomas, S.A. Exton, Z.R. Yousef (Cardiff, GB)
- 11:45 **Functional mitral regurgitation: the importance of left ventricular geometry and its repercussion on clinical outcome after combined resynchronization and cardioverter defibrillator.** **5128**
 – F. Cabrera Bueno, M.J. Molina-Mora, M. Jimenez-Navarro, J.J. Gomez-Doblas, J. Alzueta, J. Pena-Hernandez, A. Barrera, E. De Teresa (Malaga, ES)
- 12:00 **Clinical characteristics of patients with complete recovery from severe cardiac dysfunction after cardiac resynchronization therapy.** **5129**
 – K. Imamura, K. Okajima, A. Shimane, G. Kanda, T. Hayashi, Y. Taniguchi, S. Yamada, S. Iwata, K. Matsumoto, T. Kajiya (Himeji, JP)
- 12:15 **Relationship between scar tissue and pacing site in conditioning response to cardiac resynchronization therapy in ischemic heart failure.** **5130**
 – A. Dal Monte, C. Pratola, E. Agricola, M. Galderisi, F. Rigo, R. Citro, P. Della Valentina, A. Calabrese, D. Mele, R. Ferrari (Ferrara, Milan, Naples, Mestre-Venezia and Vallo Della Lucania, IT)

12:50 End of Congress



THE METABOLIC SIDE OF CARDIOVASCULAR DISEASE

Abstracts

Chairperson(s): J.L. Balligand (Brussels, BE); W. Doehner (Berlin, DE)

- 08:30 **Metabolic control of myocardial function and the role of glucose transporters.** 5131
 – D. Von Lewinski, R. Gasser, P. Rainer, B. Wilhelm, U. Roessler, T. Haas, A. Wasler, M. Grimm, E. Bisping, B. Pieske (Graz and Vienna, AT; Göttingen and Darmstadt, DE)
- 08:45 **Different mechanisms of skeletal and myocardial insulin resistance in the diabetic and failing heart.** 5132
 – C. Kleinert, A. Varela-Carver, S.A. Cook, T. Matsui, S. Das, O.E. Rimoldi, A. Rosenzweig, P.G. Camici (London, GB; Boston, US)
- 09:00 **Diabetes mellitus activates signal transduction pathways in multiple ways: basis for VEGF resistance of human monocytes.** 5133
 – V. Tchaikovski, F.-D. Boehmer, J. Waltenberger (Maastricht, NL; Jena, DE)
- 09:15 **Lipolysis and uncoupling protein 1(UCP1) expression in human visceral adipocytes are induced by neбиволol but not by other beta1 blockers.** 5134
 – R. Sarzani, M. Bordicchia, L. Scappini, P. Marcucci, W. Siquini, A. Fianchini, P. Dessi-Fulgheri, A. Rappelli (Ancona, IT)
- 09:30 **High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes.** 5135
 – B. Kingwell, B.G. Drew, S.J. Duffy, M.F. Formosa, A.K. Natoli, J.M. Forbes, D.M. Kaye, B.E. Kemp, D. Sviridov, G.R. Steinberg (Melbourne, AU)
- 09:45 **Effects of diabetes mellitus on adiponectin synthesis in subcutaneous, pericardial and femoral adipose tissue in patients with coronary atherosclerosis.** 5136
 – C. Bakogiannis, C. Antoniadis, D. Tousoulis, A.S. Antonopoulos, A. Miliou, G. Ekonomopoulos, G. Triantafyllou, D. Lymperiadis, C. Psaros, C. Stefanadis (Athens, GR)

10:00 Coffee break (Moderated Posters)



OUTER AND INNER PATHS TO MYOCARDIAL PROTECTION

Abstracts

Chairperson(s): To be announced; D. Garcia-Dorado Garcia (Barcelona, ES)

- 11:00 **Transforming growth factor beta and insulin-like growth factor one play a key role in the beneficial paracrine effects of endothelial progenitor cells in myocardial salvage post infarction.** 5137
 – B. Hynes, A.K.H.S. Kumar, S. Weiss, J. Schmeckpeper, K. Martin, N.M. Caplice (Cork, IE)
- 11:15 **Human fetal mesenchymal stem cells protect cardiac myocytes against hypoxia/reoxygenation injury.** 5138
 – P. Danieli, E. Cervio, C. Ciuffreda, M. Roccio, G. Viarengo, P.J. Schwartz, M. Gnechchi (Pavia, IT)
- 11:30 **The endothelial gap junction protein connexin40 protects against myocardial ischemia-reperfusion injury in mice.** 5139
 – S. Morel, V. Braunersreuther, I. Roth, C.E. Chadjichristos, C. De Wit, T.A.B. Van Veen, B.R. Kwak, F. Mach (Geneva, CH; Lubeck, DE; Utrecht, NL)
- 11:45 **Nrf2-dependent upregulation of antioxidative enzymes - a novel pathway for proteasome inhibitor-mediated cardioprotection.** 5140
 – H. Dreger, K. Westphal, A. Weller, G. Baumann, V. Stangl, S. Meiners, K. Stangl (Berlin, DE)
- 12:00 **Jak2-mediated cardioprotective signaling is impaired in diabetic hearts by AT1 receptor-mediated up-regulation of calcineurin.** 5141
 – T. Miura, H. Hotta, T. Miki, T. Yano, S. Ishikawa, K. Shimamoto (Sapporo, JP)
- 12:15 **Preischemic inhibition of the malate-aspartate shuttle induces cardioprotection and modulates glucose metabolism similar to ischemic precondition in isolated rat hearts.** 5142
 – N. Stottrup, B. Lofgren, J.M. Nielsen, S.B. Kristiansen, H.E. Botker, T.T. Nielsen (Aarhus, DK)

12:50 End of Congress

**CARDIOPROTECTION IN ACUTE CORONARY SYNDROMES: Abstracts
DOES IT WORK?**

Chairperson(s): To be announced; D.E. Deleanu (Bucharest, RO)

- 08:30 **Intravenous administration of immunoglobulin attenuates myocardial reperfusion injury and improves left ventricular remodeling.** 5143
– K. Ueno, T. Anzai, Y. Jo, K. Naito, T. Kohno, Y. Maekawa, T. Takahashi, T. Yoshikawa, S. Ogawa (Tokyo, JP)
- 08:45 **Staccato reperfusion improves myocardial microcirculatory function in patients undergoing coronary angioplasty. A myocardial contrast echocardiography study.** 5144
– I. Ikonomidis, E. Iliodromitis, I. Parakevaidis, S. Tzortzis, D. Farmakis, A. Antoniadis, K. Fountoulaki, D.T. Kremastinos (Athens, GR)
- 09:00 **Enhancement of the cardioprotective effect of remote ischemic postconditioning by morphine in primary percutaneous coronary interventions.** 5145
– I. Rentoukas, S. Dettferos, G. Giannopoulos, K. Tsarouchas, C. Kossyvakis, A. Antonakopoulos, I. Kaplanis, N. Kouvousis, V. Pyrgakis (Athens and Halkida, GR)
- 09:15 **Remote ischemic preconditioning in patients with STEMI: Impact on microvascular reperfusion evaluated by continuous ST-monitoring.** 5146
– C.J. Terkelsen, J.T. Soerensen, M.R. Schmidt, A.C. Christensen, K. Munk, N.H. Andersen, L. Thuesen, J.F. Lassen, T.T. Nielsen, H.E. Boetker (Aarhus, DK)
- 09:30 **Is postconditioning useless in acute myocardial infarction?** 5147
– M. Masotti, X. Freixa, N. Bellera, M. Jimenez, T. Caralt, J.T. Ortiz, C. Pare, S. Argiro, X. Bosch, A. Betriu (Barcelona, ES)
- 09:45 **Coronary collaterals reduce microvascular obstruction as assessed by MRI in patients with ST-segment elevation myocardial infarction treated by primary coronary intervention.** 5148
– S. Desch, I. Eitel, M. Sareban, G. Schuler, H. Thiele (Leipzig, DE)

10:00 Coffee break (Moderated Posters)

**REPERFUSION THERAPY IN ST-ELEVATION MYOCARDIAL Abstracts
INFARCTION – THE NEXT STAGE**

Chairperson(s): V. Kocka (Prague, CZ); H.E. Botker (Aarhus, DK)

- 11:00 **Patient- and organisation-dependent determinants of lack of reperfusion therapy in patients with STEMI. The FAST-MI registry data.** 5149
– N. Danchin, P. Goldstein, C. Boueux, H. Jambert, P.L. Michel, N. Delarche, J. Allal, G. Convert, J. Ferrieres, T. Simon (Paris, Lille, Perpignan, Libourne, Pau, Poitiers, Roanne and Toulouse, FR)
- 11:15 **Decreasing in-hospital mortality with increasing rate of early PCI in patients with ST elevation myocardial infarction complicated by cardiogenic shock. Results of the MITRA-plus registry.** 5150
– U. Zeymer, R. Zahn, A.K. Gitt, O. Koeth, C. Juenger, J. Senges (Ludwigshafen, DE)
- 11:30 **Use and impact of intra aortic balloon pump on outcome in patients with PCI for myocardial infarction complicated by cardiogenic shock. Results of the Euro Heart PCI survey.** 5151
– U. Zeymer, R. Zahn, A.K. Gitt, F. Weidinger, M. Hochadel, J. Marco (Ludwigshafen am Rhein, DE; Vienna, AT; Toulouse, FR)
- 11:45 **High-risk infarct patients derive greater mortality benefit from short door-to-balloon time.** 5152
– P.K. Kong, D.L. Connolly, C. Varma, G.Y.H. Lip, T. Millane, R.C. Davis, R.A. Ahmad (Birmingham, GB)
- 12:00 **Is the mortality benefit of primary PCI over thrombolysis also present in diabetic STEMI patients? A population study of STEMI patients.** 5153
– M.J. Claeys, A. De Meester, C. Convens, P. Dubois, J. Boland, P. Sinnaeve, B. Scott, S. Gevaert, C. Beauloye, M. Renard (Antwerp, Jolimont, Charleroi, Liège, Leuven, Brussels and Ghent, BE)
- 12:15 **Immediate angioplasty compared to standard therapy after thrombolysis for ST-elevation myocardial infarction in areas with very long transfers. Results of the NORDISTEMI study.** 5154
– E. Bohmer, P. Hoffmann, M. Abdelnoor, H. Arnesen, S. Halvorsen (Oslo, NO)

12:50 End of Congress

STATE OF THE ART – PERCUTANEOUS VALVE INTERVENTION. WHERE IS IT GOING?

Featured Research



Chairperson(s): O. Alfieri (Milan, IT); B. Lung (Paris, FR)

- 08:30 **Results of a strategy integrating transfemoral and transapical aortic valve implantation in high-risk patients with aortic stenosis.** 5155
 – D. Himbert, F. Descoutures, N. Al-Attar, B. Lung, G. Ducrocq, E. Brochet, D. Detaint, F. Francis, P. Nataf, A. Vahanian (Paris, FR)
- 08:45 **Transcatheter aortic valve implantation in patients with low Euroscore but presenting with anatomical or technical contraindications to conventional surgery.** 5156
 – M. Taramasso, F. Maisano, I. Michev, R.D. Covelto, E. Dorigo, P. Denti, O. Alfieri, A. Zangrillo, A. Colombo (Milan, IT)
- 09:00 **Initial experiences with a non-stented coronary sinus device for the treatment of functional mitral regurgitation: results of the PTOLEMY I feasibility trial.** 5157
 – S. Sack, P. Kahlert, R. Hoffmann, L. Bilodeau, L.A. Piérard, J. Bartunek, D. Marks, S.G. Ellis, R. Erbel (Munich, Essen and Aachen, DE; Montreal, CA; Liège and Aalst, BE; Milwaukee and Cleveland, US)
- 09:15 **Percutaneous treatment of the mitral regurgitation with the MitraClip System in patients with severely reduced left ventricular function - first European experience.** 5158
 – O. Franzen, S. Baldus, H. Reichenspurner, J. Schofer, A. Costard-Jaeckle, D. Koschyk, S. Meyer, H. Treede, L. Baholli, T. Meinertz (Hamburg, DE)
- 09:30 **State of the Art - Percutaneous valve intervention. Where is it going?** 5159
 – B. Lung (Paris, FR)

10:00 Coffee break (Moderated Posters)

THE AORTIC VALVE: FROM GENES TO SURGERY

Abstracts

Chairperson(s): J.J. Kaden (Mannheim, DE); A. Evangelista Masip (Barcelona, ES)

- 11:00 **ACE DD Genotype is a risk factor for ascending aortic aneurysms in patients with bicuspid or tricuspid aortic valves.** 5160
 – I. Foffa, M. Murzi, P. Festa, M. Mariani, S. Bevilacqua, M. Glauber, L. Ait-Ali, A. Mazzone, M.G. Andreassi (Pisa and Massa, IT)
- 11:15 **Does the valve morphology affect to the natural history of the bicuspid aortic valve?** 5161
 – V. Pedrosa, P. Gallego Garcia De Vinuesa, A. Castro, M. Chaparro, I. Mendez, A. Recio, R. Calvo, J. Fernandez Armenta, C. Fernandez Vivancos, J.M. Cruz Fernandez (Seville, ES)
- 11:30 **A risk score for predicting outcome in patients with asymptomatic aortic stenosis.** 5162
 – J.L. Monin, P. Lancellotti, M. Monchi, P. Lim, E. Weiss, L.A. Piérard, P. Gueret (Creteil and Massy, FR; Liège, BE)
- 11:45 **Discordant relationship between lipid-lowering changes and reduction of ischemic cardiovascular events (ICE) among patients with more severe aortic stenosis (AS) in the SEAS trial.** 5163
 – I. Holme, A.B. Rossebø, W. Malbecq, T.R. Pedersen (Oslo, NO; Brussels, BE)
- 12:00 **Is early elective surgery warranted in very severe aortic stenosis?** 5164
 – R. Rosenhek, R. Zilberszac, G. Mundigler, H. Gabriel, G. Maurer (Vienna, AT)
- 12:15 **The Ross operation: lesson from long-term follow-up.** 5165
 – L.L.A. De Kerchove, M. Boodhwani, J. Rubay, A. Pasquet, D. Glineur, A. Poncelet, T. Sluysmans, M. Buche, P. Noirhomme, G. El Khoury (Brussels, BE)

12:50 End of Congress

NEW ECHOCARDIOGRAPHIC INSIGHTS INTO PULMONARY HYPERTENSION Abstracts

Chairperson(s): I.M. Lang (Vienna, AT); P. Pruszczyk (Warsaw, PL)

- 08:30 **Pressure increase after peak velocity in the pulmonary artery: a novel echocardiography method to identify patients with increased pulmonary vascular resistance.** 5166
 – F. Lindgren, B. Rundqvist, S. Petersson, N. Selimovic, O. Bech-Hanssen (Gothenburg, SE)
- 08:45 **Echocardiographic parameters which determine survival in pulmonary hypertension: retrospective study of 1186 patients.** 5167
 – J. Grapsa, L. Malcolm-Lawes, W. Gin-Sing, R. D Smith, D. Dawson, J.S.R. Gibbs, L.S.G.E. Howard, P. Nihoyannopoulos (London, GB)
- 09:00 **Right ventricular ejection fraction during exercise as a predictor of mortality in patients awaiting lung transplantation.** 5168
 – N. Selimovic, B. Andersson, M. Lomsky, G. Riise, B. Rundqvist (Gothenburg, SE)
- 09:15 **Exercise stress echocardiography for the study of the pulmonary circulation.** 5169
 – P. Argiento, N. Chesler, P. Unger, M. D'Alto, R. Naeije (Naples, IT; Madison, US; Brussels, BE)
- 09:30 **Real time three dimensional echocardiography: right ventricular volumes and mass measurement, validated with cardiac MRI, in 112 pulmonary arterial hypertensive patients.** 5170
 – J. Grapsa, H. Pavlopoulos, D. O'Regan, G. Durighel, P. Nihoyannopoulos (London, GB)
- 09:45 **Feasibility and accuracy of real-time 3-dimensional echocardiography for right ventricular function in congenital heart disease: validation with cardiac magnetic resonance imaging.** 5171
 – H.B. Van Der Zwaan, W.A. Helbing, J.S. McGhie, M.L. Geleijnse, J.W. Roos-Hesselink, F.M. Meijboom (Rotterdam, NL)

10:00 Coffee break (Moderated Posters)

TREATMENT OF PULMONARY HYPERTENSION – RANDOMISED CONTROL TRIALS AND LONG-TERM FOLLOW-UP Abstracts

Chairperson(s): G. Simonneau (Clamart, FR); M.A. Gomez Sanchez (Madrid, ES)

- 11:00 **A meta-analysis of randomized controlled trials in pulmonary arterial hypertension.** 5172
 – N. Galie, A. Manes, L. Negro, M. Palazzini, A. Marinelli, E. Leci, E. Conficoni, S. Gambetti, M.L. Bacchi-Reggiani, A. Branzi (Bologna, IT)
- 11:15 **The effect of once-daily tadalafil on exercise capacity and clinical deterioration with up to 68 weeks of treatment in patients with Pulmonary Arterial Hypertension (PAH).** 5173
 – R. Oudiz, H.A. Ghofrani, G. Simonneau, R. Barst, B. Brundage, A. Elion-Mboussa, A. Beardsworth, N. Galie (Torrance, New York, Bend and Indianapolis, US; Giessen, DE; Clamart, FR; Bologna, IT)
- 11:30 **The dutch bosentan patient cohort: 5-year survival rates on a national scale.** 5174
 – J.C. Vis, M.C. Vonk, R.J. Snijder, L.M. Van Den Toorn, R.M.F. Berger, H.W. Vliegen, P. Bresser, G.J. Van Daal, K.A. Boomars, B.J.M. Mulder (Amsterdam, Nijmegen, Nieuwegein, Rotterdam, Groningen, Leiden, Woerden and Maastricht, NL)
- 11:45 **Pulmonary vasodilator challenge predicts survival in patients with various etiologies of pulmonary hypertension.** 5175
 – R.A. Krasuski, S.A. Hart, T. Bashore (Cleveland and Durham, US)
- 12:00 **Longer-term survival in paediatric patients with idiopathic or familial pulmonary arterial hypertension (IPAH/FPAH) treated with bosentan: data from the FUTURE-1 and FUTURE-2 studies.** 5176
 – M. Beghetti, R.M.F. Berger, R.J. Barst, X. Jais, P. Acar, A. Fraisse, D.D. Ivy, I. Schulze-Neick, D. Bonnet, S.G. Haworth (Geneva, CH; Groningen, NL; New York and Denver, US; Clamart, Toulouse, Marseille and Paris, FR; Berlin, DE; London, GB)
- 12:15 **Long-term outcome with subcutaneous treprostinil sodium in pulmonary hypertension: a 10-year single-center study.** 5177
 – R. Sadushi, D. Bomderman, N. Skoro-Sajer, J. Glatz, M.P. Kneussl, I.M. Lang (Vienna, AT)

12:50 End of Congress

STATE OF THE ART – THE CHALLENGING PATIENT WITH EISENMEGER SYNDROME **Featured Research**

Chairperson(s): E. Oechslin (Toronto, CA); A. Szatmari (Budapest, HU)

- 08:30 **Pulmonary vasoreactivity predicts long-term outcome in patients with Eisenmenger syndrome.** **5178**
 – M. D'Alto, E. Romeo, P. Argiento, B. Sarubbi, G. Santoro, G. Gaio, G. D'Alterio, M.G. Russo, R. Naeije, R. Calabro' (Naples, IT; Brussels, BE)
- 08:45 **Exercise intolerance and skeletal muscle adaptations to chronic hypoxaemia in Eisenmenger syndrome.** **5179**
 – S. Bowater, G. Shivu, R. Beadle, R.A. Weaver, S.A. Thorne, J. Marshall, M.P. Frenneaux, P. Clift (Birmingham, GB)
- 09:00 **Replacement therapy for iron deficiency improves symptoms and exercise capacity in patients with cyanotic heart disease and/or Eisenmenger syndrome.** **5180**
 – E. Tay, A.N.A. Peset, M. Papaphylactou, S. Goletto, R. Inuzuka, G. Giannakoulas, A. Tzifa, A.L. Von Lilien, K. Dimopoulos, M.A. Gatzoulis (London, GB)
- 09:15 **Bosentan-sildenafil association in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability and clinical effect.** **5181**
 – E. Romeo, M. D'Alto, P. Argiento, B. Sarubbi, G. Santoro, G. Scognamiglio, D. Alfano, G. D'Alterio, M.G. Russo, R. Calabro' (Naples, IT)
- 09:30 **State of the Art - The challenging patient with Eisenmenger syndrome.** **5182**
 – E. Oechslin (Toronto, CA)

10:00 Coffee break (Moderated Posters)

ACUTE PULMONARY EMBOLISM – DIAGNOSIS AND RISK STRATIFICATION **Abstracts**

Chairperson(s): S.V. Konstantinides (Gottingen, DE); R.N. Naeije (Brussels, BE)

- 11:00 **Impact of using validated diagnostic criteria on outcome of patients with suspected pulmonary embolism.** **5183**
 – M. Kurzyna, A. Fijalkowska, J. Zylkowska, M. Wieteska, M. Florczyk, G. Szewczyk, R. Dlugopolski, W. Ptaszynski, A. Budaj-Fidecka, A. Torbicki (Warsaw, Nowy Targ and Lodz, PL)
- 11:15 **Risk stratification of patients with acute pulmonary embolism in emergency department.** **5184**
 – S. Vanni, F. Soggi, G. Pepe, P. Nazerian, G. Viviani, S. Toccafondi, V. Scheggi, S. Grifoni (Florence, IT)
- 11:30 **The revised Geneva score in anatomically extensive pulmonary embolism: is low-probability similar to low-risk?** **5185**
 – R. Baptista, E. Jorge, R. Teixeira, P. Mendes, S. Monteiro, P. Monteiro, F. Goncalves, G. Castro, M. Freitas, L.A. Providencia (Coimbra, PT)
- 11:45 **Multidetector computed tomography to assess clinical outcome in hemodynamically stable patients with acute pulmonary embolism.** **5186**
 – C. Becattini, M.C. Vedovati, S. Grifoni, F. Casazza, R. Douma, M. Bianchi, A. Salvi, S. Konstantinides, M. Duranti, G. Agnelli (Perugia, Florence, Milan, Como and Ancona, IT; Amsterdam, NL; Gottingen, DE)
- 12:00 **Correlation of heart-type fatty acid-binding protein with mortality and echocardiographic data in patients with pulmonary embolism at intermediate risk.** **5187**
 – A. Boscheri, C. Wunderlich, M. Langer, D. Stolte, G. Elmer, T. Rauwolf, R.H. Strasser (Dresden, DE)
- 12:15 **The italian pulmonary embolism registry IPER: preliminary results.** **5188**
 – F. Casazza, C. Becattini, A. Rubboli, L. Roncon, P. Zonzin, C. D'Agostino, A. Bongarzone, P. Favretto (Milan, Perugia, Bologna, Rovigo, Bari and Treviso, IT)

12:50 End of Congress

STATE OF THE ART – IMPACT OF REVASCULARISATION STRATEGY ON CLINICAL OUTCOME IN MULTIVESSEL DISEASE

Featured Research

Chairperson(s): M. Sousa Uva (Lisbon, PT); P.W. Serruys (Rotterdam, NL)

- 08:30 **Five-year follow-up of a randomized comparison between off-pump and on-pump on stable multivessel coronary artery bypass grafting.** **5189**
 – W.A. Hueb, N.H. Lopes, B.J. Gersh, L.A.M. Cesar, R.D. Vieira, E.G. Lima, L.A.O. Dallan, F.S. Paulitsch, J.A.F. Ramires (Sao Paulo, BR; Rochester, US)
- 08:45 **Angiographic severity versus functional severity of coronary artery stenoses in the FAME study.** **5190**
 – P.A.L. Tonino, N.H.J. Pijls (Eindhoven, NL)
- 09:00 **Comparative effect on completeness of revascularisation in patients with stable multivessel coronary artery disease - MASS II trial.** **5191**
 – N.H. Lopes, A.C. Pereira, M. Farkouh, R.D. Vieira, E.G. Lima, P.R. Soares, E.E. Ribeiro, L.A.O. Dallan, J.A.F. Ramires, W.A. Hueb (Sao Paulo, BR; New York, US)
- 09:15 **Hybrid strategy for stent treatment for multivessel coronary artery disease.** **5192**
 – M. Romero, A. Medina, J. Suarez De Lezo, M. Pan, J. Suarez De Lezo Jr, J. Segura, P. Martin, S. Ojeda, D.J. Pavlovic, C. Amador (Cordoba and Las Palmas, ES)
- 09:30 **State of the Art - Impact of revascularisation strategy on clinical outcome in multivessel disease.** **5193**
 – P.W. Serruys (Rotterdam, NL)

10:00 Coffee break (Moderated Posters)

COMPLEX PERCUTANEOUS CORONARY INTERVENTIONS

Abstracts

Chairperson(s): P. Canas da Silva (Lisbon, PT); T.A. Mabin (Somerset West, ZA)

- 11:00 **Retrograde approach and procedural success in recanalisation of complex chronic total coronary occlusions.** **5194**
 – H.J. Buettner, M. Gick, M. Ferenc, F.J. Neumann (Bad Krozingen, DE)
- 11:15 **Comparison of sirolimus-eluting stent and bare metal stent for treatment of patients with chronic total coronary occlusions: results of the GISSOC II multicentre randomised trial.** **5195**
 – P. Rubartelli, A.S. Petronio, P. Sganzerla, V. Guiducci, L. Bolognese, M. Galli, I. Sheiban, F. Chirillo, A. Ramondo, S. Bellotti (Genoa, Pisa, Bergamo, Reggio Emilia, Como, Turin, Treviso and Padua, IT)
- 11:30 **Three-year mortality after unsuccessful percutaneous revascularisation of chronic total coronary occlusions.** **5196**
 – K. Obunai, R. Mehran, G. Dangas, C. Godino, G. Bassanelli, A. Chieffo, A. Colombo, G. Stone, J. Moses, M. Leon (New York, US; Milan, IT)
- 11:45 **Four-year follow-up of chronic total occlusions within the TRUE multicenter prospective registry.** **5197**
 – R.T. Gerber, A.S.P. Sharp, C. Godino, A. Ielasi, E. Romangoli, G. Parodi, C. Di Mario, D. Antoniucci, G.M. Sangiorgi, A. Colombo (Milan and Florence, IT; London, GB)
- 12:00 **Ultrasound carina morphology predicts side branch ostial damage in low risk coronary bifurcation lesions treated with provisional stenting.** **5198**
 – J. Suarez De Lezo Jr, A. Medina, P. Martin, C. Amador, E. Hernandez, F. Melian, M. Pan, J. Novoa, L. Burgos (Las Palmas De Gran Canaria and Cordoba, ES)
- 12:15 **Final kissing versus simple balloon post-dilatation in patients with bifurcation lesions treated with a simple approach.** **5199**
 – M. Pan Alvarez-Osorio, J. Suarez De Lezo, M. Romero, J. Segura, S. Ojeda, A. Moreno, J. Suarez De Lezo Jr, P. Martin, E. Hernandez, A. Medina (Cordoba and Las Palmas De Gran Canaria, ES)

12:50 End of Congress

REAPPRAISAL OF OLD THERAPIES IN ACUTE CORONARY SYNDROMES

Abstracts

Chairperson(s): D. Tousoulis (Athens, GR); P. Seferovic (Belgrade, RS)

- 08:30 **Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: impact on clinical events and on.** 5200
 – J.-P. Collet, J.S. Hulot, A.N.A. Pena, E.R.I.C. Vilard, J.B. Esteve, G. Cayla, G. Silvain, F. Beygui, L. Payot, G. Montalescot (Paris, FR)
- 08:45 **Is a loading dose of clopidogrel of more than 300mg associated with a higher frequency of intracranial bleeding?** 5201
 – P. Widimsky, C. Schmitt, P. McCollam, Z. Motovska, J. Rustige, P. Nasuti (Prague, CZ; Indianapolis, US; London, GB)
- 09:00 **Intraaortic balloon pump therapy in acute myocardial infarction complicated by cardiogenic shock: should we start before or after primary PCI?** 5202
 – M. Saad, R. Toelg, M. Abdel-Wahab, V. Geist, G. Richardt (Bad Segeberg, DE)
- 09:15 **Oxygen use in acute myocardial infarction: online survey of health professionals' practice and beliefs.** 5203
 – T. Quinn, A. Burls, J. Empananza, J. Cabello (Guildford and Oxford, GB; San Sebastian and Alicante, ES)
- 09:30 **Outcome among patients with cardiogenic shock treated with intra-aortic balloon pump counterpulsation: a long-term follow-up study of 386 patients.** 5204
 – J.M. Cheng, S.D.A. Valk, C.A. Den Uil, M. Van Der Ent, W.K. Lagrand, M. Van De Sande, R.T. Van Domburg, M.L. Simoons (Rotterdam and Amsterdam, NL)
- 09:45 **The characteristics and outcomes of non-ST-elevation acute coronary syndrome patients receiving intravenous narcotics based on accs 2008 registry.** 5205
 – A. Porter, Z. Iakobishvili, A. Battler, S. Behar, A. Roth, S. Atar, V. Boyko, A. Mager, D. Hasdai (Petah Tikva and Ramat Gan, IL)

10:00 Coffee break (Moderated Posters)

CONTROVERSIES ON ANTITHROMBOTIC TREATMENT: THE CATH LAB

Abstracts

Chairperson(s): L. Bolognese (Arezzo, IT); M. Bergovec (Zagreb, HR)

- 11:00 **Intracoronary compared to intravenous bolus Abciximab reduces mortality and target vessel revascularisation in STEMI-patients undergoing primary PCI. A randomized trial.** 5206
 – A. Iversen, S. Pedersen, U. Abildgaard, A. Galloe, P.R. Hansen, S. Galatius, J.K. Madsen, K.S. Jensen, T. Engstrom, J.S. Jensen (Copenhagen, DK)
- 11:15 **Validation of a new point-of-care test to monitor enoxaparin anticoagulation immediately before catheterization.** 5207
 – J. Silvain, F. Beygui, A. Bellemain-Appaix, A. Pena, O. Barthelemy, G. Cayla, D. Costagliola, J.P. Collet, G. Montalescot (Paris, FR)
- 11:30 **Antiplatelet therapy adjustment improved composite 30-day clinical outcome after primary percutaneous coronary intervention.** 5208
 – I. Mrdovic, L. Savic, J. Perunicic, R. Lasica, M. Asanin, Z. Vasiljevic, J. Marinkovic, M. Ostojic (Belgrade, RS)
- 11:45 **Use of Fondaparinux in patients with acute myocardial infarction and submitted to percutaneous intervention.** 5209
 – F. Schiele, N. Meneveau, M.F. Seronde, V. Descotes-Genon, J. Dutheil, R. Chopard, K. Mrabet (Besançon, FR)
- 12:00 **Mortality of patients treated with bivalirudin compared to heparin plus glycoprotein IIb/IIIa inhibitors after clopidogrel pre-treatment: a meta-analysis from randomized trials.** 5210
 – G.W. Stone, S.J. Pocock, J.W. Moses, B.J. Gersh, B. Witzenzichler, G. Guagliumi, H.D. White, A.J. Lansky, G.D. Dangas, R. Mehran (New York and Rochester, US; London, GB; Berlin, DE; Bergamo, IT; Auckland, NZ)
- 12:15 **Effect of bivalirudin vs. heparin plus glycoprotein IIb/IIIa inhibitors on drug-eluting stent strut coverage and local thrombus deposition in STEMI: an optical coherence tomography study.** 5211
 – A. Trivisonno, G. Musumeci, V. Sirbu, L. Fiocca, O. Valsecchi, H. Bezerra, M. Costa, R. Mehran, G. Stone, G. Guagliumi (Bergamo, IT; Cleveland and New York, US)

12:50 End of Congress

**ATRIAL FIBRILLATION ABLATION. NEW TECHNIQUES,
NEW HOPES**

Abstracts

Chairperson(s): G. Hindricks (Leipzig, DE); C. Pappone (Milan, IT)

- 08:30 **Three dimensional reconstruction of the left atrium and the pulmonary veins for navigation of atrial fibrillation ablation: a comparison study between rotational angiography and cardiac computed tomog.** 5212
– S. Nedios, M. Tang, M. Roser, J.H. Gerds-Li, E. Fleck, C. Kriatselis (Berlin, DE)
- 08:45 **On wire technology for pulmonary veins isolation: comparison between phased array radiofrequency ablation and balloon-cryotherapy.** 5213
– A. Abdelaal, I. Magnin-Poull, M. Andronache, J. Cedano, L. Groben, S. Magalhaes, L. Muresan, N. Boudoucha, E. Aliot, C. De Chillou (Vandouvre Les Nancy, FR)
- 09:00 **Long-term results of remote-controlled magnetic navigation for pulmonary vein isolation and differences compared to hand-navigated ablation of atrial fibrillation.** 5214
– T. Pezawas, C. Schukro, G. Stix, H. Schmidinger (Vienna, AT)
- 09:15 **Ganglionated plexi ablation for paroxysmal and persistent atrial fibrillation: a prospective rhythm analysis with continuous ECG monitoring.** 5215
– E. Pokushalov, A. Romanov, P. Shugaev, S. Artemenko, A. Turov, N. Shirokova, D. Katritsis (Novosibirsk, RU; Athens, GR)
- 09:30 **Catheter ablation of atrial fibrillation using Hansen robotic navigation - a randomised controlled trial.** 5216
– R. Liew, L. Richmond, V. Baker, F. Goromonzi, G. Thomas, M. Finlay, M. Dhinoja, M. Earley, S. Sporton, R. Schilling (Singapore, SG; London, GB)
- 09:45 **Does catheter ablation cure atrial fibrillation? Single procedure outcome of drug refractory atrial fibrillation ablation: a six-year multicenter experience.** 5217
– E. Bertaglia, C. Tondo, A. De Simone, F. Zoppo, M. Mantica, P. Turco, F. Zerbo, G. Forleo, G. Stabile (Mirano, Rome, Maddaloni and Milan, IT)

10:00 Coffee break (Moderated Posters)

HOME MONITORING AND ARRHYTHMIA ANALYSIS

Abstracts

Chairperson(s): W.R.M. Dassen (Maastricht, NL); M. Hoehner (Bayreuth, DE)

- 11:00 **Home Monitoring guided ICD-follow up with six-month intervals: a telecardiologic prospective randomized multicenter study.** 5218
– A. Schirdewan, H. Schuett, F.-M. Malur, K. Malinowski, A. Lang, K. Reinig, U. Zacharzowsky, E. Safak, L. Koch (Berlin, Erfurt, Aue and Gotha, DE)
- 11:15 **Telemedicine prediction of life-threatening ventricular arrhythmias based on recurrence quantification analysis.** 5219
– N. Balogh, S. Khor, M. Khor, B. Kail, K. Fugedi, I. Kovacs (Budapest, HU)
- 11:30 **New robust method of atrial electrograms classification to identify complex fractionated atrial electrograms.** 5220
– V. Kremen, L. Lhotska (Prague, CZ)
- 11:45 **Preliminary results of the RIONI study: Validation of intracardiac electrograms obtained by home monitoring in ICD patients.** 5221
– C. Perings, W. Bauer, H. Bondke, C. Mewis, M. James, D. Boecker, J.O. Schwab, H.-J. Trappe (Luene, Wurzburg, Berlin, Homburg/Saar, Hamm, Bonn and Bochum, DE; Somerset, GB)
- 12:00 **Relative risk of delayed detection of adverse events with standard in-office follow-up program versus Home Monitoring remote control in patients with cardiac resynchronization therapy ICD.** 5222
– E. De Ruvo, L. De Luca, A. Gargaro, L. Sciarra, M. Rebecchi, L. Zuccaro, F. Sebastiani, M.T. Laudadio, E. Lioy, L. Calo' (Rome, IT)
- 12:15 **Telemonitoring using mobile phones reduces the event rate after recent acute heart failure. Results of the MOBILE TELEmonitoring in heart failure patients study (MOBITEL).** 5223
– F.M. Fruhwald, D. Scherr, P. Kastner, A. Kollmann, G. Schreier (Graz, AT)

12:50 End of Congress



**STATE OF THE ART – WATERING
THE DESERT: CAN PARACRINE FACTORS
MAKE YOUR STEM CELLS BLOOM?**

Featured Research

Chairperson(s): C.A. Beltrami (Udine, IT); F. Fernandez-Aviles (Madrid, ES)

- 08:30 **Long term results after intracoronary injection of autologous mononuclear bone marrow cells in acute myocardial infarction. The ASTAMI study.** 5224
– J.O. Beitnes, E. Hopp, K. Lunde, S. Solheim, H. Arnesen, K. Forfang, J.E. Brinchmann, S. Aakhus (Oslo, NO)
- 08:45 **Cardiomyocyte-derived Erythropoietin is an endogenous paracrine mediator of cardiac regeneration and regulates the vasculogenic differentiation potential of cardiac progenitor cells.** 5225
– P. Fischer, M. Hoch, B. Stapel, S. Erschow, M. Scherr, H. Drexler, D. Hilfiker-Kleiner (Hannover, DE)
- 09:00 **Paracrine NO potentiates the differentiation of adult cardiac resident stem cells to cardiomyocytes.** 5226
– J. Kmecova, B. Sekkali, C. Dubroca, P. Massion, A. Friart, C. Bouzin, S. Janssens, O. Feron, C. Sibille, J.-L. Balligand (Brussels and Leuven, BE)
- 09:15 **Human mesenchymal stem cell conditioned medium improves cardiac function following chronic myocardial ischemic injury.** 5227
– L. Timmers, S.K. Lim, I.E. Hoefler, G. Pasterkamp, D.P.V. De Kleijn (Utrecht, NL; Singapore, SG)
- 09:30 **State of the Art - Watering the desert: can paracrine factors make your stem cells bloom?** 5228
– F. Fernandez-Aviles (Madrid, ES)

10:00 Coffee break (Moderated Posters)

**DISEASE MECHANISMS AND MANAGEMENT OF
MYOCARDITIS AND PERICARDITIS**

Abstracts

Chairperson(s): U. Kuehl (Berlin, DE); P. Seferovic (Belgrade, RS)

- 11:00 **Beneficial effects of eplerenone on murine coxsackievirus B3 myocarditis.** 5229
– A. Ukimura, A. Iimori, N. Fukuda, Y. Kitaura (Takatsuki-City, JP)
- 11:15 **Neoplastic pericarditis: comparison of different treatments.** 5230
– C. Lestuzzi, R. Gralec, E. Viel, L. Tartuferi, R. Piazza, A. Bearz, S. Scalone, E. Bidoli, N. Meneguzzi, W. Tomkowski (Aviano and Pordenone, IT; Warsaw, PL)
- 11:30 **Therapy of beta1-receptor antibody-induced cardiomyopathy with cardioprotective cyclopeptides: effects of 1 year treatment on cardiac function and morphometry.** 5231
– M. Mueller, T. Roeder, C. Zechmeister, Y. Ye, A. Schlipp, V. Schwarzbach, V. Boivin, G. Ertl, M.J. Lohse, R. Jahns (Wurzburg, DE)
- 11:45 **Presence of EMMPRIN and Cyclophilin A in chronic and acute inflammatory cardiomyopathy.** 5232
– P. Seizer, M. Schneider, B. Bigalke, T. Geisler, B. Kraemer, M. Kandolf, M. Gawaz, K. Klingel, A. May (Tubingen, DE)
- 12:00 **Prevalence of autoimmune diseases in patients with dilated cardiomyopathy.** 5233
– A. Richter, S. Pankuweit, V. Ruppert, A. Ramadanovic, B. Maisch (Marburg, DE)
- 12:15 **Serum organ-specific anti-heart autoantibodies in arrhythmogenic right ventricular cardiomyopathy patients and relatives: evidence for autoimmune involvement in a genetically-determined myocarditis.** 5234
– A.L.P. Caforio, E. Zachara, F. Re, P. Baratta, S. Bottaro, F. Tona, G. Thiene, S. Iliceto, C. Tondo, W.J. McKenna (Padua and Rome, IT; London, GB)

12:50 End of Congress

STATE OF THE ART – MULTIVESSEL DISEASE. LOOKING FOR AN OPTIMAL SURGICAL STRATEGY

Featured Research

Chairperson(s): D. Taggart (Oxford, GB); J. Marco (Toulouse, FR)

- 08:30 **CABG still provides long-term survival benefit over medical treatment.** 5235
 – H. Rexius, R. Ekroth, G. Brandrup-Wognsen, I. Karlberg, M. Nilsson, A. Oden, A. Jeppsson (Gothenburg, SE)
- 08:45 **Graft patency after off-pump versus on-pump multivessel coronary artery bypass surgery.** 5236
 – M. Sousa Uva, F. Matias, A. Mesquita, S. Nunes Da Silva, J. Pinho, J. Fernandes, J. Bau, S. Cavaco, M.P. Magalhaes (Lisbon and Porto, PT)
- 09:00 **The impact of surgical revascularisation completeness on long-term survival is strongly age-dependant.** 5237
 – N. Giererd, E. Charbonneau, P. Voisine, E. Dumont, D. Doyle, J. Perron, R. Baillot, F. Dagenais, P. Pibarot, P. Mathieu (Quebec, CA)
- 09:15 **Haemostatic changes on on-pump compared with off-pump in stable multivessel coronary artery bypass surgery: a prospective randomized study.** 5238
 – F.S. Paulitsch, D. Schneider, B.E. Sobel, D. Chamone, R. Rached, L.A.O. Dallan, W.A. Hueb, L.A.M. Cezar, J.A.F. Ramires, N.H. Lopes (Sao Paulo, BR; Vermont, US)
- 09:30 **State of the Art - Multivessel disease. Looking for an optimal surgical strategy.** 5239
 – D. Taggart (Oxford, GB)

10:00 Coffee break (Moderated Posters)



CORONARY ARTERY SURGERY: RISK ASSESSMENT AND STRATEGIES TO DECREASE MORBIDITY

Abstracts

Chairperson(s): P. Nataf (Paris, FR); L. Torracca (Ancona, IT)

- 11:00 **Predictors of twelve-month mortality in survivors from acute coronary syndromes referred to elective bypass surgery after discharge. Results from PL-ACS registry.** 5240
 – M. Zembala, M. Gasior, B. Hudzik, M. Gierlotka, A. Bochenek, S. Wos, Z. Kalarus, L. Polonski (Zabrze and Katowice, PL)
- 11:15 **Major risk stratification models do not predict perioperative outcome after coronary artery bypass grafting in patients with history of elective percutaneous intervention.** 5241
 – N. Bonaros, D. Hennerbichler, T. Schachner, A. Kocher, G. Friedrich, L. Mueller, O. Pachinger, G. Laufer, J. Bonatti (Innsbruck, AT; Baltimore, US)
- 11:30 **Ivabradine versus betblockers in patients with conduction abnormalities or left ventricular dysfunction undergoing coronary artery bypass grafting.** 5242
 – L. Iliuta, D. Filipescu, H. Moldovan, B. Radulescu, R. Vasile (Bucharest, RO)
- 11:45 **Acute kidney injury after cardiac surgery with cardiopulmonary bypass: risk factors for dialysis.** 5243
 – J.A. Abecasis, H. Dores, M. Abecasis, R. Rodrigues, L. Bruges, M. Moradas Ferreira, J. Calquinha, M.J. Rebocho, J.P. Neves, J. Q Melo (Lisbon, PT)
- 12:00 **Association between reduced Aspirin inhibition and platelet turnover in cardiac surgery.** 5244
 – H. Cohen Arazi, D. Doiny, S.V. Waldman, R. Spampinato Torcivia, H. Grancelli, S. Miriuka, R. Martingano, J. Celada, C. Nojek, C.E. Pensa (Buenos Aires, AR)
- 12:15 **Preoperative hemoglobin levels, hematocrit, inflammatory markers, B-Type natriuretic peptide and its relationship with postoperative morbidity and mortality in cardiac surgery.** 5245
 – E. Hernandez, R. Dennis, D. Isaza, J.P. Umana (Bog, CO)

12:50 End of Congress

POSTER SESSION 7

Posters must be set up between 08:00 and 08:30, removed between 12:30 and 13:00 and be on display between 08:30 and 12:30. The presenter should be present throughout the coffee break (10:00 and 11:00) in order to discuss the poster.



**MODERATED POSTER 1
CARDIOVASCULAR RISK FACTORS**

Chairperson(s): D. Baumgart (Essen, DE); K. Kotseva (London, GB)

The following eight abstracts were chosen for their outstanding quality and will be discussed in a special area in the poster hall during the Moderated Poster Session chaired by the two above-mentioned chairpersons between 10:00 and 11:00.

- 10:00 **Heart rate as marker of sympathetic activity in metabolic syndrome.** P5246
– G. Seravalle, F. Quarti Trevano, F. Arenare, V. Vella, G. Brambilla, G. Grassi, G. Mancia (Milan and Monza, IT)
- 10:05 **The once-daily human GLP-1 analogue, liraglutide, significantly reduces markers of cardiovascular risk in type 2 diabetes: a meta-analysis of six clinical trials.** P5247
– J. Plutzky, A.J. Garber, A. Falahati, A.D. Toft, N.R. Poulter (Boston and Houston, US; Bagsvaerd, DK; London, GB)
- 10:10 **Cigarette smoking hastens the onset of acute coronary syndrome with increasing serum oxidized low-density lipoprotein level.** P5248
– J. Ando, T. Morita, H. Fujita, H. Iwata, M. Sahara, Y. Hirata, R. Nagai, T. Kimura, H. Daida, M. Matsuzaki (Tokyo, Kyoto and Ube, JP)
- 10:15 **Depletion in endothelial progenitor cell number associated with environmental radiation exposure: the Chernobyl cancer children study.** P5249
– R. Di Stefano, M.C. Barsotti, P. Spontoni, A.I. Corciu, L. Venneri, E. Picano, C. Grigoratos, A. Balbarini (Pisa, IT)
- 10:20 **Intensive glycemic control in type 2 diabetes mellitus and the risk of cardiovascular events: meta-analysis of randomized trials.** P5250 (W)
– D.L. Brown, D.V. Menon, A. Jeremias (Stony Brook, US)
- 10:25 **Depressive symptoms have a negative impact on achieving the dual target of low LDL cholesterol and low C-reactive protein in patients with stable coronary heart disease.** P5251
– L. Rallidis, V. Sourides, A. Charalampopoulos, C. Kotakos, C. Varounis, C. Tsitlakidis, M. Zolindaki, J. Lekakis, D. Kremastinos (Athens and Piraeus, GR)
- 10:30 **Association between air pollution and postoperative and long-term cardiovascular mortality in vascular surgery patients.** P5252
– Y.R.B.M. Van Gestel, S.E. Hoeks, O. Schouten, W.J. Flu, J.P. Van Kuijk, H. Stam, R.T. Van Domburg, J.J. Bax, H.J.M. Verhagen, D. Poldermans (Rotterdam and Leiden, NL)
- 10:35 **Impact of diabetes mellitus on short- and long-term prognosis in >5500 Middle Eastern patients with acute coronary syndrome.** P5253
– A. Hammoudeh, H. Hamdan, M. Izraiq, H. Tarawneh, A. Harassis, R. Tabbalat, Y. Ismail, E. Al-Mousa, I. Alhaddad (Amman, JO)
- 10:40 **Discussion.** P5254

**MODERATED POSTER 2
NON-PERCUTANEOUS CARDIAC INTERVENTIONS**

Chairperson(s): V. Gupta (New Delhi, IN); V. Gama Ribeiro (Vila Nova De Gaia, PT)

The following eight abstracts were chosen for their outstanding quality and will be discussed in a special area in the poster hall during the Moderated Poster Session chaired by the two above-mentioned chairpersons between 10:00 and 11:00.

- 10:00 **Optimization of percutaneous balloon mitral Valvuloplasty: 10 years clinical outcome of a modified double balloon MULTI-TRACK technique.** P5255
– M. Rashwan, E. Elsharkawy, M. Sobhy (Alexandria, EG)
- 10:05 **Intervention for severe aortic stenosis improves survival in high-risk patients.** P5256
– T. Pilgrim, P.M. Wenaweser, G. Hellige, N. Roth, A. Kadner, B. Eberle, C. Zobrist, T. Carrel, B. Meier, S. Windecker (Berne, CH)
- 10:10 **Percutaneous repair of functional mitral regurgitation using CARILLON mitral contour system. Single center registry in consecutive patients.** P5257
– T. Siminiak, O. Jerzykowska, M. Woloszyn, P. Smuszkiewicz, L. Firek, R. Link, P. Kalmucki (Kowanowko K/Obornik Wlkp, PL; Kirkland, US)
- 10:15 **Paravalvular leak closure: single-center experience.** P5258
– R. Del Valle Fernandez, C. Martinez, V. Jelnin, C.E. Ruiz (New York, US)
- 10:20 **Long-term outcome after repeated balloon mitral commissurotomy in patients with restenosis after previous balloon valvotomy.** P5259
– M.S. Mourali, A.F. Demiraj, S. Abdessalem, F. Mghaieth, A. Cherif, R. Boussaada, R. Mechmeche (Tunis, TN)
- 10:25 **Does transcatheter aortic valve implantation induce myocardial injury?** P5260
– C. Tron, K. Bejar, H. Eltchaninoff, P.-Y. Litzler, B. Cauliez, M. Godin, C. Sanchez-Giron, A. Cribier (Rouen, FR)
- 10:30 **Circularity Index in deployed Edwards Sapien aortic valve bioprosthesis.** P5261
– C. Sanchez-Giron, M. De Icaza Herrera, H. Eltchaninoff, M. Godin, C. Tron, B. Baala, A. Cribier (Rouen, FR; Mexico City, MX)
- 10:35 **N-terminal pro-brain natriuretic peptide level predicts survival after transcatheter aortic valve implantation for severe aortic stenosis.** P5262
– C. Tron, H. Eltchaninoff, B. Cauliez, P.-Y. Litzler, M. Godin, F. Bauer, K. Bejar, C. Sanchez-Giron, A. Cribier (Rouen, FR)
- 10:40 **Discussion.** P5263

**ST-ELEVATION MYOCARDIAL INFARCTION AND INTERVENTION:
ANYTHING NEW?**

- Pre-hospital administration of Tirofiban in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: a sub-analysis of the ON-TIME 2 trial.** P5264
 – J.R. Timmer, J.M. Ten Berg, A.A.C.M. Heestermaans, T. Dill, J.W. Van Werkum, J.H.E. Dambrink, H. Suryapranata, J.P. Ottervanger, C. Hamm, A.W.J. Van 't Hof (Zwolle and Nieuwegein, NL; Bad Nauheim, DE)
- Evaluating the effect of everolimus on cardiomyocyte apoptosis in both an in-vitro model of hypoxia and an in-vivo drug eluting setting post myocardial infarction.** P5265
 – B. Hynes, A.K.H.S. Kumar, S. Weiss, J. O'Sullivan, K. Martin, G. Murphy, N.M. Caplice (Cork, IE)
- Sirolimus eluting- vs. paclitaxel eluting stent in patients with st-segment elevation myocardial infarction and renal insufficiency undergoing primary angioplasty.** P5266
 – S.H. Jo, H.S. Kim, Y.J. Choi, J.H. Lee, M.K. Kim, J.R. Cho, J.H. Jung, G.R. Hahn, C.Y. Rhim (Anyang-Si Gyeonggi-Do, KR)
- Small molecule GP IIb/IIIa antagonist compared with abciximab during primary percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of the available data.** P5267
 – F. Ottani, L. Lavecchia, D. Ferrini, M. Devita, S. Boarin, F. Tarantino, O. Catapano, M. Galvani (Forlì and Vicenza, IT)
- Clinical performance of risk scores in patients with ST-segment elevation acute myocardial infarction (STEMI) treated with primary percutaneous coronary intervention.** P5268
 – S. De Servi, T. Palmerini, A. Politi, A. Martinoni, D. Sangiorgi, G. Belli, F. Barlocco, R. Zanini, F. Ettori, S. Klugman (Legnano, Bologna, Gravedona, Milan, Cremona and Brescia, IT)
- Impact of bleeding on clinical outcomes after primary percutaneous coronary intervention in patients pretreated with 600 mg loading dose of clopidogrel.** P5269
 – I. Mrdovic, L. Savic, M. Asanin, J. Perunicic, R. Lasica, J. Marinkovic, Z. Vasijevic, M. Ostojic (Belgrade, RS)
- Major bleeding complications in patients with STEMI account for a doubling in hospital mortality in clinical practice: lessons from the Euro Heart Survey ACS registry.** P5270
 – A.K. Gitt, M. Gierlotka, M. Tubaro, H. Katus, W. Wojakowski, M. Tenders, F. Schiele, H. Bueno, M. Hochadel, J.P. Bassand (Ludwigshafen am Rhein and Heidelberg, DE; Zabrze and Katowice, PL; Rome, IT; Besançon, FR; Madrid, ES)
- Risk-treatment-paradox and high mortality in STEMI with impaired renal function in clinical practice in Europe: lessons from the euro heart survey ACS registry.** P5271
 – A.K. Gitt, A. Parkhomenko, Y. Hasin, H. Bueno, M. Gierlotka, F. Schiele, W. Wojakowski, H. Katus, M. Tenders, J.P. Bassand (Ludwigshafen am Rhein and Heidelberg, DE; Kiev, UA; Tiberias, IL; Madrid, ES; Zabrze and Katowice, PL; Besançon, FR)
- Impact of time to reperfusion after acute myocardial infarction on myocardial damage quantified with left ventricular longitudinal strain.** P5272
 – M. Bertini, S.A. Mollema, V. Delgado, M.L. Antoni, A.C.T. Ng, E.R. Holman, G. Boriani, M.J. Schalij, J.J. Bax (Leiden, NL; Bologna, IT)
- Mortality of patients with STEMI and cardiogenic shock treated by PCI is strongly related to the number of significantly diseased vessels. Results from PL-ACS registry.** P5273
 – M. Gierlotka, M. Gasior, A. Witkowski, M. Trusz-Gluza, R. Gil, P. Buszman, W. Ruzyllo, M. Zembala, G. Opolski, L. Polonski (Zabrze, Warsaw and Katowice, PL)
- Treatment and in-hospital outcome of elderly patients with ST-segment elevation acute MI/LBBB. Euro Heart Survey on ACS III registry (2006-2008).** P5274
 – W. Wojakowski, M. Tenders, M. Tubaro, M. Gierlotka, H. Bueno, M. Hochadel, Y. Hasin, J.P. Bassand, A.K. Gitt (Katowice and Zabrze, PL; Rome, IT; Madrid, ES; Ludwigshafen am Rhein, DE; Tiberias, IL; Besançon, FR)
- Effect of time from first medical contact-to-balloon on in-hospital mortality of patients with ST-elevation myocardial infarction (STEMI) and short onset of pain.** P5275
 – R. Jarai, K. Kalla, K. Huber (Vienna, AT)
- Transfer time is not a major determinant of in-hospital mortality in Primary PCI when performed in a well organized urban network.** P5276
 – J. Silvain, J.B. Vignalou, A. Bellemain-Appaix, A. Landivier, O. Barthelemy, F. Beygui, R. Choussat, P. Ecollan, J.P. Collet, G. Montalescot (Paris, FR)

- Mortality rates in patients with STEMI undergoing primary PCI as a function of the hemoglobin level: from anemia to polycythemia.** P5277
 – E. Lev, R. Kornowski, H. Vaknin-Assa, S. Fuchs, I. Teplitsky, D. Brosh, A. Battler, A. Assali (Petah Tikva, IL)
- Prognostic impact of complete revascularisation and diabetes mellitus in patients with acute myocardial infarction and multivessel coronary artery disease.** P5278
 – B. Hudzik, A. Lekston, M. Gasior, J. Szkodzinski, K. Wilczek, R. Wojnar, L. Polonski (Zabrze, PL)
- Invasive treatment of patients with ST-segment elevation myocardial infarction between 12 and 24 hours from the onset of symptoms. Analysis from the PL-ACS Registry.** P5279
 – M. Gierlotka, M. Gasior, A. Witkowski, J. Kubica, M. Janion, P. Buszman, R. Gil, Z. Kalarus, M. Zembala, L. Polonski (Zabrze, Warsaw, Bydgoszcz, Kielce and Katowice, PL)
- Primary percutaneous coronary intervention for ST-elevation myocardial infarction in hemodynamically unstable patients: data from the Euro Heart Survey and Registry for PCI.** P5280
 – F. Weidinger, A. Gitt, M. Hochadel, U. Zeymer, F. Eberli, R. Seabra-Gomes, P.W. Serruys, J. Marco (Vienna, AT; Ludwigshafen am Rhein, DE; Zurich, CH; Lisbon, PT; Rotterdam, NL; Monte Carlo, MC)
- Comparison of the predictive value of PAMI Risk Score and TIMI Risk Index in risk stratification of patients with STEMI undergoing primary percutaneous coronary intervention.** P5281
 – J.D. Brito, L. Raposo, J. Ferreira, P. Sousa, J. Abecasis, R. Teles, P. Goncalves, M. Almeida, F. Pereira Machado, J. Aniceto Silva (Carnaxide, PT)
- Target vessel reopening by guidewire insertion in ST-elevation myocardial infarction is a predictor of final TIMI flow and survival.** P5282
 – C. Adlbrecht, K. Distelmaier, D. Gunduz, B. Redwan, C. Plass, A. Kaider, D. Bonderman, G. Chris, I.M. Lang (Vienna, AT)
- Transradial percutaneous coronary intervention improves outcome in acute myocardial infarction. A meta-analysis.** P5283
 – A. Komocsi, A. Vorobcsuk, I. Ungi, D. Aradi, I.G. Horvath, A. Konyi (Pecs and Szeged, HU)
- Longer-term survival after primary angioplasty for ST elevation myocardial infarction: are outcomes with selective use of drug eluting stents comparable to those with bare metal stents?** P5284
 – Z. Adam, S.L. Hetherington, R. Morley, A.G.C. Sutton, J.A. Hall, R.A. Wright, D.F. Muir, J. Carter, N. Swanson, M.A. De Belder (Middlesbrough, GB)
- False positive referrals for primary percutaneous coronary intervention: impact of different strategies for interventional cardiology team activation in ST-elevation myocardial infarction.** P5285
 – E. Barge-Caballero, J.M. Vazquez-Rodriguez, R. Estevez-Loureiro, G. Barge-Caballero, R. Calvino-Santos, G. Aldama-Lopez, J. Salgado-Fernandez, P. Pinon-Esteban, N. Vazquez-Gonzalez, A. Castro-Beiras (A Coruna, ES)
- Prevalence and significance of accelerated idioventricular rhythm in STEMI-patients treated with primary percutaneous coronary intervention.** P5286
 – C.J. Terkelsen, J.T. Soerensen, A.K. Kattoft, S.S. Nielsen, L. Thuesen, H.E. Boetker, J.F. Lassen (Aarhus, DK)
- Multivessel angioplasty in ST-segment elevation myocardial infarction in clinical practise. Immediate and 12-month results from PL-ACS registry.** P5287
 – L. Polonski, M. Gierlotka, M. Gasior, M. Trusz-Gluza, R. Gil, W. Ruzylo, P. Buszman, A. Witkowski, Z. Kalarus (Zabrze, Katowice and Warsaw, PL)
- Does the increase in percentage of stents implantation during percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction, in the real world, affect mortality?** P5288
 – M. Gasior, D. Pres, A. Lekston, M. Hawranek, M. Gierlotka, M. Tajstra, G. Slonka, P. Buchta, L. Polonski (Zabrze, PL)

- Stent thrombosis up to 3 years after stenting for STEMI vs for stable angina - DES vs BMS.** P5289
 – G. Leibundgut, F. Nietlispach, U. Pittl, H.P. Brunner-La Rocca, C. Kaiser, M. Pfisterer (Basel, CH)
- Regional implementation of prehospital diagnosis in acute ST-elevation myocardial infarction and direct admission to interventional hospital: impact on system delay.** P5290
 – J.T. Sorensen, C.J. Terkelsen, J.F. Lassen, B.L. Norgaard, S. Trautner, T.M. Hansen, H.E. Botker, H.R. Andersen (Aarhus, Vejle and Copenhagen, DK)
- Reduction of time to treatment by infarct diagnosis in the ambulance with immediate triage to the nearest PCI center is higher for patients living at greater distance from a PCI center.** P5291
 – S. Postma, J.H.E. Dambrink, A.T.M. Gosselink, J.P. Ottervanger, J.C.A. Hoorntje, H. Suryapranata, M.J. De Boer, A.W.J. Van 't Hof (Zwolle, NL)
- ST-Segment resolution after fibrinolysis or primary coronary angioplasty in the first three hours in acute myocardial infarction.** P5292
 – M. Del Pinto, F. Angeli, A. Contine, S. Repaci, P. Verdecchia, S. Notaristefano, C. Cavallini (Perugia, IT)
- Impact of multivessel coronary artery disease on the outcomes of patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. 5-year follow-up.** P5293
 – A. Lekston, M. Gasior, B. Hudzik, D. Pres, T. Zebik, M. Hawranek, M. Gierlotka, L. Polonski (Zabrze and Czestochowa, PL)
- Under-representation of the left circumflex coronary artery in studies of ST-segment elevation myocardial infarction.** P5294
 – A. Krishnaswamy, A.M. Lincoff, V. Menon (Cleveland, US)

ST-ELEVATION MYOCARDIAL INFARCTION: PROGNOSTIC MARKERS AND TREATMENT

- TIMI perfusion grade compared to TIMI flow in prediction of infarct size and microvascular obstruction measured by contrast-enhanced MRI.** P5295
 – G. Fuernau, K. Schindler, I. Eitel, J. Friedenberger, E. Grebe, G. Schuler, H. Thiele (Leipzig, DE)
- A scanning electron microscope analysis of thrombi in STEMI patients: time really matters.** P5296
 – J. Silvain, J.P. Collet, C. Nagaswami, K. Edmondson, A. Bellemain-Appaix, A. Pena, O. Barthelemy, F. Beygui, J. Weisel, G. Montalescot (Paris, FR; Philadelphia, US)
- Remote ischemic postconditioning in patients submitted to primary percutaneous coronary intervention.** P5297
 – I. Rentoukas, G. Giannopoulos, S. Deftereos, K. Tsarouchas, C. Kossyvakis, S. Vavetsi, J. Kafantaris, M. Driva, N. Kouvousis (Athens, GR)
- Brain natriuretic peptide is the most powerful prognosticator of adverse prognosis in patients with acute myocardial infarction. The HEROES registry.** P5298
 – G. Lazaros, D. Tsiachris, A. Patialiakas, E. Vergopoulos, S. Vogiatzoglou, P. Aggelopoulos, I. Giatrakos, V. Zouli, D. Tousoulis, C. Stefanadis (Athens, GR)
- Prognostic role of intramyocardial haemorrhage during an acute myocardial infarction.** P5299
 – L. Monti, E. Corrada, G. Belli, L. Balzarini (Rozzano, IT)
- Early IL-6 concentration changes in coronary sinus do not correlate with their late peripheral levels and provide different information concerning long term prognosis in STEMI patients.** P5300
 – K. Kaminski, A. Kozieradzka, M. Kozuch, T. Bonda, M. Knapp, S. Dobrzycki, P. Kralisz, K. Nowak, I. Wojtkowska, W.J. Musial (Bialystok and Warsaw, PL)
- Compared efficacy and safety of a standard vs a loading dose of clopidogrel at the acute stage of MI in elderly patients. The FAST-MI registry data.** P5301
 – T. Simon, M. Gilard, J.P. Monassier, J.P. Collet, P. Henry, P. Dupouy, B. Vahdat, E. Drouet, J. Ferrieres, N. Danchin (Paris, Brest, Mulhouse, Melun, Marseille and Toulouse, FR)
- Relation between admission hyperglycemia, microvascular injury, and long-term outcome after first anterior myocardial infarction in patients with and without diabetes.** P5302
 – T. Takahashi, Y. Hiasa, S. Hosokawa, K. Kishi, R. Ohtani (Komatsushima, JP)

- Prior simvastatin treatment is associated with reduced thrombin generation and platelet activation in patients with acute ST-segment elevation myocardial infarction.** P5303
 – A. Undas, M. Pastuszczak, A. Kotlarz, M. Mostowik, J. Zalewski, K. Zmudka (Krakow, PL)
- Peak troponin-T, CK-MB, scintigraphic infarct size and 1-year mortality in a large cohort of patients with acute ST-elevation myocardial infarction.** P5304
 – R. Byrne, J. Mehilli, G. Ndrepepa, S. Schulz, A. Schoemig, A. Kastrati (Munich, DE)
- Higher uPAR expression on peripheral monocytes predicting no-reflow after primary percutaneous coronary intervention in acute myocardial infarction.** P5305
 – W. Chen, Y. Zeng, W.L. Zhu, M. Yang, M. Liu, X. Wang, Q. Fang (Beijing, CN)
- Admission blood glucose is a more powerful indicator of mortality than antecedent diabetes diagnosis in patients with acute myocardial infarction: results from 4700 patients in routine UK practice.** P5306
 – I.B. Squire, C.P. Nelson, L.L. Ng, D.R. Jones, P.C. Lambert (Leicester, GB)
- Effect of low-density lipoprotein cholesterol level on admission on in-hospital mortality in ST-segment elevation myocardial infarction in patients, with and without diabetes, undergoing PCI.** P5307
 – D. Pres, M. Gasior, A. Lekston, M. Hawranek, M. Gierlotka, P. Buchta, G. Slonka, M. Tajstra, L. Polonski (Zabrze, PL)
- Immediate ST resolution on intracoronary ECG during primary PCI predicts extent of myocardial injury using cardiac MRI.** P5308
 – M.C. Leung, D.T.L. Wong, R. Das, K.H. Soon, G. Chacko, G.W.H. Liew, M.A. Brown, M.I. Worthley, K.S.L. Teo, S.G. Worthley (Melbourne and Adelaide, AU)
- Mechanism of death depending on the type of infarction found in autopsy among patients managed to invasive treatment for acute myocardial infarction.** P5309
 – M. Hawranek, J. Nozynski, M. Gasior, M. Gierlotka, D. Pres, P. Buchta, E. Markowicz, A. Lekston, Z. Kalarus (Zabrze, PL)
- Plasma brain natriuretic peptide correlates with infarct size and cardiac function following primary percutaneous coronary intervention for acute myocardial infarction.** P5310
 – S. Chia, O. Raffel, F. Merchant, J. Tatsuno, F. Senatore, I. Jang (Singapore, SG; Boston and Warren, US)
- Expression of SDF-1 on circulating platelets is increased in patients with acute coronary syndromes and correlates with the number of CD34⁺ progenitor cells.** P5311
 – K. Stellos, B. Bigalke, H. Langer, A. Schad, S. Gnerlich, T. Geisler, P. Seizer, P. Htun, S. Lindemann, M. Gawaz (Tubingen, DE)
- Benefit of pre-hospital initiation of Tirofiban in elderly patients with acute myocardial infarction undergoing primary coronary angioplasty: a subanalysis from the On-TIME 2 trial.** P5312
 – K.G. Van Houwelingen, R. Hermanides, T. Dill, C.W. Hamm, T. Heestermans, J.W. Van Werkum, P.R. Stella, E. Boersma, J.M. Ten Berg, A.W.J. Van 't Hof (Enschede, Zwolle, Nieuwegein, Utrecht and Rotterdam, NL; Bad Nauheim, DE)
- Comparison of left ventricular global strain and left ventricular ejection fraction as determinants of left ventricular injury in patients with acute myocardial infarction.** P5313
 – B. Sjolie, S. Orn, B. Grenne, T. Vartdal, O. Smiseth, T. Edvardsen, H. Brunvand (Arendal, Stavanger and Oslo, NO)
- Heart Fatty Acid Binding Protein (h-FABP) significantly improves diagnosis in early phase of the whole spectrum of acute coronary syndromes.** P5314
 – L. Figiel, J.D. Kasprzak, M. Wraga, M. Musialowska, J.Z. Peruga, M. Klosinska, M. Krzeminska-Pakula (Lodz, PL)
- HbA1c predict no reflow phenomenon in patients with STEMI and newly detected abnormal glucose tolerance treated with primary PTCA.** P5315
 – M. Roik, Z. Huczek, J. Kochanowski, M.H. Starczewska, G. Opolski (Warsaw, PL)
- Prognostic value of NT-Pro BNP in the elderly with acute myocardial infarction.** P5316
 – L. Lorgis, M. Zeller, G. Dentan, P. Sicard, P.H. Buffet, I. L'Huillier, J.C. Beer, M. Vincent-Martin, P. Gambert, Y. Cottin (Dijon, Fontaine Les Dijon and Beaune, FR)
- Distinctive cytokine signature in patients with ST-Elevation Myocardial Infarction (STEMI) associated with high levels of circulating interleukin (IL)6.** P5317
 – E. Ammirati, N. Cristelli, C.V. Cannistraci, A. Paganoni, L. Sangalli, A. Monello, N. Uren, A.A. Manfredi, D. Cianflone, A. Maseri (Milan, Turin and Florence, IT; Edinburgh, GB)

- Impact of ruptured plaque cavity size on angiographic no-reflow phenomenon in patients with ST-segment elevation myocardial infarction.** P5318
 – K. Ohshima, S. Ikeda, K. Yamane, N. Izumi, K. Ishibashi, M. Hamada (Ehime, JP)
- The relationship between plasma hePCldin levels and coronary artery disease in patients with acute coronary syndromes.** P5319
 – E. Yeter, M. Akcay, T. Keles, T. Durmaz, N. Akar Bayram, H. Ayhan, E. Bozkurt (Ankara, TR)

A NEW LOOK TO VALVE DISEASE

- Value of different imaging techniques in the measurement of aortic valve annulus prior to implantation of the CoreValve percutaneous prosthesis: degree of agreement with the size of the prosthesis fin.** P5320
 – M. Ruiz Ortiz, M.D. Mesa Rubio, J. Suarez De Lezo Cruz Conde, M. Pan Alvarez-Osorio, M. Delgado Ortega, J. Segura Saint Gerons, R. Ysamat, S. Espejo Perez, D. Garcia Fuertes (Cordoba, ES)
- Low-flow severe aortic stenosis with preserved ejection fraction is characterized by a complex cardiovascular remodeling.** P5321
 – K. Mizia-Stec, T. Adamczyk, M. Mizia, M. Haberka, K. Gieszczyk, A. Chmiel, B. Lasota, Z. Gasior, M. Trusz-Gluzka, M. Tendera (Katowice, PL)
- A novel Doppler parameter, apical systolic flow in prediction of mitral regurgitation severity: Reappraisal of regurgitation dynamics.** P5322
 – H.C. Tokgoz, I.H. Tanboga, A. Ozkan, M.M. Can, F. Koca, T. Bezgin, N. Keles, O. Ozveren, N. Ozdemir, C. Kaymaz (Istanbul, TR)
- Re-evaluation of geometry of proximal flow convergence using three-dimensional colour Doppler echocardiography.** P5323
 – S.D. Park, J.U.N. Kwan, K.S. Park, W.H. Lee, S.I. Woo, S.H. Kim, W.G. Choi, J.K. Kim, J.H. Lee (Incheon, KR)
- Echocardiographic follow-up one year after percutaneous aortic valve replacement.** P5324
 – G. Stoschitzky, R. Maier, R. Hoedl, K. Stoschitzky, B. Pieske, O. Luha (Graz, AT)
- Color M-mode regurgitant flow propagation velocity in quantitation of mitral regurgitation: A high negative predictive value irrespective of jet eccentricity and dp/dt.** P5325
 – H.C. Tokgoz, A. Ozkan, I.H. Tanboga, F. Koca, M.M. Can, N. Keles, T. Bezgin, K. Sonmez, N. Ozdemir, C. Kaymaz (Istanbul, TR)
- Is Long-axis dysfunction related to symptomatic status and brain natriuretic peptide level in aortic stenosis?** P5326
 – K. O'Connor, J. Magne, M. Moonen, L.A. Piérard, P. Lancellotti (Liège, BE)
- The impact of transcatheter aortic valve implantation on myocardial function in high risk patients is better reflected by longitudinal strain than by left ventricular ejection fraction.** P5327
 – A. Kempny, M.A. Stenzel, G.-P. Diller, H. Reinecke, J. Mascherbauer, H. Baumgartner (Munster, DE; Vienna, AT)
- Echocardiography and cardiovascular magnetic resonance in assessing mitral apparatus deformation and left ventricular geometry in patients with chronic ischaemic mitral regurgitation.** P5328
 – A.M. Lesniak-Sobelga, E. Wicher-Muniak, M. Olszowska, M. Kostkiewicz, P. Musialek, P. Klimeczek, R. Banys, M. Pasowicz, W. Tracz (Krakow, PL)
- Speckle tracking technology: better than tissue Doppler imaging to predict long-term systolic dysfunction after mitral valve replacement.** P5329
 – J.A. De Agustin Loeches, J. Zamorano, L. Perez De Isla, C. Almeria, J.L. Rodrigo, C. Fernandez-Golfín, P. Marcos-Alberca, A. Aubele, D. Herrera, C. Macaya (Madrid, ES)
- Reduced functional myocardial reserve in patients with severe aortic stenosis. A stress echocardiography study.** P5330
 – M. Magro, H. Hermans, P. Claus, P. Herijgers, M.-C. Herregods, J. D'Hooge, J.-U. Voigt, J. Ganame (Leuven, BE)
- Noninvasive estimation of coronary flow in infarct related artery: prediction of myocardial functional recovery.** P5331
 – A. Djordjevic-Dikic, B. Beleslin, M. Ostojic, J. Stepanovic, V. Giga, B. Vujisic-Tesic, I. Nedeljkovic, M. Nedeljkovic, S. Stojkovic, Z. Petrasinovic (Belgrade, RS)

- Imaging aortic root and aortic valve stenosis in percutaneous aortic valve implantation candidates.** P5332
 – B.P. Paelinck, D. Petillot, C.J. Vrints, J.M. Bosmans (Edegem, BE)
- Impact of global left ventricular afterload on left atrial function in patients with aortic stenosis.** P5333
 – K. O'Connor, J. Magne, M. Moonen, P. Pibarot, L.A. Piérard, P. Lancellotti (Liège, BE; Quebec, CA)
- Evaluation of exercise-induced mitral regurgitation mechanism in patients with left ventricular dysfunction using transthoracic 3D-echocardiography.** P5334
 – M. Izumo (Kawasaki, JP)
- Are changes in systolic pulmonary arterial pressure during exercise related to changes in mitral regurgitation?** P5335
 – J. Magne, M. Moonen, K. O'Connor, L.A. Piérard, P. Lancellotti (Liège, BE)
- Determinants of plasma brain natriuretic peptide during exercise in patients with degenerative mitral regurgitation.** P5336
 – J. Magne, M. Moonen, K. O'Connor, L.A. Piérard, P. Lancellotti (Liège, BE)
- Analysis of NT-proBNP level at rest and after exercise echocardiography in patients with ischemic mitral regurgitation qualified for cardiosurgical treatment.** P5337
 – J. Kochanowski, P. Scislo, R. Piatkowski, M. Grabowski, M. Marchel, M. Roik, G. Opolski (Warsaw, PL)
- Differential left atrial remodeling in left ventricular diastolic dysfunction and mitral regurgitation.** P5338
 – M. Maiello, R.K. Sharma, M.M. Ciccone, H.K. Reddy, P. Palmiero (Brindisi and Bari, IT; El Dorado, US)
- Pressure gradient evaluation after mitral valve repair and mitral valve replacement at rest and under physiological ergometer exercise.** P5339
 – D. Jozwicki, L. Metreveli, M. Kowalski, F. Ritter, W. Rees, M. Krzeminska-Pakula, J. Poelng, N. Huebner, H. Warnecke, J.D. Kasprzak (Bad Rothenfelde, DE; Lodz, PL)
- NOVELTIES IN STRESS AND CONTRAST ECHO**
- Assessment of coronary artery disease by adenosine stress contrast echocardiography: a comparison with 3 Tesla cardiovascular magnetic resonance.** P5340
 – J.R. Arnold, T.D. Karamitsos, T.J. Pegg, J.M. Francis, R. Olszewski, N. Searle, R. Senior, S. Neubauer, H. Becher, J.B. Selvanayagam (Oxford and Harrow, GB; Warsaw, PL; Adelaide, AU)
- Safety of dobutamine stress-contrast echocardiography in 22,600 studies.** P5341
 – C. Aggeli, G. Giannopoulos, K.M. Lampropoulos, G. Roussakis, J. Felekos, C. Kazazaki, A. Michaelidis, C. Pitsavos, C. Stefanadis (Athens, GR)
- Tissue velocity imaging with dobutamine stress echocardiography; a quantitative technique for identification of CAD in patients with LBBB.** P5342
 – M.F. Elnoamany, H. Badran, M. Seteha (Shebeen Elkom Menoufyia, EG)
- Exercise stress echo for early detection of right heart dysfunction in systemic sclerosis without pulmonary arterial hypertension.** P5343
 – M. D'Alto, P. Argiento, A. D'Andrea, F. Allocca, A. Pazzano, G. Abignano, R. Camporotondo, C. Bonino, G. Valentini, R. Calabro' (Naples and Pavia, IT)
- Telesystolic intraventricular gradients and systolic anterior movement of the mitral valve during exercise in athletes.** P5344
 – A.R. Almeida, C. Cotrim, R. Miranda, S. Almeida, M. Celeiro, B. Stuart, M. Carrageta (Almada, PT)
- Adverse bioeffects of dobutamine stress-contrast echocardiography on the myocardium.** P5345
 – C. Aggeli, K.M. Lampropoulos, G. Giannopoulos, G. Roussakis, A. Aggelis, J. Felekos, C. Kazazaki, E. Gialafos, C. Stefanadis (Athens, GR)
- Prognostic value of erectile dysfunction in patients who underwent dobutamine stress echocardiography for suspected coronary artery disease.** P5346
 – C. Vlachopoulos, C. Aggeli, A. Aggelis, N. Ioakeimidis, D. Terentes-Printzios, G. Roussakis, K. Aznaouridis, K. Rokkas, A. Askitis, C. Stefanadis (Athens, GR)

- Extended donor criteria in heart transplantation with pharmacological stress echocardiography.** P5347
 – T. Bombardini, G. Arpesella, S. Gherardi, M. Maccherini, W. Serra, O. Leone, P. Tanganelli, E. Pasanisi, E. Picano (Pisa, Bologna, Cesena, Siena and Parma, IT)
- Abnormal coronary flow reserve is related to impairment of left ventricular function during adenosine stress echocardiography in untreated hypertensive patients.** P5348
 – I. Ikonomidis, S. Tzortzis, J. Lekakis, H. Triantafyllidi, C. Papadopoulos, C. Tsitlakidis, I. Paraskevaldis, D.T. Kremastinos (Athens, GR)
- Failure to achieve target heart rate during dobutamine stress echocardiography is associated with increased mortality.** P5349
 – V. Kalahasti, L. Rodriguez, P. Houghtaling, V. Menon, R. Grimm, J.T. Thomas, W.A. Jaber (Cleveland, US)
- Safety and prognostic value of exercise echocardiography in patients with left ventricular dysfunction.** P5350
 – P. Pazos, J. Peteiro, A. Bouzas-Mosquera, F. Brouillon, A. Castro-Beiras (A Coruna, ES)
- Feasibility of real-time 3D stress contrast echocardiography and agreement with 2D stress contrast echocardiography.** P5351
 – C. Aggeli, I. Felekos, G. Giannopoulos, C. Kazazaki, K. Lampropoulos, G. Roussakis, D. Soulis, C. Pitsavos, C. Stefanadis (Athens, GR)
- An ultrasound contrast agent targeted towards p-Selectin detects activated platelets at supra-arterial shear flow ex vivo.** P5352
 – F. Guenther, A. Klibanov, E.A. Ferrante, C. Bode, C. Von Zur Muhlen (Freiburg im Breisgau, DE; Charlottesville, US)
- Specific targeting of human inflamed endothelium and in situ vascular tissue transection using ultrasound contrast agents.** P5353
 – O. Barreiro, R.J. Aguilar, E. Tejera, A. Evangelista, F. Sanchez-Madrid (Madrid and Barcelona, ES)
- The effects of left ventricular twist and torsion on left ventricular vortex flow pattern: assessment of left ventricular mechanics and flow using contrast echocardiography and vector velocity imaging.** P5354
 – G.R. Hong, S.H. Lee, I.W. Song, J.S. Park, D.G. Shin, Y.J. Kim, B.S. Shim, J.H. Choi (Daegu, KR)
- Impact of contrast-enhanced echocardiography on the diagnostic algorithm of acute aortic dissection.** P5355
 – A. Evangelista, G. Teixido, H. Cuellar, R. Aguilar, T. Gonzalez-Alujas, J. Rodriguez-Palomares, P. Mahia, M. Thomas, A. Dugoni, D. Garcia-Dorado (Barcelona, ES)
- Novel micrometer-sized bubbles with nanometer-scale hexagonal patterning surfaces of monosaccharide and its effects on ultrasound contrast imaging.** P5356
 – J.-P. Bin, J.-F. Wu, Y.-G. Wang, L. Yang, J. Liu, Y.-L. Liu (Guangzhou, CN)
- Dynamic variation of left ventricular geometry indices during dobutamine stress echocardiography.** P5357
 – J. Azevedo, H. Custodio, J. Abecasis, S. Leal, J. Monge, L.C. Bronze Carvalho, I. Arroja, J. Coucello, A. Aleixo, A. Silva (Lisbon, PT)

MYOCARDIAL DEFORMATION

- Left ventricular dyssynchrony after acute myocardial infarction was a powerful indicator of left ventricular remodeling after acute myocardial infarction.** P5358
 – J.S. Ko, J.C. Park, M.H. Jeong, J.G. Cho, Y.G. Ahn, J.C. Kang (Gwangju, KR)
- Automated function imaging - evaluation of the clinical feasibility for assessing left ventricular deformation.** P5359
 – M. Niemann, H. Niemann, J. Strotmann, S. Herrmann, F. Weidemann (Wurzburg and Kiel, DE)
- 3-layers strain in normal subjects and in patients with regional left ventricular dysfunction. A novel speckle tracking software.** P5360
 – M. Leitman, M. Lysyansky, P. Lysyansky, Z. Friedman, V. Tyomkin, D. Adam, Z. Vered (Zerifin and Haifa, IL)

- Time delay to achieve peak circumferential strain rate predicts an echocardiographic response to CRT.** P5361
 – N.J. Artis, D.L. Oxborough, K.M. Birch, C.P. Gale, G. Williams, L.B. Tan, C.B. Pepper (Leeds, GB)
- Assessment of myocardial function by different ultrasound systems and speckle tracking software. Are conventional strain values feasible?** P5362
 – A.J. Manovel Sanchez, B.C.F. Smith, T. Coulter, D. Dawson, P. Nihoyannopoulos (London, GB)
- Early markers of left ventricular dysfunction in systemic arterial hypertension: the added value of myocardial imaging.** P5363
 – S. Goncalves, C. Sousa, F.J. Pinto (Lisbon, PT)
- Structural left ventricular changes in hypertensive patients - Can speckle tracking help identify early changes in global and segmental function?** P5364
 – C. Sousa, S. Goncalves, F.J. Pinto (Lisbon, PT)
- Right ventricular function in patients with acute exacerbation of chronic obstructive pulmonary disease.** P5365
 – B. Ozben Sadic, E. Eryuksel, M.A. Tanrikulu, N. Papila-Topal, B. Mutlu, T. Celikel, Y. Basaran (Istanbul, TR)
- High risk patients for cardiac arrhythmia after myocardial infarction can be identified by left ventricular global strain.** P5366
 – K.H. Haugaa, M.K. Smedsrud, E. Kongsgaard, O.A. Smiseth, J.P. Amlie, T. Edvardsen (Oslo, NO)
- Assessment of regional myocardial dysfunction by speckle tracking imaging in patients who had coronary artery disease.** P5367
 – S.J. Ha, W.S. Kim, J.W. Sohn, S.J. Kim, M.K. Kim, J.H. Bae, K.S. Kim (Seoul, KR)

INFLAMMATION, GROWTH FACTORS AND CARDIOVASCULAR SIGNALLING

- Diabetes is a determinant of plasma B-type natriuretic peptide concentration and renin activity in patients with systolic heart failure.** P5368
 – L.E. Pastormerlo, C. Passino, M. Fontana, A. Gabutti, C. Mammini, C. Prontera, G. Vergaro, A. Clerico, M. Emdin (Pisa, IT)
- LXR activation inhibits chemokine induced CD4-positive lymphocyte migration.** P5369
 – D. Walcher, D. Vasic, P. Heinz, H. Bach, A. Hausauer, R. Durst, V. Hombach, N. Marx (Ulm, DE)
- Prognostic value of high sensitivity C-reactive protein in patients with recurrent myocardial infarction.** P5370
 – J.H. Lee, M.H. Bae, S.C. Chae, M.H. Jeong, Y.J. Kim, K.S. Kim, S.H. Hur, I.W. Seong, T.J. Hong, M.C. Cho (Daegu, Gwangju, Daejeon, Pusan and Cheongju, KR)
- CB1 receptor inhibition leads to decreased vascular AT1 receptor expression and inhibition of oxidative stress in vitro and in vivo.** P5371
 – V. Tiyerili, S. Zimmer, S. Jung, K. Wassmann, A. Zimmer, G. Nickenig, S. Wassmann (Bonn, DE; Montreal, CA)
- Crucial role of LOX-1 in monocyte adhesion-triggered NADPH oxidase-dependent, Akt/eNOS and Ca2+ signaling pathways in endothelial cells.** P5372
 – N. Sakamoto, T. Ishibashi, K. Sugimoto, T. Sawamura, T. Sakamoto, H. Ohkawara, S. Saitoh, N. Inoue, T. Teramoto, Y. Takeishi (Fukushima, Suita and Tokyo, JP)
- Anti-senescent and anti-apoptotic effects of voluntary running exercise in the aorta.** P5373
 – C.M. Werner, M. Hanhoun, J. Poess, J. Haendeler, M. Boehm, U. Laufs (Homburg and Dusseldorf, DE)
- Leukocyte Rho Kinase (ROCK) activity and prior statin use predict clinical outcomes after percutaneous coronary intervention.** P5374
 – P.-Y. Liu, Y.-H. Li, C.-H. Lee, L.-J. Lin, T.-H. Chao, L.-M. Tsai, J.-H. Chen, J.-K. Liao (Tainan, TW; Boston, US)
- TRAF1 deficiency protects against atherosclerosis by impairing monocyte recruitment to the vessel wall.** P5375
 – A. Missiou, N. Koestlin, D. Pfeifer, C. Muenkel, S. Ernst, K. Zirlík, P. Stachon, C. Bode, P. Libby, A. Zirlík (Freiburg im Breisgau, DE; Boston, US)

- Paclitaxel and sirolimus differentially modulate the expression of vascular endothelial growth factor in human coronary smooth muscle cells.** P5376
 – K. Katsaros, C. Kaun, S. Demyanets, K. Rychli, S.P. Kastl, K. Huber, G. Maurer, J. Wojta, W.S. Speidl (Vienna, AT)
- Characterization of co-stimulatory pathways in CD4⁺CD28null T lymphocytes: implications for the pathogenesis of coronary artery disease.** P5377
 – I.E. Dumitriu, J.P. Akiyu, J.C. Kaski (London, GB)
- MicroRNA expression during the development of atherosclerosis and restenosis.** P5378
 – W. Bielenberg, A. Prock, P. Stieger, H. Tillmanns, D. Sedding (Giessen, DE)
- Proinflammatory effect of glucose on endothelial MHC II expression is mediated by endothelial cell matrix contact in a three-dimensional environment.** P5379
 – H. Methé, J.-O. Kim (Munich, DE)
- Stretching rat cardiac trabeculae increases the force by decreasing cross-bridge weakening rate in a velocity dependent manner.** P5380
 – M. Yadid, A. Landesberg (Haifa, IL)
- Proteomic and metabolomic analysis of failing human left atrium reveals insights into the mechanisms underlying atrial fibrillation.** P5381
 – A.I. De Souza, N. Patel, R. Wait, Y.-L. Chung, A. Bajpai, C. Dos Remedios, A.J. Camm (London and Sutton, GB; Sydney, AU)
- Remodelling of atrial metabolism in heart failure: insights from metabolomic profiling.** P5382
 – A.I. De Souza, S. Cardin, N. Patel, Y.-L. Chung, R. Wait, A.J. Camm, S. Nattel (London and Sutton, GB; Montreal, CA)
- Association between newly onset oral anticoagulant treatment with phenprocoumon and serum levels of the Vitamin-K dependent calcification inhibitor Matrix Gla Protein.** P5383
 – R. Koos, L.J. Schurgers, R. Westenfeld, V. Brandenburg, M. Kelm, H.P. Kuehl (Aachen, DE; Maastricht, NL)
- Alpha-ketoglutarate and pseudouridine, novel metabolites in heart failure, exhibit biological actions on the myocardium.** P5384
 – D. Oceandy, T. Nikolaidou, M. Mamas, N. Othonos, L. Neyses (Manchester, GB)
- Rapamycin induces tissue factor and promotes arterial thrombosis in vivo.** P5385
 – G.G. Camici, J. Steffel, I. Amanovic, A. Breitenstein, J. Baldinger, S. Keller, T.F. Luescher, F.C. Tanner (Zurich, CH)
- Role of cyclin-dependent kinase inhibitors p21 and p27 in arterial thrombosis.** P5386
 – A. Breitenstein, A. Akhmedov, T.F. Luescher, F.C. Tanner (Zurich, CH)
- Aortic aneurysm inflammatory infiltrate differs between patients with or without risk factors for atherosclerotic disease.** P5387
 – R. Hurks, A. Vink, I.E. Hoefler, D.P.V. De Kleijn, J.P.P.M. De Vries, C.A. Seldenrijk, F.L. Moll, G. Pasterkamp (Utrecht and Nieuwegein, NL)

GENETICS AND CARDIOVASCULAR DEVELOPMENT

- Nanoparticle mediated hypoxia-regulated vascular endothelial growth factor-165 gene transfection with myoblasts for cardiac repair.** P5388
 – L.P. Su, L. Ye, W. Zhang, K.H.H. Husnain, K.K. Poh, M. Joyce, J. Zhang, G. Songco, H.C. Tan, E.K.W. Sim (Singapore, SG; Cincinnati, US)
- The effects of VEGF Receptor-1 and VEGF Receptor-2 ligands on angiogenic responses and left ventricular properties in mouse myocardium.** P5389
 – J.M. Huusko, M. Merentie, M.H. Dijkstra, H. Karvinen, M. Vanwildemeersch, M. Hedman, J. Lipponen, U. Eriksson, M. Shibuya, S. Yla-Herttuala (Kuopio, FI; Stockholm, SE; Tokyo, JP)
- Genetic polymorphism A1675G on type 2 angiotensin receptor increases cardiovascular risk and affects the severity of coronary atherosclerosis in hypertensive individuals.** P5390
 – D. Tousoulis, N. Koumallos, C. Antoniadis, A. Miliou, A. Antonopoulos, D. Mentzifok, C. Bakogiannis, K. Marinou, E. Kallikazarou, C. Stefanadis (Athens, GR)
- Angiogenic gene transfer to rabbit hindlimb skeletal muscle induces cardiac side-effects.** P5391
 – P. Korpisalo, S. Laidinen, J. Hytonen, J. Laitinen, M. Hedman, S. Yla-Herttuala (Kuopio, FI)

- Gene's polymorphism is the major causative factor in hypertension's severity: a study of five candidate genes and their variants.** P5392
 – L. Sydorчук, K.M. Amosova, V.P. Pishak, I.I. Sydorчук, R.I. Sydorчук (Chernivtsi and Kyiv, UA)
- Possessing 4G allele of PAI-1 4G/5G polymorphism has a protective effect against development of myocardial infarction at very young ages.** P5393
 – L. Rallidis, V. Sourides, A. Gialeraki, E. Merkouri, D. Sionis, A. Travlou, J. Lekakis, D. Kremastinos (Athens, GR)
- Weight change following dietary intervention: The role of common genetic variants in FTO and MC4R.** P5394
 – J. Sehmi, B.K. Rai, J.C. Chambers, J.K. Kooner (London, GB)
- Endocardial-myocardial interactions during the development of the zebrafish atrioventricular valve.** P5395
 – S. Kalogirou, D. Tousoulis, C. Stefanadis, D. Beis (Athens, GR)
- The role of immunohistochemistry in post-mortem diagnosis of arrhythmogenic right ventricular cardiomyopathy and guided family screening.** P5396
 – A. Tsatsopoulou, E. Michalodimitrakis, A. Papadomanolakis, A. Asimaki, C. Basso, E. Spanoudaki, P. Syrris, A. Anastasakis, J.E. Saffitz, N. Protonotarios (Naxos, Heraklion and Athens, GR; Boston, US; Padua, IT; London, GB)
- Chemerin and CMKLR1 expression in human arterial wall and periadventitial adipose tissue: correlation with atherosclerosis.** P5397
 – C. Kostopoulos, S. Spiroglou, J. Varakis, H. Papadaki (Patras, GR)
- Changes in atrial function with age. Cardiovascular magnetic resonance study in healthy volunteers.** P5398
 – A.M. Maceira Gonzalez, J. Cosin-Sales, S.K. Prasad, D.J. Pennell (Valencia, ES; London, GB)
- Age-related fibrosis of the atria.** P5399
 – F. Gramley, K. Kettering, C. Weiss, E. Koellensperger, T. Munzel (Mainz and Heidelberg, DE)
- Underestimated left atrial posterior wall in detemining left atrial volume and function.** P5400
 – M.S. Shin, B.R. Kim, K.S. Kim, W.J. Chung, S.H. Han, C.I. Moon, T.H. Ahn, I.S. Choi, E.K. Shin (Incheon and Seoul, KR)
- Quantification of cross-bridge cycling between the different physicochemical conformations by optical means.** P5401
 – T. Harary, A. Landesberg (Haifa, IL)
- Immunorecognition of nucleic acids by endothelial cells and endothelial progenitor cells activates the innate immune system leading to endothelial damage and dysfunction.** P5402
 – S. Zimmer, C. Coch, I. Motz, T. Asdonk, E. Hartmann, W. Barchet, G. Hartmann, S.Z. Wassmann, G. Nickenig (Bonn, DE)
- ADAM10 activity is induced by VEGF, involves ERK1/2 signaling and mediates VE-cadherin cleavage in endothelial cells.** P5403
 – M. Donners, J. Waltenberger (Maastricht, NL)
- Involvement of the endogenous TLR-4 ligand Extra Domain A of fibronectin in collateral artery growth in mice.** P5404
 – D. De Groot, S. Grundmann, D.P.V. De Kleijn, G. Pasterkamp, I. Hoefler (Utrecht, NL; Freiburg im Breisgau, DE)
- LIPIDS AND ABOVE: ATHEROSCLEROSIS**
- Biodistribution of cardiac injected porcine mesenchymal stem cells in remote healthy organs: comparison of intracoronary and intramyocardial delivery.** P5405
 – M. Gyoengyoesi, S. Charwat, R. Hemetsberger, C. Kaun, R. De Martin, F. Gruber, N. Pavo, Z. Petrasi, G. Maurer, J. Wojta (Vienna, AT)
- Heme-catalyzed generation of nitroxyl modulates contractility in cardiac myocytes.** P5406
 – C.G. Tocchetti, S. Donzelli, W. Flores-Santana, S. Betocchi, M. Chiariello, D.J. Stuehr, D.A. Kass, D.A. Wink, N. Paolocci (Naples, IT; Bethesda, Cleveland and Baltimore, US)

- Apoa-1 gene transfer using adeno-associated viral vector serotype 8 produces sustained and high level of functional hdl.** P5407
 – G. Cimmino, W. Chen, W.S. Speidl, C. Giannarelli, B. Ibanez, V. Fuster, R. Hajjar, C.E. Walsh, J.J. Badimon (New York, US)
- Impact of elevated lipoprotein (a) concentration after acute coronary syndrome on one-year prognosis in patients referred for cardiac rehabilitation.** P5408
 – H. Voeller, R. Reibis, C. Jannowitz, B. Karmann, K. Wegscheider, K. Bestehorn (Ruedersdorf, Haar, Munich and Hamburg, DE)
- Higher likelihood of combined lipid goal attainment after treatment with statin plus niacin extended-release multi-pill combination therapy versus LDL-C targeting single pill therapy.** P5409
 – R. Simko, R. Quimbo, M.J. Cziraky, S. Balu (Abbott Park and Wilmington, US)
- The long-term effect between co-administration of simvastatin and ezetimibe and atorvastatin on central pulse wave velocity in adults with hypercholesterolemia.** P5410
 – Y.S. Lee, S.Y. Kim, J.B. Kim, J.B. Lee, J.K. Ryu, J.Y. Choi, K.S. Kim, S.G. Chang (Daegu, KR)
- Effects of exercise on EPC homing factors in the mouse heart.** P5411
 – S. Duttaroy, A. Onerup, P. Larsson, L. Karlsson, M. Borjesson (Gothenburg, SE)
- Atorvastatin worsens glucose metabolism and insulin sensitivity in hypercholesterolemic patients.** P5412 (W)
 – K. Koh, M. Quon (Incheon, KR; Bethesda, US)
- Pitavastatin is not subject to clinically relevant pharmacokinetic interactions when administered with CYP3A4 inhibitors in healthy volunteers.** P5413
 – S. Nakagawa, N. Hounslow (Wokingham, GB)
- The lipid makeup of HDL particles revealed by shotgun lipidomics.** P5414
 – R. Laaksonen, K. Tarasov, A. Verma, R. Hurme, J. Boren, M. Stahlman, H.K. Berthold, I. Gouni-Berthold, K. Ekroos (Espoo, FI; Gothenburg, SE; Bonn and Cologne, DE)
- Comparison of calculated and directly measured low-density lipoprotein cholesterol in patients with acute myocardial infarction.** P5415
 – J.H. Lee, S.C. Chae, M.H. Jeong, Y.J. Kim, K.S. Kim, S.H. Hur, I.W. Seong, T.J. Hong, M.C. Cho, C.J. Kim (Daegu, Gwangju, Daejeon, Pusan, Cheongju and Seoul, KR)
- LDL-induced impairment of human vascular smooth muscle cells migration kinetics is reversed by rosuvastatin. Proteomic analysis.** P5416
 – T. Padro, M. Garcia-Arguinzonis, R. Lugano, L. Badimon (Barcelona, ES)
- New geometric indices of atherosclerotic plaque enlargement: Association with plaque growth pattern and composition as determined by virtual histology.** P5417
 – T. Papaioannou, M. Vavuranakis, O. Katsarou, E. Sanidas, S. Vaina, C. Kavvouras, D. Flessas, K. Toutouzas, D. Tousoulis, C. Stefanadis (Athens, GR)
- Oxidized low density lipoprotein activates p66shc in human aortic endothelial cells.** P5418
 – Y. Shi, G.G. Camici, A. Akhmedov, F.C. Tanner, T.F. Luscher (Zurich, CH)
- Interrelationships of soluble receptor for advanced glycation end products with asymmetric dimethylarginine and arterial stiffness in essential hypertension: a novel insight into atherosclerosis.** P5419
 – K. Dimitriadis, C. Tsioufis, E. Andrikou, D. Syrseloudis, D. Tsiachris, I. Andrikou, D. Tousoulis, V. Tzamou, I. Kallikazaros, C. Stefanadis (Athens, GR)
- Dysfunctional high density lipoprotein contributes to preclinical atherosclerosis in primary antiphospholipid syndrome.** P5420
 – M. Charakida, C. Besler, J. Batuca, S. Sangle, D.J. Alves, C. Mackworth-Young, D. Cruz, T. Luscher, U. Landmesser, J.E. Deanfield (London, GB; Zurich, CH; Lisbon, PT)
- Interaction between vascular redox state and adiponectin synthesis from perivascular adipose tissue, in human atherosclerosis.** P5421
 – C. Antoniadis, C. Bakogiannis, D. Tousoulis, A.S. Antonopoulos, A. Miliou, G. Triantafyllou, G. Ekonomopoulos, C. Psaros, K.M. Channon, C. Stefanadis (Oxford, GB; Athens, GR)

RVX-208 an orally active small molecule increases ApoA-I, pre-beta-HDL, HDL functionality and inhibits markers of inflammation. P5422

– N.C.W. Wong, A. Gordon, G.S. Wagner, S. Atwell, R. Jahagirdar, K. Mclure, F.S. Chiacchia, J. Johansson, D. Bailey, J. Genest (Calgary and Montreal, CA; San Francisco, US)

RISK FACTORS

Night-time heart rate is a stronger predictor of all cause death than resting heart rate and average 24-hour heart rate. P5423

– A. Sajadieh, M. Mouridsen, Z. Binici (Copenhagen, DK)

Trends in resting heart rate from 1991 to 2007 in 332,578 French adults. P5424

– M. Plichart, F. Thomas, J.P. Empana, K. Bean, B. Jengo, B. Pannier, N. Danchin, X. Jouven (Paris, FR)

Elevated resting heart rate in COPD is associated with greater risk of both cardiovascular and all-cause death. The Copenhagen city heart study. P5425

– J.L. Marott, M.T. Jensen, M. Appleyard, G.B. Jensen (Copenhagen, DK)

Diabetes and palpitations are risk factors of atrial fibrillation. The Tromso study. P5426

– A. Nyrnes, E. Arnesen, I. Njolstad, E.B. Mathiesen, T. Wilsgaard, M.L. Lochen (Tromso, NO)

Is there an increased incidence of coronary artery disease in patients with atrial fibrillation? P5427

– R. Liew, T.S. Pham, S.H. Ewe, K.L. Ho, C.K. Ching, L.F. Hsu, W.S. Teo, S.Y. Tan (Singapore, SG)

Cardiovascular versus non-cardiovascular mortality in stroke patients with and without atrial fibrillation and the impact of the CHADS2 score. P5428

– K. Henriksson, B. Farahmand, S. Johansson, S. Aasberg, A. Terent, N. Edvardsson (Lund, Stockholm, Gothenburg and Uppsala, SE)

First documented atrial fibrillation following stroke. P5429

– B. Farahmand, K.M. Henriksson, S. Johansson, S. Aasberg, A. Terent, N. Edvardsson (Stockholm, Lund, Gothenburg and Uppsala, SE)

Short stature is associated with coronary heart disease: a systematic review of the literature and a meta-analysis. P5430

– T.A. Paajanen, N.K.J. Oksala, P. Kuukasjarvi, P.J. Karhunen (Tampere, FI)

Waist-to-hip ratio and prevalent coronary atherosclerosis in women with chest pain. P5431

– B. Shivalkar, K. Wollaert, E. Roelant, R. Salgado, W. Teurfs, L. Leenhouts, P. Parizel, C. Vrints (Antwerp, BE)

Accuracy of anthropometric indexes of obesity to predict diabetes mellitus among hypertensive individuals. P5432

– S.C. Fuchs, A. Marcadenti, P. Maximiliano, L.B. Moreira, F.A. Oliveira, J.L. Neyeloff, M. Gus, F.D. Fuchs (Porto Alegre, BR)

The impact of migration on cardiovascular risk is not uniform across risk factors. P5433

– J. Miranda, R.H. Gilman, L. Smeeth (Lima, PE; Baltimore, US; London, GB)

Risk factors in patients with an out-of-hospital cardiac arrest. P5434

– A. Hamilton, M.J. Moore, K.J. Cairns, A.A.J. Adgey, F. Kee (Belfast, GB)

Long-term antirheumatic therapy induced reversible coronary endothelial dysfunction in patients with early rheumatoid arthritis. P5435

– M. Turiel, S. Sitia, L. Tomasoni, B.D. Bodini, G. Bacchiani, F. Atzeni, P. Sarzi-Puttini, V. De Gennaro Colonna (Milan, IT)

A positive family history for coronary artery disease is significantly associated with a positive family history for hypertension and diabetes. Results of the REACH registry. P5436

– I. Schramm, K.G. Parhofer, J. Roether, T. Limbourg, U. Zeymer (Ludwigshafen am Rhein, Munich and Minden, DE)

Relative risks for total mortality, incident myocardial infarction and incident stroke among Japanese hemodialysis patients. P5437

– M. Ohsawa, K. Itai, K. Tanno, K. Kato, Y. Fujishima, R. Konda, T. Fujioka, M. Nakamura, K. Sakata, A. Okayama (Morioka and Tokyo, JP)

- Cardiovascular risk stratification by the second peak radial systolic blood pressure.** P5438
 – C. Matsumoto, H. Tomiyama, M. Odaïra, J. Yamada, M. Yoshida, K. Shiina, A. Yamashina (Tokyo, JP)
- Risk factors for pre-hypertension in adolescents.** P5439
 – E. Silva, J.J. Villasmi, G. Bermudez, A. Gonzalez, M. Bracho, C. Esis, S. Briceno (Maracaibo, VE)
- The long-term risk of ischemic events in patients with peripheral arterial disease after infrainguinal bypass surgery.** P5440
 – E.S. Van Hattum, M.J.D. Tangelder, J.A. Lawson, B.C. Eikelboom, G.H. Ho, A. Algra, F.L. Moll (Utrecht, Amstelveen and Breda, NL)
- Does depression predict coronary heart disease and cerebrovascular disease equally well? The HESSUP prospective cohort study.** P5441
 – H. Nabi, M. Kivimaki, S. Suominen, M. Koskenvuo, A. Singh-Manoux, J. Vahtera (Villejuif, FR; London, GB; Turku and Helsinki, FI)
- Increased risk of out-of-hospital cardiac arrest associated to treatment with selective serotonin reuptake inhibitors and tricyclic antidepressants - a nationwide study.** P5442
 – P. Weeke, F. Folke, G. Gislason, J. Olesen, L. Kober, H.E. Poulsen, C. Torp-Pedersen, J. Kanfers (Hellerup and Copenhagen, DK)
- Relative contribution of depressive mood to first coronary and first ischemic stroke events over 10 years. The PRIME study.** P5443
 – F. Canoui-Poitrine, J. Ferrieres, J.B. Ruidavets, M. Montaye, J. Yarnell, D. Arveiler, F. Kee, P. Amouyel, P. Ducimetiere, J.P. Empana (Lyon, Toulouse, Lille, Strasbourg and Villejuif, FR; Belfast, GB)
- Relationship between alcohol intake HDL-cholesterol levels, confounding risk factors and cardiovascular disease in a large French cohort: is the cardioprotective action of alcohol a myth?** P5444
 – B. Hansel, F. Thomas-Jean, B. Pannier, K. Bean, A. Kontush, M.J. Chapman, L. Guize, E. Bruckert (Paris, FR)
- Caffeine consumption and risk of incident atrial fibrillation in women.** P5445
 – D. Conen, B.M. Everett, S.M. Zhang, J.E. Buring, C.M. Albert (Basel, CH; Boston, US)
- Prolactin as a possible cardiovascular risk factor in early menopause women.** P5446
 – G. Georgiopoulos, K.S. Stamatelopoulos, I. Lamprinouadaki, M. Lykka, K. Kyrkou, D. Rizos, I. Terzis, G. Christodoulakos, P. Stikakis, C. Papamichael (Athens, GR)
- Elevated heart rate independently predicts mortality and adverse cardiovascular outcome in the elderly.** P5447
 – D. Zachariah, P.R. Kalra, R.N. Foley (Portsmouth, GB; Minneapolis, US)
- Effect of red and white wine on circulating progenitor cells and endothelial function in type 2 - diabetics.** P5448
 – C. Seck, A. M Nia, G. Kreuter, J. Muller-Ehmsen, K.H. Hauser, C. Scheid, P. Frommolt, K. Wielckens, E. Erdmann, M. Flesch (Cologne, DE)
- Paradoxical impact of alcohol consumption on coronary heart disease.** P5449
 – A. Roy, D. Prabhakaran, P. Jeemon, K.R. Thankappan, V. Mohan, L. Ramakrishnan, P. Joshi, F.U. Ahmed, B.V.M. Mohan, K.S. Reddy (New Delhi, Thiruvananthapuram, Chennai, Nagpur, Gulbarga and Bangalore, IN)
- Effect of different cardiovascular risk factors on age at presentation with first acute coronary syndrome.** P5450
 – C.M. Tavares Aguiar, J. Ferreira (Carnaxide, PT)
- Increased hair cortisol levels in patients with acute myocardial infarction.** P5451
 – D. Pereg, R. Gow, G. Koren, M. Lishner, S. Van Uum, M. Mosseri (Kfar Saba, IL; Toronto and London, CA)

RISK PREDICTION

- Doctor-free risk estimation.** P5452
 – A. Dudina, M.T. Cooney, I.M. Graham (Dublin, IE)
- Total arterial compliance: a marker of arterial function to guide risk assessment in intermediate Framingham risk patients.** P5453
 – B.A. Haluska, L.J. Jeffriess, S.G. Carlier, T.H. Marwick (Brisbane, AU)

- A new specific heart score for the elderly of Mediterranean countries.** P5454
 – R. Gabriel, M. Alonso, F. Rodriguez-Salvanes, S. Vega, C. Suarez, L. Lorenzo, J. Muniz (Madrid, Segovia and A Coruna, ES)
- Prediction of cardiovascular death in the general population by Framingham risk score can be significantly improved by addition of soluble plasminogen activator receptor, but not C-reactive protein.** P5455
 – S. Lyngbaek, J. Eugen-Olsen, T.W. Hansen, A. Linneberg, P.R. Hildebrandt, S.B. Haugaard, O. Andersen, M.H. Olsen, J. Jeppesen (Glostrup and Hvidovre, DK)
- Updating prediction models in stead of developing new prediction models.** P5456 (W)
 – K.J.M. Janssen, K.G.M. Moons, D.E. Grobbee, Y. Vergouwe (Utrecht, NL)
- Unifactorial versus multifactorial risk - how single risk factors perform compared with Framingham and ASSIGN cardiovascular risk scores: the SHHEC study.** P5457
 – H. Tunstall-Pedoe, M. Woodward (Dundee, GB)
- Can incorporation of resting heart rate improve risk estimation systems?** P5458
 – M.T. Cooney, E. Vartiainen, T. Laatikainen, A. Juolevi, A. Dudina, I.M. Graham (Dublin, IE; Helsinki, FI)
- Framingham risk score inadequately predicts cardiac risk in young patients presenting with a first myocardial infarction.** P5459
 – L.C. Lee, C.W.Y. Liu, K.M.G. Lee, S.L. Lim, L.M. Shi, H.Y. Ong, Y.T. Lim, T.C. Yeo (Singapore, SG; Sydney, AU)
- Recalibration and validation of the SCORE risk chart in the Australian population: the AusSCORE chart.** P5460
 – L. Chen, A. Tonkin, L. Moon, D. De Bacquer (Melbourne and Canberra, AU; Ghent, BE)
- Determining the precipitants of myocardial infarction: a cohort-case-crossover study.** P5461
 – S.F. Mattschoss, M. Horsfall, C. Astley, H. Morrison, J.C. Vaile, M. Joseph, D.P. Chew (Adelaide, AU)
- Evaluation of cardiovascular risk in the working population.** P5462
 – I.N. Ryamzina, E.N. Koltyrina, A.E. Budalina, N.A. Koryagina (Perm, RU)
- Do SCORE and the current indications for statin treatment allow effective prevention of acute coronary syndromes?** P5463
 – C.M. Tavares Aguiar, J. Ferreira, P. Carmo, A. Ferreira, L. Raposo, P. Goncalves, M. Trabulo, J.M. Aniceto Silva (Carnaxide, PT)
- Multimarker risk model predicts 4 year cardiovascular risk in patients with acute coronary syndromes, independently of clinical patient characteristics.** P5464
 – R.M. Oemrawsingh, T. Lenderink, C. Heeschen, S. Baldus, S. Fichtlscherer, C.W. Hamm, M.L. Simoons, E. Boersma (Rotterdam and Heerlen, NL; Munich, Hamburg, Frankfurt am Main and Bad Neuheim, DE)
- Combined effect of resting heart rate and physical activity on ischaemic heart disease: mortality follow-up in a population study.** P5465
 – J. Nauman, T. Nilsen, U. Wisloff, L. Vatten (Trondheim, NO)
- Increased heart rate is associated with microalbuminuria.** P5466
 – F.P.J. Brouwers, F.W. Asselbergs, A.A. Voors, H.L. Hillege, W.H. Van Gilst (Groningen, NL)
- Impact of baseline heart rate and change in heart rate on mortality in a presumably healthy population. The IPC cohort.** P5467
 – N. Danchin, F. Thomas, K. Bean, J.P. Huby, O. Hanon, J.M. Simon, T. Simon, B. Jego, B. Panier (Paris, FR)

EFFECTS OF PRIMARY AND SECONDARY PREVENTION

- Studying the gap between actual and perceived risk for cardiovascular diseases: results from the Heart Attack Prevention Program for You (HAPPY).** P5468
 – M.K. Stoel, F. Dijk, J. Narula, E.M. Laufer, L. Hofstra (Maastricht, NL; Irvine, US)
- Heart Attack Prevention Program for You (HAPPY): Effects of a mass screening and communication intervention.** P5469
 – F. Dijk, M.K. Stoel, J. Narula, E.M. Laufer, L. Hofstra (Maastricht, NL; Irvine, US)
- Estimates of the magnitude of improvements in cardiovascular risk factors in a diabetes mellitus sub-population enrolled in large-scale primary care intervention programmes.** P5470
 – L. Jessop, C.C. Kelleher, M. Lonergan, H. Ulmer, P. Fitzpatrick (Dublin, IE; Innsbruck, AT)

- A multidisciplinary programme for changes in life style in primary prevention.** P5471
 – S. Scalvini, E. Zanelli, P. Bernocchi, L. Comini, F. Rivadossi, A. Paini, M.L. Muienes (Lumezzane and Brescia, IT)
- Effect of a personalized physical activity programme on weight reduction and endothelial progenitor cells in overweight subjects.** P5472
 – F. Cesari, F. Sofi, I. Corsani, N. Pucci, R. Caporale, R. Abbate, G.F. Gensini, A. Casini (Florence, IT)
- Effect of weight changes on blood pressure and other parameters of cardiovascular risk. ICARIA Study 2004-2007.** P5473
 – M.A. Sanchez Chaparro, A. Garcia Garcia, I. Echeverria Lucotti, J. Roman Garcia, E. Calvo Bonacho, M. Cabrera Sierra, J.V. Monsonis Artero, E. Delgado Palomar, I. Marco Zarazaga, A.E. Gonzalez Fernandez (Madrid, ES)
- Improvement of cardiovascular disease risk factors in middle-aged men by means of health counseling.** P5474
 – R. Siren, J. Eriksson, H. Vanhanen (Helsinki, FI)
- The successful two-year campaign MOST as a powerful instrument for the implementation of the European Heart Health Charter in Slovakia.** P5475
 – G. Kamensky, J. Murin, E. Goncalvesova (Bratislava, SK)
- Adverse events and subsequent changes in beta-blocker treatment in coronary heart disease patients in UK primary care.** P5476
 – E. Setakis, G. Kassianos, S. Cockle, T.P. Van Staa, C. Morley (London, Bracknell, Slough and Bradford, GB)
- Acute coronary syndromes: another gender difference.** P5477
 – M.P. Donataccio, E. Zorzi, P. Lipari, G. Castellani, G. Menegatti, C. Vassanelli (Verona, IT)
- Cardiovascular disease risk factor control and treatment in multiethnic U.S. adults with known coronary heart disease NHANES 2003-2004.** P5478
 – D. Vulic, B. Lee, V. Lopez, N.D. Wong (Banja Luka, BA; Irvine, US)
- Effect of valsartan administration on cardiovascular disease risk in Japanese hypertensive women irrespective of baseline cardiovascular diseases: sub-analysis by gender from the Jikei heart study.** P5479
 – H. Yoshida, M. Shimizu, K. Ikwaki, I. Taniguchi, N. Tada, M. Yoshimura, G. Rosano, B. Dahlof, S. Mochizuki (Kashiwa, Tokorozawa and Tokyo, JP; Rome, IT; Gothenburg, SE)
- Sex-age interaction effect on outcome of patients with stable multivessel coronary artery disease treated by medical, angioplasty or surgery strategy.** P5480
 – N.H. Lopes, J.M. Tsutsui, E.G. Lima, R.D. Vieira, P.R. Soares, F.S. Paulitsch, C.L. Garzillo, L.A.M. Cezar, J.A.F. Ramires, W.A. Hueb (Sao Paulo, BR)
- Gender differences in symptom-to-balloon time and outcomes in patients with STEMI undergoing primary PCI: insights from the Melbourne interventional group (MIG) registry.** P5481
 – N. Andrianopoulos, T. Yip, M. Sebastian, G. New, D. Clark, A.E. Ajani, S.J. Duffy, A. Brennan, C. Reid (Melbourne, AU)
- Women presenting with acute coronary syndromes have similar outcomes compared to men with the same coronary revascularisation strategies.** P5482
 – A. Mansoor, J. Chambers, P. Jain, J. Sehmi, J. Kooner, A. Sethi (London, GB)
- PERIPHERAL ARTERIAL DISEASE – PATHOPHYSIOLOGY AND TREATMENT**
- Aortic aneurysms are associated with inflammation and chemokine upregulation in the vasa vasorum.** P5483
 – O. Dewald, P. Madan, H. Loriz, T. Leucker, H.-J. Kweon, A. Welz, N.G. Frangogiannis (Bonn, DE; Houston, US)
- Malignant vascular phenotypes in Loey-Dietz Syndromes associated with mutations in the TGFBR1 and TGFBR2 genes.** P5484
 – F.I. Gambarin, R. Dore, M. Grasso, N. Marziliano, V. Favalli, A. Serio, M. Pasotti, E. Disabella, S. Mannarino, E. Arbustini (Pavia, IT)
- Prognostic value of intraoperative changes of plasma N-terminal pro-B-type natriuretic peptide in vascular surgery patients.** P5485
 – D. Goei, M.M. Pelka, T.A. Winkel, W.J. Flu, J.P. Van Kuijk, S.E. Hoeks, Y.R.B.M. Van Gestel, O. Schouten, J.J. Bax, D. Poldermans (Rotterdam and Leiden, NL)

- Serum high mobility group box 1 protein elevation is associated with acute respiratory distress syndrome following thoracic aortic aneurysm repair.** P5486
 – T. Kohno, T. Anzai, H. Shimizu, H. Kaneko, Y. Jo, S. Yamada, T. Yoshikawa, A. Ishizaka, R. Yozu, S. Ogawa (Tokyo and Sagami, JP)
- Eight-year experience in aortic valve sparing reimplantation for aortic root aneurysms.** P5487
 – A. Panza, R. Leone, A. Longobardi, P. Masiello, A. Alfano, G. Mastrogianni, F. Cafarelli, S. Iesu, G. Di Benedetto (Salerno, IT)
- Outcomes with type A aortic dissection at a referral center.** P5488
 – S. Unzek, J. Sengupta, S. Senter, D.J. Kumbhani, D. Khan, V. Menon (Cleveland, US)
- Transcatheter reconstruction of the aortoiliac bifurcation in patients with Leriche syndrome.** P5489
 – H. Krankenberg, M. Schlueter, C. Schwencke, D. Walter, A. Pascotto, J. Sandstede, T. Tuebler (Hamburg, DE)
- Aneurysm-induced changes in the mechanical properties and structure of the ascending thoracic aorta.** P5490
 – D.P. Sokolis, E.P. Kritharis, K.M. Lampropoulos, A.T. Giagini, S.A. Papadodima, D.C. Iliopoulos (Athens, GR)
- Utilization of the IRAD death predictive model for Type A aortic dissections at a quaternary institution.** P5491
 – S. Unzek, S. Senter, J. Sengupta, D.J. Kumbhani, D. Khan, V. Menon (Cleveland, US)
- Insights from transesophageal echocardiography into mechanisms of aortic regurgitation associated with dilatation of aortic root. Impact on valve sparing surgery.** P5492
 – P. Gallego Garcia De Vinuesa, A. Castro, J.M. Barquero, O. Araji, M. Chaparro, V. Pedrosa, L. Wu Amen, G. Brunstein, J.M. Cruz Fernandez, C. Infantes (Seville, ES)
- Endovascular treatment of traumatic descending aortic lesions: 9 years of experience.** P5493
 – E.D. De Cillis, A.B. Bortone, V.P. Paradiso (Bari, IT)
- Factors that contributed to the decrease in cerebrovascular mortality in the Czech population from 1985 to 2007/08.** P5494
 – J. Bruthans, R. Cifkova, Z. Skodova, V. Lanska, V. Adamkova, M. Jozifova, M. Galovcova, P. Wohlfart, A. Krajcoviechova, J. Holub (Prague, CZ)
- A simple, new risk factor based approach to refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation: The Euro Heart Survey on atrial fibrillation.** P5495
 – G.Y.H. Lip, R. Nieuwlaat, D. Lane, R. Pisters, H. Crijns (Birmingham, GB; Hamilton, CA; Maastricht, NL)
- Prevalence and impact of previous heart disease in patients with stroke and sinus rhythm.** P5496
 – R. Margato, H. Ribeiro, S. Carvalho, C. Ferreira, J. Gabriel, A. Velon, P. Guimaraes, P. Fontes, P. Mateus, I. Moreira (Vila Real, PT)
- Doctors' choice of antithrombotic therapy after ischemic stroke, a cohort study of 87 111 patients reported to the Swedish Stroke Register (Riks-Stroke).** P5497
 – S. Aasberg, K.M. Henriksson, B. Farahmand, A. Terent (Uppsala, Lund and Stockholm, SE)
- Recruitment of circulating dendritic cell precursors into the brain following stroke.** P5498
 – A. Yilmaz, T. Fuchs, B. Dietel, R. Altendorf, P. Schellinger, I. Bluemcke, S. Schwab, W.G. Daniel, C.D. Garlachs, R. Kollmar (Jena and Erlangen, DE)
- Bone marrow-derived progenitor cells and outcome in patients with ischemic stroke.** P5499
 – F. Cesari, A.M. Gori, R. Marcucci, P. Nencini, G. Pracucci, V. Palumbo, D. Inzitari, G.F. Gensini, R. Abbate (Florence, IT)
- Prospective analysis of 153 patients presenting with cryptogenic stroke treated with percutaneous patent foramen ovale closure: the importance of a strict cardiologic and neurologic follow-up program.** P5500
 – R. Bonvini, R. Sztajzel, P.A. Dorsaz, C. Bonvin, M. Roffi, J. Sztajzel (Geneva, CH)
- Circulating osteoprotegerin levels and long-term prognosis in acute ischemic stroke.** P5501
 – J.K. Jensen, T. Ueland, D. Atar, L. Gullestad, H. Mickley, J.L. Januzzi (Odense, DK; Oslo, NO; Boston, US)

- Cognitive impairment is related to increased arterial stiffness and microvascular damage in patients with never treated essential hypertension.** P5502
 – H. Triantafyllidi, C. Arvaniti, J. Lekakis, I. Ikonomidis, N. Sifakakis, S. Tzortzis, P. Trivoulou, L. Zerva, E. Stamboulis, D. Kremastinos (Athens, GR)

PERIPHERAL ARTERIAL DISEASE – CHALLENGES IN THERAPY

- Open versus closed cell stents for carotid artery stenting (CAS): Does it really matter? Results from the German ALKK CAS registry.** P5503

– R. Zahn, T. Ischinger, J. Jung, M. Hochadel, U. Zeymer, B. Mark, K.E. Hauptmann, I. Janicke, J. Senges, H. Mudra (Ludwigshafen am Rhein, Munich, Worms, Trier and Duisburg, DE)

- Symptomatic vertebral artery stenting with the use of bare-metal and drug-eluting stents: Results from a prospective registry followed by a randomized study.** P5504

– P. Paluszczek, P. Pieniazek, P. Musialek, T. Przewlocki, A. Kablak-Ziembicka, R. Motyl, L. Tekieli, A. Lesniak-Sobelga, K. Zmudka, W. Tracz (Krakow, PL)

- Distal embolization of macroscopic debris during carotid artery stenting is predicted by circulating levels of LDL cholesterol and C-reactive protein.** P5505

– M. De Carlo, A. Rizza, D. Giannini, C. Palmieri, F. Buttitta, G. Trianni, S. Sorbo, A.S. Petronio, S. Berti, A. Balbarini (Pisa and Massa, IT)

- Cerebral reperfusion injury after carotid stenting: the role of transcranial colour-coded Doppler ultrasonography.** P5506

– A. Kablak-Ziembicka, T. Przewlocki, P. Pieniazek, P. Musialek, L. Tekieli, M. Pieculewicz, W. Tracz (Krakow, PL)

- Differences in the rate of cerebral ischemia during carotid artery stenting by type of embolic protection device.** P5507

– T. Tuebler, A. Pascotto, J. Schofer (Hamburg, DE)

- Carotid artery stenting (CAS) for recurrent stenoses after prior CAS: Is it different to CAS for de novo carotid stenoses? Results of the ALKK CAS.** P5508

– M. Meinzer, T. Ischinger, J. Jung, M. Hochadel, U. Zeymer, B. Mark, K.E. Hauptmann, I. Janicke, J. Senges, R. Zahn (Ludwigshafen am Rhein, Munich, Worms, Trier and Duisburg, DE)

- Pre-interventional degree of stenosis and clinical outcome of stenting of the carotid arteries (CAS). Results from the ALKK CAS registry.** P5509

– R. Zahn, T. Ischinger, E. Roth, M. Hochadel, U. Zeymer, B. Mark, K.E. Hauptmann, I. Janicke, H. Mudra, J. Senges (Ludwigshafen am Rhein, Munich, Worms, Trier and Duisburg, DE)

- 'Tailored' carotid artery stenting is associated with a low complication rate: 30-day results from the TARGET-CAS study in 807 consecutive procedures.** P5510

– L. Tekieli, P. Pieniazek, P. Musialek, A. Kablak-Ziembicka, R. Motyl, T. Przewlocki, A. Lesniak-Sobelga, P. Paluszczek, K. Zmudka, W. Tracz (Krakow, PL)

- Is carotid stenting a durable technique? Acute and up to 7 years long-term clinical results from a single-center consecutive series of patients.** P5511

– P. Montorsi, C. Boiti, S. Galli, P. Ravagnani, A. Lualdi, F. Fabbicocchi, D. Trabattoni, G. Teruzzi, A.L. Bartorelli, C. Fiorentini (Milan, IT)

- The prostacyclin analogue iloprost exhibits pro-angiogenic properties in vitro.** P5512

– R. Di Stefano, M.C. Barsotti, C. Armani, C. Ristori, M. Iorio, R. De Caterina, A. Balbarini (Pisa and Chieti, IT)

- Medication underuse during late follow-up in patients with peripheral arterial disease.** P5513

– S.E. Hoeks, W.J.M. Scholte Op Reimer, Y.R.B.M. Van Gestel, W.J. Flu, O. Schouten, J.P. Van Kuijk, C.H. Latour, T.A. Winkel, J.J. Bax, D. Poldermans (Rotterdam and Amsterdam, NL)

- Iloprost positively affects endothelial progenitor cell apoptosis and cytokine paracrine release.** P5514

– R. Di Stefano, M.C. Barsotti, C. Armani, M. Iorio, F. Chiellini, R. De Caterina, A. Balbarini (Pisa and Chieti, IT)

- Sustained release of granulocyte colony-stimulating factor using biodegradable gelatin hydrogel improves limb ischemia.** P5515
 – I. Kawamura, G. Takemura, H. Kanamori, L. Li, A. Tsujimoto, H. Ushikoshi, T. Fujiwara, H. Fujiwara, Y. Tabata, S. Minatoguchi (Gifu, Kyoto and Amagasaki, JP)
- Exercise training on top of standard medication increases endothelial progenitor cells and decreases ADMA levels in patients with PAD.** P5516
 – S. Steiner-Boeker, O. Schlager, A. Giurgea, O. Schuhfried, D. Seidinger, R. Koppensteiner (Vienna, AT)
- Eight-year outcome after endovascular aortic repair for abdominal and thoracic aortic disease: a single centre experience.** P5517
 – C. D'Andrea, F. Piscione, G. Iannelli, L. Di Tommaso, C. D'Anna, A. Pierri, C. Vosa, M. Chiarriello (Naples, IT)
- Superficial femoral artery stenting: insights from a 1000-patient registry.** P5518
 – H. Krankenberg, M. Schlueter, T. Zeller, H. Steinkamp, M. Fischer, T. Tuebler (Hamburg, Bad Krozingen and Berlin, DE)
- What is optimal stent size of self-expandable stent in superficial femoral artery?** P5519
 – Y. Soga, H. Yokoi, T. Urakawa, M. Iwabuchi, M. Nobuyoshi (Kitakyusyu, JP)
- Distal embolic protection device (Emboshield) following local thrombolysis plus conventional angioplasty for acute and subacute limb ischemia: immediate and 1 month results.** P5520
 – G. Aprigliano, A. Palloschi, S. Frigerio, M. Bianchi, F. Glavina, D. Gastaldi, L. Li Volsi, L. Scuteri, S. Bonizzato, A. Anzuini (Milan, IT)
- Efficacy and safety of closing postcatheterisation pseudoaneurysms with ultrasound-guided thrombin injection with two modalities: bolus versus slow injection. A prospective randomized trial.** P5521
 – P. Lewandowski, W. Wasek, P. Maciejewski, A. Budaj (Warsaw, PL)
- Emergency PTA with stenting to internal carotid artery in acute ischemic stroke improves recanalization rates and outcomes.** P5522
 – P.V. Raghava Sarma, R. Murali Babu Rao, M. Sunitha, P. Madhusudhan, S. Anil, P. Anuradha, P. Vijaya (Guntur, IN)

PERIPHERAL ARTERIAL DISEASE – PATHOPHYSIOLOGY AND PROGNOSIS

- Peripheral arterial disease is a predictor of worse prognosis at one year in individuals with an incident stroke.** P5523
 – S.C. Inglis, C. Harkins, J.D. Lewsey, P. Langhorne, S. Capewell, P. Jhund, M. Gillies, S. Stewart, J.J.V. McMurray, K. Macintyre (Melbourne, AU; Glasgow and Liverpool, GB)
- Association between chronic obstructive pulmonary disease and kidney disease in patients with peripheral arterial disease.** P5524
 – Y.R.B.M. Van Gestel, S.E. Hoeks, M. Chonchol, G.M.J.M. Welten, H. Stam, F.W. Mertens, J.J. Bax, H.J.M. Verhagen, R.T. Van Domburg, D. Poldermans (Rotterdam and Leiden, NL; Denver, US)
- Walking performance predicts long-term health in patients with normal or impaired ankle brachial index.** P5525
 – I.I. De Liefde, S.E. Hoeks, K.G. Smolderen, J. Klein, J.J. Bax, H.J.M. Verhagen, R.T. Van Domburg, D. Poldermans (Rotterdam, Tilburg and Leiden, NL)
- Health related quality of life predicts long-term survival in patients with peripheral arterial disease independent of traditional risk factors.** P5526
 – S.E. Hoeks, S.M. Issa, W.J.M. Scholte Op Reimer, S.S. Pedersen, Y.R.B.M. Van Gestel, M.J. Lenzen, R.T. Van Domburg, H.J.M. Verhagen, D. Poldermans (Rotterdam, Amsterdam and Tilburg, NL)
- Metabolic syndrome and cardiovascular risk prediction in peripheral arterial disease.** P5527
 – E. Laurenzano, G. Brevetti, G. Giugliano, S. Lanero, G. Sirico, L. Brevetti, R. Luciano, M. Chiarriello (Naples, IT)
- Prevalence of peripheral artery disease in at risk individuals in the community: Results from a mobile cardiovascular risk assessment program.** P5528
 – M.C. Carrington, S. Nagendrarajah, S. Stewart (Melbourne, AU)

- Reclassification of intermediate and low risk Framingham risk scores using carotid duplex imaging.** P5529
 – G. Tsimiklis, D.W. Armstrong, J. Vyselaar, M. Matangi (Kingston, CA)
- Atherothrombotic event recurrences in diabetic patients account on the same vascular bed. Implications for secondary prevention. The Barbanza diabetes study.** P5530
 – F. Otero-Ravina, R.C. Vidal Perez, J. Alvear-Garcia, C. Caneda-Villar, J. Torres-Colomer, L. Grigorian, J.R. Gonzalez-Juanatey (Santiago de Compostela, ES)
- Upper limb embolectomy - incidence and prognosis. National cohort study.** P5531
 – L.V. Andersen, L.S. Mortensen, J.S. Lindholt, O. Faergeman, E.W. Henneberg, L. Frost (Odense, Aarhus, Viborg and Silkeborg, DK)
- Reduced availability of eNOS-NO axis parameters adversely influences vessel wall characteristics in South Asian stroke survivors compared to European Caucasians in the United Kingdom.** P5532
 – H.M.I. Gunarathne, J.V. Patel, B. Gammon, N. Panja, E.A. Hughes, G.Y.H. Lip (Birmingham, GB)
- Relationship of monocyte count and peripheral vascular changes in patients with erectile dysfunction.** P5533
 – K. Aznaouridis, C. Vlachopoulos, N. Ioakeimidis, G. Antoniou, D. Terentes-Printzios, A. Aggelis, D. Tsiachris, K. Rokkas, A. Askitis, C. Stefanadis (Athens, GR)
- Leukocyte count in peripheral arterial disease: a simple, reliable, inexpensive approach to cardiovascular risk prediction.** P5534
 – G. Giugliano, G. Brevetti, V. Schiano, E. Laurenzano, L. Spadera, J.I. De Maio, M. De Laurentis, M. Chiariello (Naples, IT)
- Nitro-oxidative stress mechanisms are associated with conversion of stable into unstable plaques in symptomatic carotid disease.** P5535
 – I. Andreadou, A. Kotsinas, S. Markantonis, A. Papalambros, K. Filiis, P. Sigalas, A. Niforou, E.K. Iliodromitis, V. Gorgoulis, F. Sigala (Athens, GR)
- ACE D/-240T haplotype modulates the predisposition to peripheral arterial disease.** P5536
 – F. Sofi, C. Fatini, E. Sticchi, A. Abdullahi Said, G. Pratesi, C. Pratesi, R. Abbate, G.F. Gensini (Florence, IT)
- In search for predictors of carotid plaque destabilization: findings from the prospective, ongoing carotid virtual histology and biomarkers (CRACK-VH) study.** P5537
 – P. Musialek, P. Pieniasek, L. Tekieli, A. Kablak-Ziemicka, T. Przewlocki, A. Undas, E. Stepien, M. Pasowicz, K. Zmudka, W. Tracz (Krakow, PL)
- SMAD3 and SMAD7 expression in thoracic and abdominal aortic aneurysm.** P5538
 – M.J. West, M. Nataatmadja, P. Walker (Brisbane, AU)
- Prevalence of peripheral arterial disease in subjects at moderate cardiovascular risk; results of the PANDORA study.** P5539
 – C. Cimminiello, C. Borghi, S. Kownator, J.C. Wautrecht, C.P. Carvounis, S.E. Kranendonk, B. Kindler, A. Agrawal, M. Mangrella (Vimercate, Bologna and Basiglio, IT; Thionville, FR; Brussels, BE; Athens, GR; Tilburg, NL; Zurich, CH)
- Statin therapy in patients with subclinical and evident peripheral artery disease: a meta-analysis.** P5540
 – P. Costanzo, P. Perrone-Filardi, G. Brevetti, S. Paolillo, E. Vassallo, M. Chiariello (Naples, IT)
- What are the factors responsible for radial artery spasm during transradial coronary angiography?** P5541
 – S. Mikami, H. Teragawa, K. Nishioka, N. Mitsuba, Y. Fujii, J. Soga, T. Okada, F. Tadehara, Y. Higashi, Y. Kihara (Hiroshima, JP)
- Assessment of renal artery stenosis using fractional flow reserve - correlation with angiography and ultrasonography.** P5542
 – J.M. Kadziela, A. Witkowski, A. Januszewicz, K. Cedro, I. Michalowska, M. Januszewicz, M. Kabat, A. Prejbisz, L. Kalinczuk, P. Zielen (Warsaw, PL)

MORPHOLOGY, PATHOLOGY, GENETICS AND FETAL CARDIOLOGY

- The burden of cardiovascular manifestations in men and women presenting with FBN1 mutations.** P5543
 – D. Detaint, L. Olivier-Faivre, A. Child, B.L. Loeys, L.C. Ades, E. Arbustini, P.N. Robinson, A. De Paepe, C. Boileau, G. Jondeau (Paris, Dijon and Boulogne, FR; London, GB; Ghent, BE; Sydney, AU; Pavia, IT; Berlin, DE)
- Endothelial dysfunction in aneurysmal fibulin-4 deficient mice.** P5544
 – E. Moltzer, J.W. Roos-Hesselink, J.H.M. Van Esch, J. Essers, A.H.J. Danser (Rotterdam, NL)
- Detailed description of cardiovascular findings in fifty patients with loeys dietz syndrome: all or nothing?** P5545
 – J. De Backer, E. Fishman, P. Spevak, D. Devos, A. De Paepe, H. Dietz, B. Loeys (Ghent, BE; Baltimore, US)
- Outcomes and prognosis in patient with TGFBR2 or FBN1 gene mutation.** P5546
 – D. Attias, C. Stheneur, G. Colod-Beroud, D. Detaint, L. Faivre, M.A. Delrue, H. Plauchu, M. Claustres, C. Boileau, G. Jondeau (Paris, Montpellier, Dijon, Bordeaux, Lyon and Boulogne, FR)
- Environmental exposure of both parents affects the risk of children with congenital heart disease.** P5547
 – M. Cresci, N. Botto, L. Ait-Ali, S. Vittorini, S.V. Luisi, I. Foffa, U. Bottone, M.G. Andreassi (Massa and Pisa, IT)
- Familial kinship analysis of the Utah population database demonstrates a strong familial risk for patients with atrial shunt.** P5548
 – A.D. Michaels, M.H. Steenblik, R. Pimentel, G.P. Mineau (Salt Lake City, US)
- X-chromosome inactivation patterns in left ventricular outflow tract obstruction: epigenetic factors of disease expression.** P5549
 – G. Sarquella Brugada, O. Campuzano, J.L. Bigras, P. Chetaille, A. Richter, G. Andelfinger (Montreal and Quebec, CA)
- Marfan syndrome affects arterial stiffness and endothelial function by modifying the expression of matrix metalloproteinases.** P5550
 – S. Brilli, D. Tousoulis, C. Antoniadis, G. Hatzis, N. Ioakeimidis, C. Vlachopoulos, G. Papazoglou, N. Papageorgiou, A. Antonopoulos, C. Stefanadis (Athens, GR)
- Clinical course of non immune isolated atrio-ventricular block in childhood: a French multicentric study.** P5551
 – A.E. Baruteau, J.J. Schott, E. Villain, H. Le Marec, P. Mabo, V. Probst (Rennes, Nantes and Paris, FR)
- Effect of genotype on biventricular function in adult patients with Marfan syndrome.** P5552
 – A. Kiotsekoglou, A. Gavin, P. Comeglio, J.C. Moggridge, M.J. Mullen, N. Bunce, D.K. Nassiri, A.J. Camm, G.R. Sutherland, A.H. Child (London, GB)
- Immature hearts respond metabolically different to remote ischemic preconditioning than mature hearts: A tracer study.** P5553
 – N. Stottrup, M.R. Schmidt, M.M. Michelsen, R.K. Kharbanda, A. Redington, T.T. Nielsen, H.E. Botker (Aarhus, DK; Oxford, GB; Toronto, CA)
- How useful is serial echocardiography and early transplacental treatment in preventing maternal anti-Ro/SSA and anti-La/SSB antibody-induced fetal cardiac complications?** P5554
 – E.T. Jaeggi, R. Weber, C. Laskin, E.D. Silverman (Toronto, CA)
- Impact of prenatal diagnosis on outcome of univentricular heart disease.** P5555
 – B. Stiasny, M. Fasnacht, R. Pretre, U. Bauersfeld, E. Valsangiacomo Buechel (Zurich, CH)
- Human fetal cardiomyocytes: a novel model for developmental toxicity screening.** P5556
 – C. Danielsson, R. Genead, M. Simonsson, E. Wardell, A. Adersson, K.H. Grinnemo, M. Westgren, E. Sundstrom, L. Dencker, C. Sylven (Stockholm and Uppsala, SE)
- The effect of maternal hypertension on fetal cardiac function: fetal echocardiography study.** P5557
 – A. Sabry (Ismailia, EG)

VALVULAR HEART DISEASE – BASIC PRINCIPLES

- Cardiac manifestations in primary and secondary antiphospholipid syndrome.** P5558
 – N. Chapaveva, A. Demin, M. Trifonova (Novosibirsk, RU)
- Evidence for fibrin presence and tissue factor expression in aortic valves in patients with aortic stenosis: association with transvalvular gradient.** P5559
 – J. Natorska, G. Marek, M. Hlawaty, J. Sadowski, W. Tracz, A. Undas (Krakow, PL)
- Anisotropic conduction and increased vulnerability to reentry in patients with rheumatic mitral stenosis.** P5600
 – C.X. Wong, B. John, S.T. Chandy, M.K. Stiles, A.G. Brooks, P. Kuklik, D.H. Lau, H. Dimitri, M. Alasady, P. Sanders (Adelaide, AU; Vellore, IN)
- Proteomic analysis of clonal interstitial aortic valve cells acquiring a pro-calcific profile.** P5611
 – M. Rattazzi, E. Bertacco, R. Millioni, E. Faggini, L. Iop, G. Arrigoni, S. Sartore, P. Tessari, P. Pauletto (Padua, IT)
- Increased thrombin generation and platelet activation as a compensatory mechanism in patients with aortic stenosis and deficiency in large von Willebrand factor multimers.** P5622
 – A. Undas, K. Bykowska, M. Hlawaty, R. Topor-Madry, B. Sobien, J. Windyga, W. Tracz (Krakow and Warsaw, PL)
- Atorvastatin attenuates severe myxomatous mitral regurgitation via Lrp5/Sox9 chondrocyte formation.** P5633
 – N. Rajamannan, R. Rosenhek, S. Rahimtoola (Chicago and Los Angeles, US; Vienna, AT)
- Human aortic stenosis: potential role of tissue factor in disease development.** P5644
 – J. Breyne, F. Juthier, S. Marechaux, D. Corseaux, C. Zawadzki, E. Jeanpierre, A. Vincentelli, T. Le Tourneau, B. Jude (Lille, FR)
- High-Density Lipoproteins (HDL) are present in stenotic aortic valves and may protect them against calcification.** P5655
 – J.I. Lommi, P.T. Kovanen, M. Jauhiainen, M. Lee-Rueckert, M. Kupari, S. Helske (Helsinki, FI)
- Atorvastatin induces regression of Lrp5 mediated bicuspid aortic stenosis.** P5666
 – N. Rajamannan (Chicago, US)
- Tissue and serum gamma-glutamyltransferase (GGT) activity in degenerative aortic valve stenosis as expression of oxidative and inflammatory process linking dislipidemia to calcification.** P5677
 – A. Mazzone, A. Vianello, S. Cappelli, M.C. Epistolato, M. Glauber, M. Franzini, A. Paolicchi, P. Tanganelli, A. Pompella, S. Berti (Massa, Siena and Pisa, IT)
- Circulating myeloid dendritic cells correlate with disease progression in patients with calcific aortic stenosis.** P5688
 – A. Martischnig, A. Panzenboeck, M. Pfeffer, R. Seitelberger, I.M. Lang, D. Bonderman (Vienna, AT)
- Statins stimulate RGS mediated ERK 1/2 activation in human calcified and stenotic aortic valves.** P5699
 – T. Anger, M. Weyand, M. Hoeher, C.D. Garlachs (Bayreuth and Erlangen, DE)
- High sensitive CRP as a risk marker for progression of aortic stenosis and coronary artery disease in patients with aortic stenosis.** P5710
 – K. Wachtell, K. Boman, M.H. Olsen, R. Willenheimer, K. Egstrup, E. Gerdtts, C. Gohlke-Barwolf, A. Kesaniemi, A.B. Rossebo, T.R. Pedersen (Copenhagen, Glostrup and Svendborg, DK; Umea and Malmo, SE; Bergen and Oslo, NO; Bad Krozingen, DE; Oulu, FI)

PERICARDITIS AND MYOCARDITIS FROM BENCH TO BEDSIDE

- Pericarditis following ST segment elevation myocardial infarction treated by primary coronary angioplasty.** P5711
 – M. Imazio, A. Negro, R. Belli, F. Beqaraj, A. Chinaglia, D. Forno, M. Giammaria, R. Trincherio, Y. Adler, D. Spodick (Tel Hashomer, IL; Worcester, US)
- CD28 mAb alleviating inflammation by blocking the costimulatory signal in murine viral myocarditis.** P5722
 – B. Han, Y. Zhang, L. Zhao, Z. Liu, K. Lu, J. Xi (Jinan, CN)

- Cardiac MRI in a rat model of acute myocarditis.** P5573
 – P. Nassar, O. Merceron, R. Vrancks, L. Louedec, D. Le Guludec, J.B. Michel, J.M. Serfaty (Paris, FR)
- Modulation of dendritic cells quantity and maturation during acute viral myocarditis.** P5574
 – R. Chen, P. Chen, Y.Z. Yang, Y. Yu, Y.Q. Xie, Y.Z. Zou, J.B. Ge, H.Z. Chen (Shanghai, CN)
- Is low voltage in surface ECG in patients with pericardial effusion suggestive of cardiac tamponade?** P5575
 – M. Misra, A. Mall, M. Mittal (Gorakhpur, IN)
- Identification of myocardial inflammation in systemic lupus erythematosus and primary Sjogren's syndrome by cardiovascular magnetic resonance imaging.** P5576
 – S. Mavrogeni, M.N. Manoussakis, K. Spargias, A.K. Tsirogianni, M. Douskou, H.M. Moutsopoulos, D.V. Cokinos (Athens, GR)
- The prevalence, correlates and outcome of atrial fibrillation in tuberculous pericarditis.** P5577
 – F.F. Syed, K.A. Wilkinson, R.J. Wilkinson, M. Ntsekhe, B.M. Mayosi (Newcastle-upon-Tyne and London, GB; Cape Town, ZA)
- Clinical presentation and long term outcome of constrictive pericarditis.** P5578
 – J.M. Santos, E.D. Gabe, J.H. Casabe, F. Renedo, N. Pizzi, R.P. Boughen, R.R. Favalaro (Buenos Aires, AR)
- Clinical utility of cardiac magnetic resonance in tissue characterization in myocarditis.** P5579
 – M. Perazzolo Marra, L. Cacciavillani, M. De Lazzari, R. Turri, F. Corbetti, P. China, A.B. Ramondo, G. Thiene, S. Illiceto (Padua, IT)
- Catalytic subunit LMP2 of stress-induced immunoproteasomes is crucial in the pathogenesis of enterovirus myocarditis.** P5580
 – A. Voigt, E. Opitz, K. Savvatis, K. Stangl, K. Klingel, G. Baumann, P.M. Kloetzel (Berlin and Tübingen, DE)
- Surgical treatment of left sided heart tumours.** P5581
 – R. Vitovsky, V. Popov, G. Knyshev, K. Popova (Kiev, UA)
- Contribution of cardiac MRI to early evaluation and 3-month follow-up in acute myocarditis. a 27-cases prospective study.** P5582
 – P. Paule, Y. Chabrilat, D. Mioulet, J. Quilici, C. Jegou, S. Kerebel, J.-M. Gil, P. Heno, J.-L. Bonnet, L. Fourcade (Marseille, FR)
- The treatment effect of CD40lg in coxsackievirus B3-induced acute viral myocarditis.** P5583
 – B. Han, Z. Liu, L. Zhao, Y. Zhang, K. Lu, J. Xi (Jinan, CN)
- CD69 regulates inflammation and heart failure in experimental autoimmune myocarditis.** P5584
 – A. Cruz-Adalia, L.J. Jimenez-Borreguero, M. Ramirez-Huesca, E. Lopez-Conesa, J. Ruiz-Cabello, F. Sanchez-Madrid, P. Martin (Madrid, ES)
- Diagnostic features of clozapine-induced myocarditis.** P5585
 – J.J. Mcneil, K.J. Ronaldson, A.J. Taylor, P.B. Fitzgerald, D.J. Topliss (Melbourne, AU)
- Long term prognostic evaluation of myopericarditis: a prospective study.** P5586
 – F. Roubille, S. Machado, L. Cornillet, T.T. Cung, C. Sportouch-Dukhan, F. Raczka, J.L. Pasquie, R. Gervasoni, C. Piot, F. Leclercq (Montpellier, FR)
- Impaired right ventricular function in human immunodeficiency virus infected patients. A tissue Doppler imaging approach.** P5587
 – A. Karavidas, D. Tsiachris, G. Lazaros, G. Xylomenos, S. Arapi, N. Potamitis, V. Matzaraki, P. Gargalianos, E. Matsakas, V. Pyrgakis (Athens, GR)
- Vitamin C but not thiamine deficiency in black African patients with heart failure in South Africa: identifying the need for nutritional intervention in the urban African setting.** P5588
 – S. Pretorius, S. Stewart, K. Walker, T. Snyman, N. Crowther, K. Sliwa (Johannesburg, ZA; Melbourne, AU)
- Subclinical contractility impairment in HIV-infected patients: dependence on the class of antiretroviral drugs.** P5589
 – C. Cadeddu Dessalvi, S. Nocco, M. Deidda, D. Pasqualucci, S. Mameli, F. Ortu, P.E. Manconi, G. Mercurio (Monserrato, IT)

The usefulness of scintigraphy with 99mTc-Anti-Granulocyte antibody for diagnosis and follow-up in children with myocarditis. P5590

– L. Ziolkowska, W. Kawalec, M. Biernatowicz, E. Swiatek-Rawa, A. Kaminska, A. Turska-Kmieciak, A. Boruc, E. Czarnowska, M. Pronicki, G. Brzezinska-Rajszys (Warsaw, PL)

Eosinophilic carditis is rare but not to be overlooked. P5591

– B. Maisch, U. Baandrup, R. Moll, S. Pankuweit (Marburg, DE; Hjoerring, DK)

N-terminal pro-B-type natriuretic peptide as a predictor of the disease progression in patients with pericardial effusions. P5592

– S.-J. Kim, E.-S. Shin, S.-G. Lee (Ulsan, KR)

Peculiar aspects of cardiac involvement in children with acquired immunodeficiency syndrome. P5593

– A.-G. Dimitriu, C. Jitareanu (Iasi, RO)

Diosgenin suppress cardiac apoptotic pathway in ovariectomized rats. P5594

– S.-D. Lee, W.-W. Kuo, C.-Y. Huang (Taichung, TW)

Characterization and outcomes of patients with constrictive pericarditis. P5595

– R. Lopes, P. Lourenco, P. Dias, J.C. Silva, M.J. Maciel, P. Bettencourt (Porto, PT)

Atorvastatin attenuates Cocksackievirus B3-induced viral myocarditis in mice. P5596

– G.G. Wang, J. Guan (Beijing, CN)

Elevated expression of ADAMTS-1 in CVB3 induced murine acute and chronic myocarditis and the relationship with myocardial fibrosis. P5597

– R. Chen, E. Shen, Y.Z. Yang, J.B. Ge, H.Z. Chen (Shanghai, CN)

The value of serum tumour markers in the prediction of the etiology and follow-up of the patients with pericardial effusion. P5598

– U. Bildirici, D. Ural, T. Sahin, T. Kilic, Y.U. Celikyurt, E. Acar, E. Ural (Kocaeli, TR)

CARDIAC RESYNCHRONISATION THERAPY: RESPONDERS AND NON-RESPONDERS

Evolution of QRS duration in patients hyper responder to cardiac resynchronization therapy. P5599

– P. Castellant, E. Orhan, M. Fatemi, Y. Etienne, V. Bertault-Valls, J.J. Blanc (Brest, FR)

Cardiac resynchronization therapy: antiarrhythmic and mortality effect of reverse ventricular remodeling in hyperresponders. P5600

– R. Ramos, M. Oliveira, M. Nogueira Da Silva, P. Cunha, A. Mamede, L. Branco, A. Galrinho, S. Alves, P. Sarmiento, R.C. Ferreira (Lisbon, PT)

Coronary artery bypass grafting with and without concomitant epicardial cardiac resynchronization therapy in patients with ischemic heart failure: long-term results. P5601

– A. Romanov, E. Pokushalov, A. Cherniavskiy, D. Prohorova, A. Boboshko, A. Marchenko, S. Alsov (Novosibirsk, RU)

Post-implant CRT optimisation using stroke distance converts non-responders to responders. P5602

– D. Thomas, A.G. Fraser, A. Penny, Z.R. Yousef (Cardiff, GB)

Influence of the preimplantation QRS axis on responses to cardiac resynchronization therapy. P5603

– F.J. Garcia Seara, J.M. Sande, J. Elices, B. Cid, X. Fernandez, A. Roman, E.G. Babarro, J.G. Juanatey (Santiago De Compostela, ES)

Upgrading to resynchronization therapy after chronic right ventricular pacing improves left ventricular remodeling. P5604

– G.M. Froehlich, J. Steffel, F. Enseleit, T.F. Luescher, F. Duru, F. Ruschitzka, A. Hasan, W.T. Abraham, J. Holzmeister (Zurich, CH; Columbus, US)

Prognostic significance of reduction of functional mitral regurgitation after cardiac resynchronization therapy. P5605

– K. Matsumoto, H. Kawai, T. Onishi, Y. Fukuda, M. Okada, K. Norisada, K. Tatsumi, K. Ryo, K. Hirata, T. Kajiya (Kobe and Himeji, JP)

Efficacy of cardiac resynchronization therapy depends on outcome definitions. P5606

– M. Aarones, S. Aakhus, H. Aass, T. Moum, R. Wergeland, L. Gullestad, E. Kongsgaard (Oslo and Tonsberg, NO)

- Successful cardiac resynchronization therapy prevents new onset atrial fibrillation during long term follow up.** P5607
 – S. Buck, A.H. Maass, B.A. Schoonderwoord, D.J. Van Veldhuisen, I.C. Van Gelder (Groningen, NL)
- Atrio-biventricular pacing for severely symptomatic hypertrophic obstructive cardiomyopathy. Feasibility and long-term results.** P5608
 – D. Perez, A. Berruezo, R.G. Vatasescu, G. Papiashvili, B. Vidal, M. Sitges, L. Mont, J. Brugada (Barcelona, ES)
- Dyssynchrony severity before and after cardiac resynchronization therapy is dependent on the number of wall segments and velocity timing parameter used in the analysis.** P5609
 – B. Gordon, E.W. Chew, M. Harbinson (Belfast, GB)
- Gender effect in selecting patients for cardiac resynchronization.** P5610
 – S. De Feo, A. Fusco, C. Muto, T. Maounis, A. Schuchert, T. Guidotto, E. Boulogne, L. Padeletti (Peschiera del Garda, Naples and Florence, IT; Athens, GR; Hamburg, DE; Zaventem, BE)
- Acute hemodynamic response to cardiac resynchronization therapy by non contact mapping.** P5611
 – A. Ricco, A. Dello Russo, R. Remoli, M. Casella, G. Pelargonio, F. Bellocchi, C. Tondo, P. Zecchi, A. Natale (Rome, IT; Texas, US)
- Long term survival in very elderly patients receiving cardiac resynchronization with defibrillator (CRT-D) therapy.** P5612
 – M. Jeilan, D. Das, S. Wong, J.H. Tuan, W. Nicolson, R.K. Pathmanathan, F. Osman, I. Loke, D. Chin, G.A. Ng (Leicester, GB)
- Routine Iterative AV delay optimisation post CRT: is it worthwhile?** P5613
 – N. Shanmugam, M. Bizrah, S. Jones, G.R. Sutherland, L.J. Anderson (London, GB)
- AV-optimization by finger photoplethysmography.** P5614
 – L.M. Permentier, A.H. Maass, S. Buck, B.A. Schoonderwoerd, D.J. Van Veldhuisen, I.C. Van Gelder (Groningen, NL)
- A new ecg criterion devised for cardiac resynchronisation therapy outcome prediction.** P5615
 – A. Vereckei, V. Kutyifa, L. Geller, M. Kiss, G. Szenasi, E. Zima, B. Merkely (Budapest, HU)
- Surface sonR signal: a new tool for non invasive estimation of systolic and diastolic time intervals in CRT patients.** P5616
 – E. Donal, L. Giorgis, S. Cazeau, G. Jaubert, A. Hernandez, C. Leclercq, P. Mabo (Rennes and St Cloud, FR)
- CRT optimisation: a double-blind crossover study examining a transthoracic impedance guided strategy.** P5617
 – D. Thomas, S.A. Exton, Z.R. Yousef (Cardiff, GB)
- Cardiac resynchronization therapy: what concordance between clinical, functional, echocardiographic and neurohormonal responses?** P5618
 – G. Boriani, E. Cervi, C. Martignani, M. Biffi, D. Saporito, I. Diemberger, C. Valzania, G. Domenichini, M. Ziacchi, A. Branzi (Bologna, IT)

CARDIAC RESYNCHRONISATION THERAPY: DEVICE AND IMAGING

- The trade off between device and patient longevity in cost-effective analyses of CRT-D.** P5619
 – M. Jeilan, D. Das, J.H. Tuan, W. Nicolson, S. Kundu, S. Yusuf, F. Osman, S. Wong, I. Loke, G.A. Ng (Leicester, GB)
- Prevalence and risk factors related to infections of cardiac resynchronization therapy devices.** P5620
 – A. Da Costa, C. Romeyer-Bouchard, L. Bisch, M. Messier, B. Samuel, K. Isaaz (Saint Etienne, FR)
- Incidence and severity of sleep apnoea syndromes in patients with congestive heart failure: Is there a difference between optimal CHF medication, CRT-ICD and ICD therapy?** P5621
 – W. Maeuser, R. Amschler, S. Sandrock, B. Weidtmann, M. Reppel, H. Bonnemeier (Lubeck, DE)

- Management strategy in patients with phrenic nerve stimulation during the implant of left ventricular leads for cardiac resynchronization therapy. A 6-year cohort study.** P5622
 – E. Arbelo Lainez, F. Melian Nuez, E. Caballero Dorta, B. Moreno Djadou, C. Rios Diaz, M. Diaz Escofet, R. Ramirez Rodriguez, A. Medina Fernandez-Aceytuno (Las Palmas de Gran Canaria, ES)
- Incidence and causes of inappropriate detection and therapy in patients with CRT-D. A 6-year cohort study.** P5623
 – E. Arbelo Lainez, A. Garcia Quintana, E. Caballero Dorta, B. Moreno Djadou, J. Novoa Medina, C. Rios Diaz, R. Ramirez Rodriguez, A. Medina Fernandez-Aceytuno (Las Palmas de Gran Canaria, ES)
- Survival and incidence of ventricular tachyarrhythmias among recipients of combined resynchronisation and primary prevention defibrillators versus conventional defibrillators.** P5624
 – M. Stockburger, A. Krebs, O. Celebi, T. Knaus, A. Nitardy, D. Habedank, R. Dietz (Berlin, DE)
- Usefulness of epicardial electrogram to select optimal site of left ventricular pacing in cardiac resynchronisation therapy.** P5625
 – M. Fatemi, G. Le Gal, Y. Etienne, I. Fersi, P. Castellant, J.J. Blanc (Brest, FR)
- Long term results with coronary sinus side branch stenting to anchor the coronary sinus lead.** P5626
 – L. Geller, S.Z. Szilagy, E. Zima, L. Molnar, T. Tahin, E.M. Vegh, B. Merkely (Budapest, HU)
- Changes in arrhythmia occurrence and antitachycardia pacing efficacy during cardiac resynchronization therapy: results of the advance crt-d substudy.** P5627
 – J.O. Schwab, M. Gasparini, F. Anselme, J. Clementy, M. Santini, J. Martinez Ferrer, T. De Santo, E. Santi (Bonn, DE; Rozzano and Rome, IT; Rouen and Bordeaux, FR; Vitoria, ES)
- Efficacy of cardiac resynchronization therapy to cardiac sympathetic function evaluated by 123I-MIBG myocardial scintigraphy.** P5628
 – K. Imamura, K. Okajima, A. Shimane, G. Kanda, Y. Taniguchi, T. Hayashi, S. Yamada, K. Mizutani, S. Iwata, T. Kajiya (Himeji, JP)
- Development of novel method for assessing myocardial synchrony.** P5629
 – Y.E. Yoon, H.J. Chang, S.I. Choi, H.K. Kim, Y.J. Kim, D.W. Sohn, B.J. Fetics, D.A. Kass, A.C. Lardo (Seoul, KR; Baltimore, US)
- Strain delay index by speckle tracking to identify responder to CRT in narrow QRS population.** P5630
 – P. Lim, O. Lairez, J.L. Dubois Rande, R.A. Grimm, P. Gueret (Creteil, FR; Cleveland, US)
- Understanding dyssynchrony: Is septal flash caused by reversed transeptal pressure gradient or by early unopposed septal contraction?** P5631
 – O. Gjesdal, E.W. Remme, A. Opdahl, H. Skulstad, K. Russell, E. Kongsgaard, O.A. Smiseth, T. Edvardsen (Oslo, NO)
- Loss of opposite left ventricular basal and apical rotation predicts response to cardiac resynchronization therapy.** P5632
 – I.K. Russel, M.J.W. Gotte, G.J. De Roest, J.T. Marcus, S.R. Tecelao, C.P. Allaart, C.C. De Cock, R.M. Heethaar, A.C. Van Rossum (Amsterdam, NL)
- Left ventricular twist and mechanical dyssynchrony in heart failure patients undergoing cardiac resynchronization.** P5633
 – A. Ciarka, M. Bertini, V. Delgado, C.J.W. Borleffs, R.J. Van Bommel, N. Van De Veire, M.J. Schalij, J.J. Bax (Leiden, NL)
- Electrical activation and wall motion in post-infarction patients with narrow QRS complex and mechanical dyssynchrony.** P5634
 – H.U. Klemm, K.T. Krause, R. Ventura, M.A. Aydin, N. Gosau, C. Schneider, C. Johnsen, S. Boczor, T. Meinertz, K.H. Kuck (Hamburg, DE)
- Regression of LV radial dyssynchrony assessed by speckle tracking imaging after CRT is more predictive of 6-month reverse remodelling than changes in longitudinal dyssynchrony assessed by DTI.** P5635
 – C. Jego, L. Tafaneli, A. Salem, R. Saad, Y. Ledolley, S. Kerebel, A. Pena, F. Franceschi, J.C. Deharo, G. Habib (Marseille, FR)

Detecting abnormal septal motion by combining spatial and electrical information from endocardial mapping data in CRT candidates. P5636

– O. Camara-Rey, S. Oeltze, M. De Craene, R. Sebastian, E. Silva, D. Tamborero, L. Mont, M. Sitges, B.H. Bijnens, A.F. Frangi (Barcelona, ES; Magdeburg, DE)

Could cardiac resynchronization therapy impact on right ventricle remodelling? P5637

– E. Hatzinikolaou-Kotsakou, G. Moshos, T.H. Belevelisli, E. Reppas, E. Karapatsoudi, M. Kotsakou, K. Tsakiridis (Thessaloniki and Edessa, GR)

CARDIAC RESYNCHRONISATION THERAPY: MOLECULAR ASPECTS

Gln27Glu beta-2 adrenergic receptor gene polymorphism influences the magnitude of left ventricular reverse remodelling and the relative risk of cardiovascular events after CRT. P5638

– N. Pezzali, M. Metra, L. Covolo, A. Curnis, U. Gelatti, F. Donato, L. Dei Cas (Brescia, IT)

Changes in the matricellular protein osteopontin, reflect ventricular remodelling in patients undergoing cardiac resynchronisation therapy. P5639

– M. Elsik, H. Pfluger, C. Hayward, D.L. Prior, H. Schneider, A. Broughton, C. Wong, B. Wang, A. Taylor, H. Krum (Melbourne and Sydney, AU)

Interleukin 6 and NT-proBNP in heart failure patients with cardiac resynchronization therapy. P5640

– T. Minarik, R. Dolecek, D. Brecka, K. Grussmannova (Ostrava, CZ)

Tumor necrosis factor alpha correlates with LV reverse remodeling and with clinical events in heart failure patients treated with cardiac resynchronization therapy. P5641

– R. Rordorf, A. Sanzo, S. Savastano, A. Vicentini, B. Petracci, M. De Amici, F. Canevese, E. Gandolfi, C. Torre, M. Landolina (Pavia, IT)

Effects of cardiac resynchronization therapy on left ventricular twist. P5642

– M. Bertini, N. Ajmone Marsan, V. Delgado, G. Nucifora, R.J. Van Bommel, C.J.W. Borleffs, G. Boriani, M. Biffi, M.J. Schalij, J.J. Bax (Leiden, NL; Bologna, IT)

Long term effects of upgrading from right ventricular pacing to cardiac resynchronisation pacing in patients with heart failure. P5643

– P.W.X. Foley, S. Muhyaldeen, S. Chalil, R.E.A. Smith, J.E. Sanderson, F. Leyva (Birmingham, GB)

Cardiac resynchronization therapy with fusion can be maintained during long term follow-up in HF patients with normal AV conduction. P5644

– R.-G. Vatasescu, A. Berruezo, C. Iorgulescu, A. Fruntelata, M. Dorobantu (Bucharest, RO; Barcelona, ES)

Echocardiographic myocardial scar burden predicts response to cardiac resynchronization therapy in ischemic heart failure. P5645

– A. Dal Monte, E. Agricola, M. Galderisi, F. Rigo, R. Citro, P. Della Valentina, A. Calabrese, S. Giatti, D. Mele, R. Ferrari (Ferrara, Milan, Naples, Mestre-Venezia and Vallo Della Lucania, IT)

Septal rebound stretch reflects the functional substrate to cardiac resynchronization therapy and predicts volumetric and neurohormonal response. P5646

– G.E. Leenders, B.W.L. De Boeck, A.J. Teske, M. Meine, M.J. Cramer, F.W. Prinzen, P.A. Doevendans (Utrecht and Maastricht, NL)

Is long-term response to the morphology discrimination algorithm stable in CRT-D patients? P5647

– A.M. Sinha, A. Lang, A. Kloppe, G. Ritscher, K.J. Gutleben, M. Schmidt, C. Mahnkopf, H. Rittger, F. Birkenhauer, J. Brachmann (Coburg, Erfurt, Ludenscheid and Eschborn, DE)

Does right ventricular pacing lead have a role in non-responsiveness to cardiac resynchronization therapy in patients receiving biventricular pacemakers. P5648

– L.E. Sade, O. Demir, I. Atar, B. Ozin, H. Muderrisoglu (Ankara, TR)

Incremental value of assessing intraventricular dysscoordination of regional myocardial contraction in patients referred for cardiac resynchronization therapy. P5649

– Y. Seo, T. Ishizu, M. Yamamoto, T. Machino, R. Kawamura, H. Yamasaki, Y. Sekiguchi, H. Tada, K. Aonuma (Ibaraki, JP)

- Reverse remodeling induces progressive ventricular resynchronization after cardiac resynchronization therapy: from vicious to virtuous circle.** P5650
 – K. Matsumoto, H. Kawai, T. Onishi, Y. Fukuda, M. Okada, K. Norisada, K. Tatsumi, K. Imamura, K. Hirata, T. Kajiya (Kobe and Himeji, JP)
- Beta-blocker therapy uptitration enhances reverse remodeling after CRT.** P5651
 – G. Borelli, L. Rondinini, F. Bellini, E. Galli, I. Kardasz, E. Soldati, G. Zucchelli, M.G. Bongiorno, R. Mariotti (Pisa, IT)
- The advantage of triangle ventricular pacing over conventional biventricular pacing becomes more prominent during the tachycardia setting.** P5652
 – H. Tada, H. Yamasaki, Y. Sekiguchi, T. Arimoto, K. Kuroki, M. Igarashi, T. Machino, T. Ishizu, Y. Seo, K. Aonuma (Tsukuba, JP)
- Invasive validation of a modified myocardial performance Index (TEI-index) which is applicable to heart failure patients with atrial fibrillation, left bundle branch block or AV-conduction disorders.** P5653
 – K. Bonaventura, W. Koglek, S. Jander, A. Fengler, W. Franz, J. Brandl, G. Grimm, M. Hoffmann (Potsdam, DE; Klagenfurt, AT)
- A critical comparison of echocardiographic measurements used for optimising CRT: stroke distance is best.** P5654
 – D. Thomas, Z.R. Yousef, A.G. Fraser (Cardiff, GB)

HEART FAILURE CO-MORBIDITIES

- The importance of aggravated renal dysfunction on mortality in patients with acute heart failure.** P5655
 – A. Vaz Perez, K. Otawa, A.V. Zimmermann, R. Herrmann, M. Stockburger, W. Doehner, K. Werdan, H. Schmidt, M. Rauchhaus (Berlin and Halle, DE)
- High prevalence of atherosclerotic renal artery stenosis in the cardiorenal syndrome; negative association with diabetes mellitus.** P5656
 – M.E. Emans, K. Van Der Pulten, B.K. Velthuis, M.J.M. Cramer, L. Meiss, B. Braam, P.A.F.M. Doevendans, C.A.J.M. Gaillard (Utrecht and Amersfoort, NL; Edmonton, CA)
- Prognostic value of three commonly used different methods of assessing renal function in ambulatory patients with chronic heart failure and systolic dysfunction.** P5657
 – C. Leuzzi, A. Barbieri, F. Bursi, L. Reggiani, C. Manicardi, M.G. Modena (Modena, IT)
- Worsening renal function in acute heart failure: change in BP and effects of relaxin.** P5658
 – A.A. Voors, G.M. Felker, M. Metra, J.R. Teerlink, P. Ponikowski, B.H. Greenberg, E. Unimori, G. Filippatos, G. Cotter, S.L. Teichman (Groningen, NL; Durham, San Francisco and San Diego, US; Brescia, IT; Wroclaw, PL; Athens, GR)
- The impact of renal transplantation on the evolution of severe congestive heart failure in patients with end stage renal disease.** P5659
 – C. Bucsa, D. Tacu, C. Ceck, A. Bucsa, I. Sinescu (Bucharest, RO)
- The consequences of the presence of cardio-inflammatory-anemic-renal syndrome in heart failure patients.** P5660
 – G.-A. Dan, A.-R. Dan, C. Stanescu, A. Buzea, I. Daha, S. Caraiola (Bucharest, RO)
- Comparison between anemia and blood volume hematocrit for mortality prediction in heart failure patients.** P5661
 – F.M. Perea, M. Diez, M. Descalzo, L. Favaloro, D. Puente (Buenos Aires, AR)
- Sex-related differences in the prevalence of anemia and renal dysfunction in patients with chronic heart failure.** P5662
 – E. Karapatsoudi, K. Koskinas, K. Oikonomou, K. Karali, A. Ioannidis, Z. Alekou, P. Makridis (Edessa and Thessaloniki, GR)
- Glycaemic status estimated by OGTT and HbA1C is not associated with severity of heart failure and metabolic variables in outpatients with systolic heart failure.** P5663
 – M. Egstrup, M. Schou, C. Kistorp, I. Gustafsson, C. Tuxen, P. Hildebrandt (Frederiksberg, Hilleroed, Gentofte and Glostrup, DK)
- Thyroid hormone administration diminishes left ventricular remodeling and improves cardiac function in rats when started both early and late after experimental myocardial infarction.** P5664
 – I. Mourouzis, G. Galanopoulos, N. Tsagoulis, K. Markakis, D. Spanou, C. Pantos, D.V. Cokkinos (Athens, GR)

- Ovarian sex hormones are involved in the protection against diabetes-induced left ventricular dysfunction in female mice.** P5665
 – K. Koide, T. Meguro, Y. Nagatomo, T. Anzai, S. Ogawa, T. Yoshikawa (Tokyo, JP)
- Serum prolactin levels are elevated and correlated with immune activation in chronic heart failure patients with depressive symptoms.** P5666
 – D. Farmakis, J.T. Parisis, M. Nikolaou, D. Birmpa, D. Karatzas, F. Tsakalis, C. Tsimplis, C. Olympios, G. Filippatos, D. Kremastinos (Athens, GR)
- Short term depressive symptoms seem to confer to endothelium dysfunction in patients with chronic heart failure.** P5667
 – G. Metallinos, C. Chrysohoou, C. Pitsavos, C. Kastorini, A. Miliou, S. Athanasopoulou, P. Aggelopoulos, C. Stefanadis (Athens, GR)
- Selective serotonin reuptake inhibitor administration reduces markers of oxidative stress in depressed patients with chronic heart failure.** P5668
 – M. Nikolaou, J.T. Parisis, I. Andreadou, C. Michalakeas, N. Antonellos, A. Douzenis, S. Kiroudis-Markantonis, G. Filippatos, E. Lykouras, D. Kremastinos (Athens, GR)
- High prevalence of vitamin D deficiency and association of vitamin D levels with left ventricular function in elderly chronic heart failure patients.** P5669
 – P. Ameri, M. Casu, A. Denegri, M. Bovio, D. Ronco, F.E. Gianiorio, M. Murialdo (Genoa, IT)
- Determinants of quality of life and mood in patients with heart failure and chronic obstructive disease: an analysis across five projects of the German competence network heart failure.** P5670
 – G. Gueder, G. Gelbrich, S. Stork, S. Brenner, S. Pankuweit, J. Weil, R. Wachter, V. Regitz-Zagrosek, G. Ertl, C. Angermann (Wurzburg, Leipzig, Marburg, Gottingen and Berlin, DE)
- Prevalence of anderson fabry disease (afd) and cardiac involvement.** P5671
 – F.I. Gambarin, V. Favalli, A. Serio, M. Pasotti, P. Cassini, N. Marziliano, M. Grasso, E. Arbustini (Pavia, IT)
- HSPA1L 2437C>T polymorphism as a risk factor for deterioration of left ventricular function in coronary artery disease.** P5672
 – I. Portig, F. Kliebe, C. Kliebe, B. Maisch (Marburg, DE)
- Age-dependent values of NT-proBNP are superior to a single cut-point for ruling out heart failure. The international collaborative study of natriuretic peptides in primary care (ICON-PC).** P5673
 – P. Hildebrandt, P. Collinson, R.N. Doughty, A. Fuat, D. Gaze, F. Gustafsson, J. Januzzi, J. Rosenberg, R. Senior, M. Richards (Glostrup, Copenhagen and Frederiksberg, DK; London and Darlington, GB; Auckland and Christchurch, NZ; Boston, US)
- Increased incidence of hypogonadism in patients with heart failure and diabetes mellitus.** P5674
 – V. Markussis, S. Mavrogeni, E. Demerouti, E. Papadopoulou, G. Kolovou, D. Degiannis, A. Chaidaroglou, D.V. Cokkinos (Athens, GR)

ACUTE HEART FAILURE: PROGNOSIS AND BIOMARKERS

- NT-proBNP: independent risk factor for myocardial damage and 1 year mortality.** P5675
 – M. Meyer, S. Djouhri, R. Cailliod, A. Mengin, C. Girard (Dijon, FR)
- Endothelial and white blood cells microparticle levels are elevated in congestive heart failure and related to diastolic load.** P5676
 – K. Dierickx, E. Barbato, L. Delrue, E. Weinberg, J. Sarma, P. Meeus, M. Vanderheyden, J. Bartunek (Aalst, BE; Boston, US)
- Usefulness of ventilatory pattern evaluation during cardiopulmonary exercise test in elderly patients suffering from chronic heart failure.** P5677
 – A.B.S. Scardovi, D.M.R. De Maria, A.F. Ferraironi, A.C. Celestini, S.S. Sciarretta, B.L. Bordi, N.A. Aspromonte, R.R. Ricci, M.G. Guazzi (Rome, Milan and Civitavecchia, IT)
- High prevalence of sleep disordered breathing in a general heart failure population, especially in patients with preserved systolic function.** P5678
 – T. Bjorkeng, H. Akre, B. Overland, A. Westheim (Oslo, NO)

Apolipoprotein E genotypes are associated with lipid levels and CRP but not outcomes in heart failure. P5679

- S. Padmanabhan, J.J.V. McMurray, J. Kjekshus, P. Dunselman, A. Hjalmarson, H. Wedel, F. Waagstein, J. Wikstrand, J.C. Fox, O. Bengtsson (Glasgow and Macclesfield, GB; Oslo, NO; Breda, NL; Gothenburg and Moindal, SE)

Prognostic ability of a Mediterranean dietary score in heart failure: Preliminary analysis of the GISSI-Heart failure Trial. P5680

- R. Marchioli, M.G. Franzosi, R. Latini, A.P. Maggioni, R.M. Marfisi, C. Minneci, G.L. Nicolosi, M. Romei, G. Tognoni, L. Tavazzi (Santa Maria Imbaro, Milan, Florence, Pordenone, Poggibonsi and Cotignola, IT)

Neurohormonal and functional correlates of linear and fractal behavior indexes of heart rate variability in HF patients. P5681

- G. D'Addio, R. Maestri, G.D. Pinna, M.T. La Rovere, G.M. Corbi, A. Accardo, N. Ferrara (Telese Terme, Montescano, Campobasso and Trieste, IT)

The assessment of clinical and prognostic role of flow-mediated vasodilatory response depending on etiology of chronic heart failure. P5682

- I. Shkurat (Kyiv, UA)

Factors associated with heart failure and coronary heart disease mortality during 24-years follow-up in Japan: NIPPON DATA80. P5683

- Y. Nakamura, T. Turin, N. Rumana, K. Miura, Y. Kita, N. Takashima, T. Hayakawa, T. Okamura, H. Ueshima (Kyoto, Otsu, Fukushima and Suita, JP)

Is persistent hyponatremia associated with increased mortality in heart failure patients in the community? P5684

- S. Ghosh, P. Stimson, J. Smith, J. Dexter, C. Carroll-Hawkins, N.I. O'Kelly (Leicester, GB)

Prognostic importance of co-enzyme Q10 in heart failure and interaction with statin therapy in the controlled rosuvastatin multinational trial in heart failure trial (CORONA). P5685

- J.J.V. McMurray, J. Kjekshus, P. Dunselman, A. Hjalmarson, H. Wedel, M. Lindberg, F. Waagstein, J. Wikstrand (Glasgow, GB; Oslo, NO; Breda, NL; Gothenburg and Moindal, SE)

Hypertension emergencies presenting as acute heart failure. The studying the treatment of acute hypertension registry. P5686

- W.F. Peacock, A. Amin, C. Granger, A. Wyman, P. Levy, J.M. Gore, C. Pollack, K. Kleinschmidt, J. Varon (Cleveland, Irvine, Durham, Boston, Detroit, Philadelphia, Dallas and Houston, US)

The effects of B-type natriuretic peptide testing at the emergency settings for acute heart failure on clinical outcomes (Meta-analysis). P5687

- L. Lam, H. Schneider, N. Andrianopoulos, H. Krum, M. Abramson, C. Mueller, P. Cameron (Melbourne, AU; Basel, CH)

Clinical profile and management are different in acute pulmonary edema and acutely decompensated chronic heart failure in ALARM-HF survey. P5688

- J.T. Parissis, A. Mebazaa, M. Nikolaou, I. Ikonomidis, F. Vilas-Boas, J. Delgado, H. Smith, F. Follath (Athens, GR; Paris, FR; Salvador, BR; Madrid, ES; London, GB; Zurich, CH)

Impact of diastolic dysfunction on the development of heart failure in diabetic patients after acute myocardial infarction. P5689

- D. Aronson, A. Musallam, H. Hammerman, D. Mutlak, Y. Agmon (Haifa, IL)

Holter-ECG-monitoring as a simple and feasible method to identify sleep apnoea syndromes in patients with congestive heart failure. P5690

- H. Bonnemeier, W. Maeuser, S. Sandrock, R. Amschler, B. Weidtmann, M. Reppel (Lubeck, DE)

HEART FAILURE: NOVEL MANAGEMENT STRATEGIES

Outcomes after aortic valve replacement in patients with severe aortic regurgitation and significantly reduced left ventricular ejection fraction. P5691

- M.A. Castel, A. Sionis, A. Garcia-Alvarez, M. Cordero, F. Perez-Villa, M. Josa, E. Roig (Barcelona, ES)

- Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy.** P5692
 – B. Vrtovec, M. Sever, L. Lezaic, D. Domanovic, G. Poglajen, J. Fettich, P. Cernelc, F. Haddad, G. Torre-Amione (Ljubljana, SI; Stanford and Houston, US)
- Heart failure patients with Cheyne-Stokes respiration: effects of adaptive servoventilation in compliant patients.** P5693
 – O. Oldenburg, T. Bitter, S. Korte, A. Schmidt, R. Lehmann, C. Prinz, L. Faber, D. Horstkotte (Bad Oeynhausen, DE)
- Positive pressure ventilation increases arterial haemoglobin oxygen saturation after acute but not after prolonged exposure to high altitude hypoxia. Evidence from the HIGHCARE study.** P5694
 – G. Caldara, P. Agostoni, M. Valentini, M. Bussotti, F. Gregorini, A. Faini, C. Lombardi, G. Bilo, M. Revera, G. Parati (Milan, IT)
- Advanced decompensated heart failure and intraventricular mechanical dyssynchrony: relation to hemodynamic responses to intensive medical therapy.** P5695
 – A. Navazio, L. Tarantini, M. Piepoli, G. Tortorella, M. Calzolari, M. Pantaleoni, T. Grimaldi, M. Iori, F. Manca, C. Menozzi (Reggio Emilia, Belluno and Piacenza, IT)
- The use of impedance cardiography for optimizing the interventricular stimulation interval in cardiac resynchronization therapy: a comparison with left ventricular contractility.** P5696
 – E. Sciaraffia, H. Malmberg, S. Lonnerholm, P. Blomstrom, C. Blomstrom Lundqvist (Uppsala, SE)
- Brachial artery diameter decrease, concomitant with flow mediated dilatation increase, related to congestion correction in heart failure.** P5697
 – D.M. Olinic, M. Olinic, N. Olinic (Cluj-Napoca, RO)
- Effects of levosimendan versus dobutamine on ventricular arrhythmias and autonomic indexes in patients with advanced heart failure.** P5698
 – D. Duman, E. Simsek, O. Yildiz, P. F. A. Fatih, S. Atalay (Istanbul, TR)
- Left sympathetic blockade by endoscopic clipping: a novel surgical treatment for systolic heart failure?** P5699
 – G.E.C.S. Souza, P.M. Pego-Fernandes, L.F.P. Moreira, M.L.C. Vieira, G.V. Guimaraes, F. Bacal, V.S. Issa, S.M.A. Ferreira, P.R. Chizzola, E.A. Bocchi (Sao Paulo, BR)
- Targeting pressure-overload induced heart failure by administration of folic acid.** P5700
 – A. Moens, H.C. Champion, M.S. Wollin, D.A. Kass (Maastricht, NL; Baltimore and New York, US)
- Effects of statin therapy according to plasma high sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure trial (CORONA).** P5701
 – J.J.V. McMurray, J. Kjekshus, P. Dunselman, A. Hjalmarson, H. Wedel, M. Lindberg, F. Waagstein, J. Wikstrand (Glasgow, GB; Oslo, NO; Breda, NL; Gothenburg and Moindal, SE)
- Effects of marine n-3 fatty acids on circulating levels of soluble adhesion molecules in patients with chronic heart failure.** P5702
 – O. Eschen, J.H. Christensen, M.T. La Rovere, P. Romano, P. Sala, E.B. Schmidt (Aalborg, DK; Montescano, Milan and Cremona, IT)
- The role of Mediterranean diet on subclinical inflammation and quality of life in patients with newly diagnosed systolic heart failure (The Hellenic heart failure study).** P5703
 – C. Chrysohoou, I. Kotrogiannis, C. Vasiladou, C. Kastorini, P. Aggelopoulos, G. Metallinos, S. Athanasopoulou, C. Pitsavos, C. Stefanadis (Athens, GR)
- Heart failure management in the CRT optimisation clinic.** P5704
 – N. Shanmugam, M. Bizrah, S. Jones, G.R. Sutherland, L.J. Anderson (London, GB)
- The disease management/telemonitoring programme CORDIVA for patients with heart failure reduces hospitalizations and costs in both rural and urban areas.** P5705
 – S.M. Sonntag, H. Sohn, V. Klauss, M. Ziegler, H. Moehlmann, M. Seidel, F.X. Kleber (Berlin and Munich, DE)

Daily maximum and median respiratory rate becomes elevated several weeks before HF hospitalization in patients with implantable devices. P5706

– J. Mont I Girbau, B. Lemke, B. Merkely, Y. Zhang, T. Kayser, V. Averina, N. Wold, P. Bloch Thomsen (Barcelona, ES; Ludenscheid, DE; Budapest, HU; St Paul, US; Brussels, BE; Hellerup, DK)

MISCELLANEOUS

Aerobic interval training improves myocardial function more than moderate intensity training in essential hypertension. P5707

– H.E. Moelmen-Hansen, T. Stolen, A.E. Tjonna, I.L. Aamot, I.S. Ekeberg, G.A. Tyldum, U. Wisloff, C.B. Ingul, A. Stoylen (Trondheim, NO)

Establishing the links between the soluble receptor for advanced glycation end products, asymmetric dimethylarginine and low-grade inflammation in essential hypertension. P5708

– K. Dimitriadis, C. Tsioufis, E. Andrikou, D. Syrseloudis, C. Thomopoulos, I. Andrikou, D. Chatzis, S. Sideris, I. Kallikazaros, C. Stefanadis (Athens, GR)

Assessment of blood pressure measurement accuracy by electronic duo control devices at atrial fibrillation patients. P5709

– S. Farsky, K. Benova, J. Sirotiakova, P. Vyskocilova, D. Krausova (Martin, SK)

Exposure dependent effects on coagulation assays by the oral direct thrombin inhibitor AZD0837 in patients with atrial fibrillation. Results from two phase II studies. P5710 (W)

– G.Y.H. Lip, S.B. Olsson, L.H. Rasmussen, A. Tveit, E. Jensen, U.G. Eriksson, M. Elg, P. Wessman, K. Wahlander (Birmingham, GB; Lund and Molndal, SE; Aalborg, DK; Rud, NO)

Angiotensin receptor antagonists versus calcium antagonists effect on resting and exercise blood pressure. P5711

– C. Liakos, G. Vyssoulis, A. Michaelides, K. Tsioufis, C. Vlachopoulos, D. Tousoulis, K. Masoura, D. Tsiachris, E. Chatzistamatiou, C. Stefanadis (Athens, GR)

Atorvastatin lowers blood pressure as well as oxidized-LDL and epinephrine concentrations in normolipemic hypertensive patients. P5712

– A. Kuklinska, R. Sawicki, B. Mroczko, W.J. Musial, A. Kozieradzka, M. Usowicz-Szarynska, M. Szmitkowski (Bialystok, PL)

Left ventricular mass in patients with masked hypertension, hypertension, normotension and white coat hypertension. P5713

– D.W. Armstrong, G. Tsimiklis, J. Vyselaar, M. Matangi (Kingston, CA)

Reduced insulin sensitivity is associated with adrenergic overdrive in hemochromatosis independently on obesity and hypertension. P5714

– G. Seravalle, R. Dell'oro, G. Brambilla, M. Volpe, R. Mariani, A. Piperno, G. Grassi, G. Mancia (Milan and Monza, IT)

Assessment of renal function in risk stratification in hypertensive patients. P5715

– S. Villevalde, N. Gudgalis, K. Isikova, Z. Kobalava (Moscow, RU)

Maternal haemodynamic changes and heart remodelling in pregnancies complicated by early onset pre-eclampsia. P5716

– K. Melchiorre, G.R. Sutherland, A.T. Baltabaeva, B. Thilaganathan (London, GB)

Cardiovascular risk profile and blood pressure control in diabetic hypertension patients treated in primary care practices. P5717

– D. Wu, H. Phatak, C. Wentworth (Whitehouse Station and Wakefield, US)

Physiological variability and influential factors of aldosterone and serum renin activity. P5718

– S. Zhang, G.S. Yin, L. Yan, M.T. Xu, F. Li, M.C. Wu, S.L. Liu, Y.Q. Qin, Z.Z. Fu, H. Cheng (Guangzhou, CN)

Incidence, and Correlates of Nuisance Bleeding Following Anti-platelet Therapy for Patients with Drug Eluting Stents. P5719

– R. Torguson, I. Ben-Dor, K. Kaneshige, A. Pichard, L. Satler, K. Kent, W. Suddath, R. Waksman (Washington, US)

Effect of methotrexate associated to a cholesterol-rich nanoemulsion evidently displays atherosclerosis regression in rabbits. P5720

– A. Bulgarelli, C.J. Valduga, L. Higushi, R.C. Maranhao (Sao Paulo, BR)

- Effect of vardenafil on arterial stiffness and wave reflection.** P5721
– D. Terentes-Printzios, C. Vlachopoulos, K. Aznaouridis, K. Rokkas, N. Ioakeimidis, K. Baou, A. Bratsas, C. Stefanadis (Athens, GR)
- Differences in risk of ST segment elevation myocardial infarction (STEMI) or non STEMI associated with NSAIDs use. A study with the PGRx database.** P5722
– L. Grimaldi, M. Rossignol, N. Danchin, J. Dallongeville, P.G. Steg, B. David, L. Abenham (Paris and Lille, FR; Montreal, CA; London, GB)
- Silymarin (flavonolignans complex from milk thistle) protects endothelial progenitor cells against senescence and apoptosis induced by rapamycin.** P5723
– M. Naruszewicz, A. Parzonko (Warsaw, PL)
- End-organ damage, therapy and course in patients with arterial hypertension: short-term prognosis following cardiac rehabilitation.** P5724
– H. Voeller, M. Karoff, W. Kamke, K. Schroeder, R. Reibis, V. Do, R. Kreutz, M. Huber, K. Wegscheider (Ruedersdorf, Ennepetal, Burg/Spreewald, Bad Neustadt A.D.Saale, Berlin and Hamburg, DE)
- Arterial stiffness in hypertensives is strongly associated with the expression of angiotensin 1 and 2 genes in peripheral monocytes.** P5725
– M. Marketou, J. Kontaraki, N. Tsakountakis, E. Zacharis, G. Kochiadakis, D. Arfanakis, G. Chlouverakis, P. Vardas (Heraklion, GR)
- The influence of different salt-reactivity types of blood pressure on the structural and functional features of arteries in essential hypertension.** P5726
– K.A. Bobrishev, V.V. Kolomiets, E.V. Bobrova (Donetsk and Kiev, UA)